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Chapter 1
General introduction on psoriasis
and day-care, and Aims of study
With the growing attention for patients’ quality of life, and the ongoing restraint on budgets
of health care, new cost effective day-care principles are becoming more and more impor-
tant, for patients, for dermatologists, and for policymakers. To establish the efficiency of
short contact dithranol treatment of psoriasis in a day-care setting using a care-instruction
programme, we performed a multi-centre cost effectiveness analysis. This cost effectiveness
study on dithranol short contact treatment of psoriasis in a care instruction programme
was chosen to serve as an indication for dermatological day-care in general. Part I of this
thesis deals with the cost effectiveness analysis and a related study on health related quality
of life. Part II is compounded of studies on new developments to improve short contact
dithranol treatment of psoriasis.
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1.1 Psoriasis
Psoriasis is a common chronic skin disease, which course is unpredictable. A large area
of the body can be covered with psoriatic lesions. The extent of the lesions may vary con-
siderably between patients, and in time within one patient. Typically lesions are sharply
demarcated, thickened, red and scaly. Additionally, the lesions can be painful and may itch
and occasionally bleed. Many patients with psoriasis indicate that their social and relatio-
nal life is influenced substantially by the extent of their skin disease.1
Epidemiology
Psoriasis is a disease with a prevalence of 2-3% in Western Europe and the USA.2,3 The
prevalence of psoriasis in Caucasians has been reported to be between 1.5 and 3%.4 The pre-
valence of psoriasis appears to be significantly higher among whites compared with African-
Americans, Asians or Pacific Islanders.2 The incidence of psoriasis is equally distributed
between both sexes.5 The disease can start at any age. There are two reported peaks of inci-
dence: one occurring at the age of 16 years (women) or 22 years (men), the other at the age
of 60 (women) or 57 years (men).6 Over one third of the patients with psoriasis first develop
their disease before the age of 20 years.7
Clinical appearance and differential diagnosis
Psoriasis is an erythematosquamous skin disorder, that clinically can manifest according
to four different types.8
1. 90% of all cases have the chronic plaque type psoriasis (psoriasis vulgaris). In this type,
psoriatic lesions are sharply demarcated, symmetrically distributed, erythematous, indu-
rated and with a typical silvery scaling. Sites of predilection are the scalp, elbows, knees
and the sacral region. Lesions can also be present in the flexures (intertriginous psoriasis
or psoriasis inversa).
2. In psoriasis guttata small droplet like lesions, disseminated over the body, appear. It is
often preceded by an upper respiratory tract infection. The lesions hardly show scaling
and this manifestation is mostly seen in children and adolescents. 
3. In pustular psoriasis small macroscopic pustules are visible. Pustular psoriasis can be lo-
calised and generalised. Localised manifestations comprise pustulosis palmoplantaris,
acrodermatitis continua of Hallopeau, and other non acral, non palmoplantar localised
forms. The generalised form can be categorised into the acute generalised pustular pso-
riasis of Von Zumbusch, impetigo herpetiformis, annular pustular psoriasis, juvenile-, and
infantile pustular psoriasis.9
4. Psoriatic erythroderma is a rare form of psoriasis. It may occur in patients without a his-
tory of psoriasis, but is often seen in patients with chronic plaque psoriasis after with-
drawal of corticosteroids, after irritation by dithranol or phototherapy, or triggered by
other drugs. It is a severe form of psoriasis, with a risk of hypothermia, dehydration, and
protein loss.
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Figure 1. 
(1.1)
Clinical picture of psoriasis,
elbow 
(1.2)
Clinical picture of scalp
psoriasis 
(1.3)
Clinical picture of psoriasis
on legs
Figure 2. 
Histological picture of
psoriasis
Figure 1.1
Figure 1.3Figure 1.2
When ‘psoriasis’ is mentioned in this thesis the chronic plaque type psoriasis is meant
(Figures 1.1, 1.2, 1.3). The lesions are so characteristic that the diagnosis can often be
made ‘à vue’. The lesions can vary in size from pinpoint to large plaques. Larger lesions
develop out of smaller lesions by centrifugal expansion. Lesions may also form polycyclic,
annular or gyratory configurations of plaques. The erythema may vary between slight pink
discoloration and very intense redness with almost a purple aspect. The induration may
vary between slight elevation to profoundly indurated plaques. Because of the thickening
the lesions are easily palpable. Characteristic for the scaling in psoriasis is the so-called
‘signe de la tache de bougie’, or ‘candle phenomenon’. This means that if scales are scratched
off from a lesion, the scales cohere similarly as the wax flakes scraped from a candle. When
all the scales are scratched off, characteristic pinpoint bleedings can be observed. This
phenomenon is called ‘signe d’Auspitz’. The amount of scales can vary: from no or discrete
scales (as in early psoriasis guttata and in the flexures) to very profound scaling.8 The clini-
cal picture of psoriasis depends on the localisation of the lesions. Very thick plaques with
rather severe scaling are generally observed on the scalp, whereas intertriginous psoriasis is
more mild and generally without scaling. Fissures and lichenification are typically seen in
psoriasis of the sacral region.
The differential diagnosis is broad: seborrhoeic dermatitis, lichen simplex chronicus,
hyperkeratotic eczema of palms and soles, vesicular and scaling eczema of hands, syphi-
lis, flexural candidiasis, dermatophytic infections, Reiter’s disease, subcorneal pustulosis
(Sneddon Wilkinson), mycosis fungoides, Bowen’s disease, erythroplasia of Queyrat, pity-
riasis lichenoides chronica, hypertrophic lichen planus, pityriasis rubra pilaris, subacute
cutaneous lupus erythematodes (SCLE), and erythema annulare.8 It goes beyond the scope
of this thesis to describe these dermatoses into detail. The reader is referred to the text-
books.10
Histology and pathogenesis
Psoriasis is characterised by cutaneous inflammation and epidermal hyperproliferation.
The epidermis in psoriasis vulgaris shows parakeratosis, elongated rete-ridges, suprapapil-
lary thinning and absence of the granular layer. There is infiltration by T-lymphocytes and
aggregation of polymorphonuclear leucocytes (PMN’s). These aggregations lead to charac-
teristic micro-abscesses of Munro in the stratum corneum and spongiform pustules of
Kogoj within the stratum spinosum. In the dermis the papillae are elongated and edema-
tous, further it contains dilated and tortuous capillaries and an inflammatory infiltrate,
which is predominantly characterised by T-lymphocytes and some PMN’s. 
The histological aspect varies with the stage of the lesion. When lesions develop, PMN’s
move up from the capillary loops in the tip of the dermal papillae into the epidermis. Espe-
cially dermal changes characterise newly developing lesions, with capillary dilatation, der-
mal edema and a mononuclear infiltrate around the capillaries. Acute psoriatic lesions also
show a thickening of the stratum corneum and parakeratosis (Figure 2).11
Why psoriasis evolves is not known, the pathogenesis involves abnormalities in the
immune system, the stroma, the epidermis and cutaneous inflammation. Early events are
changes in the stroma and inflammation. While the lesions develop, increased epidermal
proliferation and abnormal keratinisation are observed. The hyperproliferation of the epi-
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dermis is a result of an increased recruitment of cycling epidermal cells with normal cell
cycle times. In the psoriatic plaque, but also in the symptomless skin, the intercellular com-
munication, concerning mediators of inflammation and signal transduction systems, is
abnormal. Immunological mechanisms are considered critical in psoriasis pathophysiology,
psoriasis is viewed as an epidermal response to immunological injury.12,13
Genetics and aetiology
Hereditary factors play an important role in the aetiology of psoriasis. The mode of
inheritance is still controversial and the genetic basis of psoriasis is complicated. Genetic
studies have located some chromosome loci (6p2114, 17q15,16, 4q17), but the complicated
and controversial ideas on the mode of inheritance makes appropriate genetic counselling
difficult. For an overview of genetic studies in psoriasis, review articles are available.18,19
Although a genetic predisposition is present, it is difficult to estimate the chance that
psoriasis will become manifest in any particular person. The risk of getting psoriasis is
dependent on the number of, and relation to affected family members. If one parent suffers
from psoriasis, and no brothers or sisters, the risk to get psoriasis is estimated to be 10%. If
one parent and one brother or sister is affected, the risk is 16%, and if both parents are
affected the risk of getting psoriasis is 50%. If second or third grade family is affected, the
risk is 4 and 2 percent respectively.3
Triggering factors
In predisposed persons several exogenous and endogenous factors are known, which can
trigger the onset or exacerbation of psoriasis. 
• Trauma may elicit psoriasis in previously uninvolved skin. This was first described by
Köbner and is therefore called the Köbner phenomenon.20 Any physical injury of the
skin may induce a Köbner reaction, which usually occurs 7 to 14 days after the injury.21
• The climate plays a role as the prevalence of psoriasis has been reported to be higher in
colder regions and lower in warmer, humid countries. Patients can experience an aggra-
vation of their psoriasis when they move into colder climates, whereas a warmer envi-
ronment generally improves the disease.22,23 In about 5% of the patients however sun-
light might induce an exacerbation in psoriasis caused by photosensitivity.24
• Infections, especially tonsillitis caused by streptococcal infection, but also chronic infec-
tion and viral infections are described to be associated with the induction of psoriasis.25-27
• Endocrine factors may play a role in the onset or the course of psoriasis. The incidence
shows peaks at puberty and at the menopause and postpartum psoriasis tends to deterio-
rate.6,28
• Metabolic factors like hypocalcaemia and dialysis may worsen psoriasis.29
• Although more than 200 drugs have been described to either exacerbate or initiate pso-
riasis some drugs have a marked increased risk to aggravate psoriasis.30 These include li-
thium31,32, β-adrenergic blocking agents33, non-steroidal anti-inflammatory agents34,35,
the withdrawal of systemic corticosteroids9, anti-malarials36,37, Angiotensin Converting
Enzyme inhibitors38, and interferon-alpha.39,40
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• The role of psychological stress in the induction and severity of psoriasis is not fully un-
derstood but there is evidence that reduction of psychological stress can improve pso-
riasis.41,42
Extracutaneous manifestations
Psoriasis is not limited to the skin. Psoriatic arthropathy may occur in 10 to 20 percent
of all psoriatic patients and may even occur in the absence of cutaneous lesions. The
symptoms of psoriatic arthritis resemble those seen in rheumatoid arthritis and Morbus
Bechterew. The most frequent manifestation is arthritis of the distal interphalangeal joints
of hand, but a mono/polyarthritis of larger joints can also be observed. Psoriatic arthritis is
seronegative, but an increased frequency of HLA-B27 and HLA-Bw38 has been found.43-45
The nails are affected in 25-50% of all cases and can be involved in all types of psoriasis.
Characteristic nail changes in psoriasis are pitting, onycholysis, discoloration, and sub-
ungual hyperkeratosis. The prevalence of nail changes is reported between 10% and 78%.
Fingernails are more frequently involved than toenails.46,47 Involvement of the mucous
membranes is rare. In pustular psoriasis the oral mucosa may be involved.8
Prognosis
Psoriasis is a disease of the skin with a chronic course, and characterised by remissions
and relapses. Complete remissions are reported in varying frequencies of 0.4%, 39%, and
53%.22,48,49 Disease-free intervals vary, depending to some degree on the treatment used.
Disease-free intervals of more than 5 years were reported in 1% to 3%. In concordance
with our study results50, one investigation showed that intensive outpatient treatment gave
longer lasting remissions compared to the remission time of inpatients.51 It is very difficult
to predict the course of psoriasis for an individual patient, but certain characteristics and
predictive factors can be distinguished. 
Early onset of the disease and a positive family history predict a more severe course.
Psoriasis shows a strong tendency to become generalised in those patients with an early
onset.52 The course of psoriasis also varies depending on the type of psoriasis. 
Guttate psoriasis carries a better prognosis compared to the chronic plaque type pso-
riasis, and is known to have longer remissions after treatment. Chronic plaque psoriasis has
been reported to develop from guttate psoriasis in approximately 33%.53
Erythrodermic psoriasis is the only form of psoriasis that can give rise to mortality, be-
cause of complications that may occur. The erythrodermia is difficult to treat and often re-
quires prolonged hospitalisation and oral therapy.54,55
Pustular psoriasis can vary from localised forms (pustulosis palmoplantaris) to general-
ised forms. Localised forms do not give rise to systemic symptoms, but are difficult to treat
and relapses occur frequently. Fever, malaise, and a relatively high mortality accompany
generalised pustular psoriasis.51
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Treatment
Because of the chronic course of psoriasis there is a recurring need for therapy, which
needs to match and support the needs of the patient for as far as possible. Several reviews
highlight treatments available for psoriasis.56-58
There is a large inter-individual variation in treatment response, which makes instruc-
tion and guidance of patients through the labyrinth of psoriasis therapies of great impor-
tance. Rotation of potential harmful therapies is advised and strict compliance is needed to
make any therapy a successful one. The most important therapies will be discussed briefly.
Dithranol therapy will be discussed into detail in Chapter 4.
Firstline topical treatments
Emollients and keratolytics are the basics for every psoriasis treatment. The skin has to
be kept smooth, and in case of marked scaling the skin should be pre-treated with salicylic
acid (5-10%) in an ointment formulation.
Firstline treatment is a topical treatment with a vitamin D3 analogue. Three vitamin D3
analogues are available for the treatment of psoriasis: calcipotriol, calcitriol and tacalcitol.
The latter is not available in The Netherlands. Vitamin D3 analogues reduce inflammation,
inhibit epidermal proliferation, and promote epidermal differentiation. Their effectiveness
is comparable to that of a potent corticosteroid.59-61 Because vitamin D3 analogues are very
safe and have a favourable side-effect profile, it is the treatment of first choice for psoriasis
in primary health care settings. It can be used as mono-therapy or in combination therapies
with corticosteroids or phototherapy.62-64
Topical corticosteroids were used as first choice mono-therapy for decades (since 1952).
Corticosteroids suppress inflammation, modulate immunocompetent cells and affect epi-
dermal proliferation. Because of its side-effects (atrophy of the skin, striae, allergic contact
dermatitis and habituation of the skin) intermittent use of a topical corticosteroid, as mo-
notherapy or in combination with a vitamin D3 analogue, is advised. Potent corticosteroids
are used to treat a recalcitrant localised psoriasis, low and medium potent steroids are used
for maintenance therapy.65
Crude coal tar and more refined tars can be used in itchy psoriasis.66 Combinations of
tar and other therapies give better results compared to tar alone. A time-honoured approach
has been described many decades ago by Goeckerman67, who used crude coal tar in combi-
nation with phototherapy (UVB), and Ingram68, who combined tar with dithranol and UVB.
Phototherapy and dithranol treatment
In more extensive plaque psoriasis, treatment with UVB, photo-chemotherapy (PUVA),
or dithranol is indicated. 
Ultraviolet radiation (UVR), alike sunlight, has a beneficial effect on psoriasis. In pso-
riasis therapy this principle is used, either using artificial sunlamps or as climathotherapy,
like in the ‘dead sea’ treatment.69 In an outpatient clinical setting patients can be treated
with broad spectrum UVB (290-320nm) or narrow-band UVB (311 nm), two- or three times
weekly. Also UVA (320-400nm) has substantial photodynamic effects, although it is not
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effective in psoriasis as mono-therapy, as it requires a 1000 fold higher intensity than UVB
to be therapeutically active. By the use of psoralens (topical or systemic), the skin becomes
more sensitive to the effects of UVA, which enhances the therapeutic effect of UVA.
P(soralens)UVA was a well-established approach for the treatment of severe psoriasis, but
because of an increased risk of UVR induced skin carcinomas and an accelerated photo-
aging of the skin, it is becoming less popular. Because of the cumulative toxicity potential of
any ultraviolet therapy, treatment is restricted to a limited number of treatment courses.70,71
In 1916 Galewski introduced dithranol treatment in Europe, which is highly effective
and safe with two limitations, staining and irritation. Dithranol may be used in different
formulations and application schemes. The efficacy of any dithranol treatment is highly
dependent on adequate dose management. Dithranol treatment has been used for nearly
one century to treat moderate- to severe psoriasis, and has persisted to be well appreciated
as inpatient treatment. Dithranol treatment is receiving new enthusiasm since it is used as
short contact outpatient treatment in a day-care instruction programme.72-74 In Chapter 4
dithranol therapy is described in detail.
Systemic treatment
In severe or disabling psoriasis systemic treatments such as methotrexate, cyclosporin A
and acitretin may be considered. All systemic therapies have substantial side effects.
Methotrexate is a safe treatment for recalcitrant psoriasis and psoriasis arthropatica, pro-
vided that the guidelines for methotrexate therapy are followed. Side effects are mainly sup-
pression of the haemopoeitic system and liver damage.75,76
Cyclosporin A is mainly used as a short period intervention in very severe psoriasis. It is
primarily metabolised in the kidneys, which explains the most important side effects: hyper-
tension and renal impairment.77,78
Retinoids (acitretin, etretinate), derivatives of vitamin A acid, are especially effective in
pustular psoriasis and in active guttate psoriasis. Side effects are hypertriglyceridaemia,
hypercholesterolaemia and teratogenity. The latter limits its use in women of the child-
bearing age. It also causes dose-dependent mucocutaneous side effects like dryness of the
skin, reversible hair loss or hypertrichosis, generalised pruritus and paronychia.79
Fumaric acid is available in The Netherlands, but not licensed. It is described to be
effective and safe in the treatment of psoriasis. Side-effects (flushes, gastrointestinal dis-
turbances) occur relatively frequent, but decrease after continuing therapy. Regular blood
and urine controls are necessary to check for systemic side effects.80,81
Systemic corticosteroids are contra-indicated, and reserved for a small group of patients
who are unresponsive to any other treatment. Corticosteroids can cause a significant re-
bound after withdrawal and also may precipitate psoriasis pustulosa in patients with the
plaque type of psoriasis.65,82
In an individual patient the risk-benefit profile of a systemic treatment should be con-
sidered. All systemic treatments necessitate frequent follow-up visits with blood investiga-
tions.
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Combination of treatments
The combination of different topical treatments, or of systemic and/or topical treat-
ments with phototherapy can be very effective in the long-term management of psoriasis.
The combination of different systemic treatments should be reserved for patients with re-
calcitrant psoriasis, who failed to respond to other treatments.83,84
New developments
In topical psoriasis treatment new developments are to be expected, like new vitamin D3
analogues, and topical retinoids (Tazarotene). In phototherapy new promising develop-
ments in the treatment of psoriasis are the use of the 308-nm excimer laser and photodyna-
mic therapy.84
Immunomodulatory treatments such as Tacrolimus (FK-506), Ascomycine, LFA3TIP,
Interleukin-2 Receptor Antagonists (basiliximab), anti-TNFα (infliximab), and many more
systemic treatment modalities are under research and promising for the management of
psoriasis in the future.84-87
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1.2 Day-care
During the last decades, day-care has become an important alternative in the different
treatment options any specialist has to offer. Changing views on medical care lead to a
growing demand for day-care facilities. Important motivations for day-care are improve-
ment in quality of care, growth in productivity, and cost-reduction.88
The Dutch Society of Medical Specialists (LSV, Landelijke Specialisten Vereniging) de-
scribed the advantages and disadvantages of day-care treatment compared to inpatient
treatment. In their report day-care treatment is less expensive, attractive to the patient,
leads to a quicker moving on of the stream of patients, less hospitalisation, quicker mobili-
sation, shorter absence by illness, and a larger involvement of the first line. Closely related
to these advantages are the disadvantages; day-care treatment puts great demand on the
nursing staff and medical specialists, the organisation has to meet more stringent require-
ments, and it is a more intensive form of care which also puts heavier load on the first line.89
The first official day-care unit in the Netherlands was established in 1975 in Zwolle
(ziekenhuis ‘de Weezenlanden’). Since then there is a growing number of day-care centres
and combined day- and home care centres.89 The quality institute CBO (kwaliteits instituut
voor de gezondheidszorg Centraal Begeleidings Orgaan) is an independent foundation of the
Dutch Society of Medical Specialists and the Dutch Society of Hospital Directories (Neder-
landse Vereniging van Ziekenhuisdirecteuren). The fundament of the organisation is quality
of care, it produces consensus reports that are used in clinical practice to guarantee the
quality of the given care.90 In 1992 the CBO undertook a study concerning the quality of
day-care.89 In their report, which concerns day-care facilities in non-dermatological depart-
ments, day-care is defined as a form of medical care that involves the admission, treatment,
nursing care and the discharge of a patient within one day. The Dutch Association for Day-
care and Short-stay (NVDK, Nederlandse Vereniging voor Dagverpleging en Kortverblijf), was
founded in 1995 and aims at improving the quality of day-care. The attention of the asso-
ciation is especially focussed on internal, anesthesiological and surgical day-care. 
Dermatological day-care
Dermatological day-care has some overlap with day-care in other disciplines, but must
be considered as an entity on its own. The basic conditions each day-care facility has to
fulfil are optimal aftercare in the first line and sound agreements between medical
specialists, general practitioners and patients. Guidelines for dermatological day-care were
proposed by ‘ipso facto’ in 1993. ‘Ipso facto’ is a “foundation for the promotion of policy-
analysis and policy-decisions by means of social research”, in Houten, the Netherlands. This
foundation studied and described guidelines and quality standards for psoriasis day-care.
The study was funded by the National Committee Chronic Diseases, and was performed
under the authority of the National Psoriasis Skin Foundation. Using the input of derma-
tologists, patient associations and insurance companies they composed minimal criteria for
psoriasis day-care. Their definition of psoriasis day-care was ‘a specific admission of maxi-
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mally eight hours on a facilitated ward for the benefit of a therapeutic activity.’ Derma-
tologists, outpatient departments, or day-care centres can offer psoriasis day-care treatment.
The main points of these guidelines are described in Table 1, divided in four categories:
medical professional treatment, treatment indication, medical facilities, and logistics.
Different facilities for dermatological day-care are available in the Netherlands. Tradi-
tional day-care centres provide programmes for different dermatological diseases, consisting
of different treatment modalities in combination with psychosocial support. Besides those,
(extramural) centres for balneo-phototherapy are available, where treatment of psoriasis
takes place.91,92 The department of dermatology of the University Medical Centre st Rad-
boud, Nijmegen, installed a care instruction day-care programme. The principle of this care
instruction programme is combining optimal care and time efficiency. Goals are effective
treatment of moderate to moderate-severe dermatological diseases, education about the dis-
ease and its treatment, instruction and psychosocial support. A day-care unit with a care
instruction principle can easily be installed in any general hospital. Dermatological day-care
treatment diminishes the need for hospitalisation of otherwise healthy people with a skin
disease. The therapies are inpatient treatments adjusted to outpatient instruction program-
mes. Therapies are given according to protocols, but individual variation is possible. 
In our centre, the doctors of our outpatient- and inpatient clinic refer patients to the day-
care unit. A doctor visit at the day-care centre takes 10 to 20 minutes and a nursing consult
takes 30 to 150 minutes. Although day-care offers many advantages, limitations of treat-
ment on a day-care unit with a care instruction principle must also be noted. Higher de-
mands on the compliance of the patient to the treatment (compared to outpatient treatment)
and the lack of (temporary) changes in the environmental situation of the patient (com-
pared to inpatient treatment), meaning that only well-motivated patients are eligible for this
approach. Our care instruction programme was started in 1991. A first pilot investigation
of the treatment of psoriasis with short contact dithranol in the care instruction programme
indicated that the treatment was effective and well appreciated by the patients.93
Therapies used in the care-instruction programme are based on the traditional external
inpatient therapy. Tar is used in the treatment of atopic dermatitis and chronic hand- and
foot dermatoses, dithranol is used in the treatment of psoriasis. Different groups of patients
can be treated in the care instruction programme: 
1. Patients with moderate to moderate-severe psoriasis. These patients are treated with
dithranol according to the short contact principle, if necessary supplemented by other
treatment modalities. 
2. Patients (also children) with moderate to moderate-severe atopic dermatitis. The patients
are treated with coal tar preparations and if necessary dermatocorticosteroids. 
3. Patients with invalidating skin diseases of hands and/or feet. These patients are treated
with coal tar preparations and if necessary supplemented with other local or systemic
therapies. 
4. Patients with ulcers or lymph oedema with a need for extensive wound care or inter-
mittent pneumatic compression therapy. 
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1. Medical professional treatment
• Day-care centres have to be able to offer all regular dermatological treatments, of which a substantial part has to be
performed in the day-care centre. 
• The dermatologist decides which treatment is most appropriate and carries the responsibility for this treatment.
• Alternative treatments do not belong in a day-care centre, treatments that are often practised but not registered      
(i.e.: salt-water baths) are the responsibility of the dermatologist. 
• Treatments have to be performed in a standardised way (protocols). Protocols can vary between day-care centres but
have to be developed by the professional group. 
• A medical doctor has to set the medical diagnose.
• The treatment results have to be registered. 
• There has to be a good contact between the referring doctor and the dermatologist of the day-care centre. 
• There is no obligation of psychosocial care in a day-care centre. If a patient needs psychosocial care, the dermatolo- 
gist has to refer the patient to the general practitioner. 
• There has to be the possibility of contact with fellow-patients.
2. Treatment indication
• The patient can be referred to a day-care centre by a general practitioner or a dermatologist. 
• The dermatologist who is connected to the day-care centre decides if treatment in a day-care centre is indicated.
• The following criteria can be used: 
The severity of the skin disease (10% or more of the skin has to be affected or there are lesions in the face, on the  
hands or/and the genitalia.)
A heavy psychic load by the skin disease. 
Motivation of the patient to participate actively. 
No diseases that interfere with ambulant treatment.
3. Medical facilities
• There has to be a dermatologist connected to the day-care centre. The dermatologist has final responsibility.
• The dermatologist performs the intake, regular controls during treatment and a final control at the discharge of the
patient. 
• The dermatologist has to be available during the opening hours of the day-care centre. Besides regular office hours,
it has to be able to consult the dermatologist within a reasonable time (the same day). 
• During opening hours of the day-care centre personnel with a (para-)medical background has to be present who is  
responsible for the performed treatments.
• The dermatologist is responsible for the training and experience of the assistants. 
• During treatment the same dermatologist and assistants see the patient. 
• There has to be written information about the treatments and its side effects on short and long term. 
• There has to be written information about the day-care centre. 
• There has to be general information about the skin diseases that are treated in the day-care centre and there has to
be information regarding patients associations. This information has to be clearly visible presented in the centre.
• There has to be a formalised complaint procedure for clients. The patient firstly tries to solve the problems with the 
day-care centre. If this does not succeed, the complaint can be deposed at a controlling organ.
4. Logistics
• There have to be guidelines for the accommodation of the centres. The centre at least has to have a reception, a    
waiting/coffee room, a consulting room, dressing rooms, treatment rooms, showering facilities, a resting room and 
toilets.
• Day-care centres have to be accessible by wheelchair users. Day-care centres have to be well scattered nation-wide.
• The day-care centre has to have flexible times of opening, also outside ordinary business-hours, when this is desir-   
able. The dermatologist (on call) always has to be accessible (by phone).
• There have to be guidelines concerning hygiene, safety and privacy. Day-care centres have to be supervised by the  
chief medical officer of community health (Geneeskundige Hoofdinspectie van Volksgezondheid).
21
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
Table 1.
Guidelines for dermatological day-care based upon a report from ‘ipso facto’ for psoriasis day-care
Why dermatological day-care
In 1984 the need for day-care to treat psoriasis was described in the following words.
“There must not only be looked at the immediate medical effectiveness of the treatment
and of the organisation of care in the limited sense. The whole wider situation of the pa-
tient has to be taken into account. The organisation of medical care must not unnecessary
interfere with the normal social life of the patient in the community setting. Psoriasis care
is a life-long process and becomes an important, integral part of the life-pattern of the
psoriasis patient. Treatment in hospital wards is effective but expensive and does not al-
ways give the best quality of life for the patient. The introduction of day-care centres has
greatly improved the situation both with regard to cost and quality of life. There are day-
care centres that oblige the patient to be present for a large part of the day and others that
only require about one hour, three days a week. The latter type of day-care centre usually
makes effective psoriasis treatment compatible with full-time work and a normal social life.
Day-care centres may also function as educational centres for psoriasis patients to facilitate
self-care or treatment in the home of the patient”.94
Ideally, day-care treatment in dermatology is a form of treatment that combines topical
therapy (creams/ointments and/or phototherapy) with education about the (chronic) skin
disease and its treatment as well as psychosocial support. Compared to the regularly out-
patient setting there is more time and personnel available per patient, without the necessity
of admittance to a hospital. Dermatological day-care treatment is a good alternative for
inpatient treatment of healthy people with a chronic dermatological disease; it fills in the
void between inpatient and outpatient care. Optimal combination therapies for psoriasis are
possible and the use of systemic treatment can be minimised. The Psoriasis day-care centre
in Stanford (USA) is the most well known dermatological day-care centre. This centre
works since 1974 on the basis of the Ingram- and the Goeckerman-regimen (see topical
treatments). Patients are treated during the day or parts of the day and then go home again.95
Especially on a day-care unit there is time to instruct patients in how to treat at home
and how to react (by therapy) on the variable symptoms of their skin disease. Meeting of
other patients with the same disease in a day-care centre can lead to more comprehension
of the disease, while encouragement from fellow-patients can lead to a more successful
treatment.91,92 Day-care treatment also meets with the growing need of the hospital for
extra-budgetary financing, and the patients’ need for treatment alternatives.
Medical care and so also dermatological care in the twenty-first century will emphasise
on efficiency. Dermatological departments will sharpen their quality criteria with respect to
cost effectiveness. They will exist of well-equipped inpatient departments for the treatment
of severely affected dermatological patients, efficient functioning outpatient departments
for the treatment of patients who are mild to moderately affected. Besides that, there will be
intra- en extramural day-care facilities for the treatment of patients who are moderate to
moderate-severe affected. As an indicative study for the efficiency of a care instruction pro-
gramme, as a more advanced principle of dermatological day-care, we performed a cost
effectiveness analysis of dithranol short contact treatment for moderate to moderate-severe
psoriasis in a care instruction programme, and compared this with UVB phototherapy and
inpatient dithranol treatment. As described in chapter 2 the Health Care Insurance Board
(College voor Zorgverzekeringen, voorheen ziekenfondsraad) funded this research. 
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Medical technologies with a proven cost effectiveness for one defined indication are
often also used for other indications without a proven efficiency.90 If this research leads to
acceptance of the short contact dithranol treatment of psoriasis in a day-care setting in the
package of benefits of the social security insurance companies (ziekenfondsen), this will in-
directly lead to a broader use of the day-care modality in dermatological practice. To pre-
vent inefficient use of dermatological day-care, the efficiency of dermatological day-care
treatment has to be established and treatments improved where necessary. Traditional
treatments have to be adapted to day-care treatments, quality projects have to be imple-
mented and treatment protocols have to be formulated. In this process, the ward for day-
care can function as a working place for clinical scientific research.
23
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
1.3 Aims and study design
The studies described in Part I of this thesis both were part of a national cost effective-
ness analysis, funded by the National Fund for Investigative Medicine (NFIM; fonds ontwik-
kelingsgeneeskunde) of the Health Care Insurance Board (College voor Zorgverzekeringen,
voorheen Ziekenfondsraad). The NFIM is one of the most prominent Dutch programmes in
medical technology assessment. The purpose of the NFIM is to stimulate academic research
on effectiveness and efficiency of new or existing medical technologies and thereby provid-
ing decision-makers with information on aspects like efficacy and cost effectiveness. The
goal of this study was to investigate the cost effectiveness of dithranol short contact treat-
ment of psoriasis in a care instruction programme day-care setting and to compare it to
treatment with UVB phototherapy or inpatient dithranol treatment, using a multi-centre
randomised approach. In particular two aims were defined:
1.1 To assess the cost effectiveness of treatment of moderate to severe psoriasis with
dithranol short contact treatment in a care instruction programme at a day-care
centre, compared to inpatient dithranol treatment and UVB phototherapy.
1.2 To study Health-Related Quality of Life (HRQoL) in patients with moderate to
severe psoriasis treated with dithranol short contact treatment in a care instruction
programme at a day-care centre, inpatient dithranol treatment, or UVB phototherapy.
Implementation of the dithranol short contact treatment in a care instruction pro-
gramme into the daily practice of a dermatologist implies that the treatment has to be easily
practised by dermatology centres in the Netherlands. But first the treatment has to be
accepted into the package of benefits of the social health insurance companies (ziekenfond-
sen). A Cost Effectiveness Analysis (CEA) of this size on this subject was never performed
before, but is required for a balanced judgement by the Health Care Insurance Board for
acceptance of the treatment. Results of other studies in other countries concerning
dithranol short contact treatment could not be used to reflect the Dutch situation. Differ-
ences in health care settings in other countries influence the results of cost analyses too
much, which makes application of the results in the Dutch policymaking context difficult.
Furthermore day-care with a care instruction programme has never been under study. 
During four years (March 1996 until December 1999) we worked on the fulfilment of
this study. All details can be read in a comprehensive report on this study which is written
to inform the Health Care Insurance Board.50 In Chapter 2 of this thesis, the methodology
we used to perform the cost effectiveness analysis and subsequently a scientific publication
on this study is presented. In Chapter 3 a review on the impact of psoriasis on the Health
Related Quality of Life (HRQoL) is given. The effect of psoriasis and its treatment (with
either of the three treatment alternatives used in the CEA) on HRQoL is discussed.
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During the performance of the CEA we had the opportunity of seeing many psoriasis
patients. Besides establishing the efficiency of dithranol short contact treatment in a care
instruction programme, we searched for methods to optimise and popularise the existing
treatment protocol. The studies are described in Part II of this thesis. In particular two
aims were defined:
2.1 To improve dithranol short contact treatment by studying the influence of the di-
thranol cream vehicle and the way dithranol was proceeded in this cream.
2.2 To investigate and broaden the spectrum of use of dithranol short contact treatment.
The history and therapeutic properties of dithranol are discussed in Chapter 4. In Chapter
5 the importance of the used cream formulation in dithranol short contact therapy is em-
phasised, by showing the relevance of different vehicles, and of how the dithranol is pro-
ceeded in a cream. Chapter 6 describes the broad use in actual practice of dithranol short
contact treatment. Dithranol application on patients who are sensitive to dithranol irrita-
tion, application on the scalp and application in more personally adjusted application schemes
are discussed.
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Part I
Cost effectiveness and
Health-Related Quality of Life
The publications presented in part I originated from a national cost effectiveness analysis,
funded by the National Fund for Investigative Medicine (NFIM, fonds ontwikkelingsgenees-
kunde) of the Health Care Insurance Board (College voor Zorgverzekeringen, voorheen Ziek-
enfondsraad). The study was performed from April 1996 till December 1999. The NFIM is one
of the most prominent Dutch programmes in medical technology assessment. The purpose of
the NFIM is to stimulate academic research on effectiveness and efficiency of new or existing
medical technologies, and thereby providing decision-makers with information on aspects
like efficacy, cost effectiveness, and ethics.
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Chapter 2
A Cost Effectiveness Analysis
The front of the patient
information brochure
on the national
Cost Effectiveness Analysis
described in Chapter 2.2.
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Chapter 2.1
Introduction to the Cost Effectiveness Analysis
(CEA)
As an introductory to the cost effectiveness analysis described in Chapter 2.2, the basics of
the financial construct of the Dutch health care system is explained. The origin of the National
Fund for Investigative Medicine (NFIM, fonds ontwikkelingsgeneeskunde), that funded this
study, is discussed as well. Also the basic elements of a cost effectiveness analysis (CEA)
are highlighted.
The Dutch health care system
The Dutch health care system is mainly based on an insurance system. Social health in-
surance companies (ziekenfondsen) and private insurance companies form an intermediary
between health care providers and consumers (patients) in contracting and financing
health care. The Health Council (Gezondheidsraad) advises the government on the scien-
tific state of the art of medicine and health care. It has a role in gathering (scientific) infor-
mation on medical technologies. Increasingly, Health Council committees base their assess-
ment on information on effectiveness as well as costs. The Health Council may come up
with ‘state of the art’ reports or propose further research.1 Especially for new technologies
the Health Council has an ‘early warning’ function and an influential advisory role in the
political decision-making on the introduction of this new technology in the Netherlands.2
Up to the year 2000, the Health Care Insurance Board (College voor Zorgverzekeringen,
voorheen Ziekenfondsraad) advised the Minister of health on the package of benefits that is
included in the social health insurance schemes. The Health Care Insurance Board super-
vises the social health insurance companies and also has a role in monitoring and evaluat-
ing health care provision from the viewpoint of efficiency and adequate use of scarce
resources, especially on drugs. Recently the Health Care Insurance Board developed the
pharmaco-economic guidelines.3
The National Fund for Investigative Medicine (fonds ontwikkelingsgeneeskunde)
The Health Care Insurance Board plays a role in the identification of technologies that
should be assessed and in priority setting for economic evaluation. In order to perform this
task, the Health Care Insurance Board, in co-operation with the Ministry of Education,
Culture and Science (ministerie van OCW) and the Ministry of Health, Welfare and Sport
(ministerie van VWS), introduced the National Fund for Investigative Medicine (NFIM,
fonds ontwikkelingsgeneeskunde). This fund was raised in 1988 on request of the Dutch
government.4 It is one of the main Dutch programmes in medical technology assessment.
This thesis comprises a Cost Effectiveness analysis performed as a project funded by the
NFIM. The purpose of the NFIM is to stimulate academic research on effectiveness and
efficiency of new or existing medical technologies and thereby providing decision-makers
with information on aspects like efficacy, cost effectiveness and ethics.
The specific aim of the NFIM is to support decision-making on:
• Acceptance of new medical technologies in the package of benefits
• Withdrawing an existing one from the package
• Restrictions on the indications to qualify for a benefit in kind
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• Improving the efficiency or effectiveness of the use of a medical procedure
by means of legislation or through agreement on a protocol
• Planning decisions
• Tariff decisions
The programme of the NFIM is budgeted and is run by a special committee for Inves-
tigative Medicine. The budget is allocated to research projects of three years each. In the
selection of the projects researchers are free to make their own choices for research topics
and submit proposals to the committee. The committee decides on the funding of the
proposals, after scientific and methodological evaluation of the proposal by experts.1 Up to
December 2000, the Dutch Organisation for Scientific Research (Nederlandse Organisatie
voor Wetenschappelijk Onderzoek, NWO), played an important advisory role. Without a posi-
tive judgement of the NWO-committee, research proposals would hardly ever be financed.4
Beginning from January 2001, the fund has entirely moved to the NWO and all projects
started in 2001, fall under responsibility of the NWO. Just like our project, most projects
are run by medical specialists in university hospitals and take the form of a prospective
randomised trial, with an added component for cost effectiveness analysis.1
The basics of a cost effectiveness analysis
A cost effectiveness analysis (CEA), or efficiency analysis, is a form of economic evalua-
tion where both the costs and the consequences of health care programmes or treatments
are examined. Because the Dutch health care system is largely decentralised, economic eva-
luation is not only an instrument for the government (macro-level), but also for the medical
doctors (micro-level), as well as for insurance companies in their contractual relation with
health care providers (meso-level).1,5 Economic research in The Netherlands focuses on the
introduction of new technologies and decision-making on the macro-level (package of bene-
fits, planning).1
A CEA is performed to gather information about the relative efficiency of medical
technologies. This is achieved by the comparison of alternative courses of action for
consideration.6 When performing an economic evaluation, first it is of importance to em-
ploy an appropriate methodology, and ultimately to give valid results. The intention of this
paragraph is to help the reader of this thesis to understand what it takes to perform a CEA,
and assist in the interpretation of our study results. First the characteristics of a CEA will
be described, followed by the key elements of the CEA on dithranol short contact treat-
ment, that is described in detail in Chapter 2.2. 
The alternative(s) to which an intervention under study is compared to, is (are) essen-
tial for the findings of a study. For decision-makers, the alternative(s) should be relevant in
the sense that the study should reflect the actual decision at stake.3,6 To be able to compare
the alternatives in a study it is of importance that all treatment alternatives lead to a com-
parable treatment result.
When looking at costs and consequences it is of importance that the study covered a
sufficient period of time to capture all major health and economic outcomes. This is called
the time horizon of the study. Another important factor in the design of an analysis is the
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perspective, a study can be performed from different points of view (perspectives). The
viewpoint for an analysis may be that of a group of patients, a clinician, an institutional
management or a policy-maker.6 All will have different points of interest to explore.
The Costs
Depending on the choice of the perspective different kinds of costs will be considered
relevant.6 As mentioned before our study was funded by the NFIM (fonds ontwikkelings-
geneeskunde) of the Health Care Insurance Board, that advises the Minister of Health, Wel-
fare and Sports on the package of benefits that is included in the social health insurance
schemes.1 To be able to advise properly, the viewpoint of a study concerning the costs of a
medical programme is obliged to be as broad as possible.3
The costs of a health care programme can be divided in healthcare resources, and patient
and family resources. The healthcare resources consist of the costs to organise and perform
the treatments and include the time needed by the health professionals, materials needed
and overhead costs (light, heat, cleaning, depreciation of equipment etc.). To calculate the
costs, all cost-generating healthcare procedures and materials are expressed as volumes of
care (numbers of doctor visits, nurse visits, drugs needed, etc.). These volumes are valued,
and the costs are calculated by multiplying the number of volumes with the attached value.
An important item in cost evaluation is the valuation. In valuing the healthcare resources it
is of importance that the prices calculated correspond as much as possible with the real cost
prices. This is not always easy, as many hospital-costs are interwoven. Hospital charges do
not reflect the real costs of an inpatient treatment, they are a closing entry to balance the
hospital budget. Physician fees may be out of date and not accurately reflect the relative
skill level and time required for different procedures. Drug prices may be set in negotiations
between the pharmaceutical company and the hospital. Also in the valuation of the costs of
the needed equipment and buildings, there has to be accounted for the use of these facilities
for other purposes, and the depreciation of these facilities.
The patient and family resources include any expense made by the patient and/or family
members, that contribute to their treatment. This also includes the value of their spare
time, and the time lost from work while being treated.
Accurate measurement of costs and consequences is important. The choice for which
costs are analysed is of influence on the final results of a cost analysis. Also the incor-
poration of productivity costs in an economic evaluation can have a substantial influence
on the study findings.6 When analysing the productivity cost of study participants, ques-
tionnaires are used to measure absence due to illness caused by the disease under study or
treatment for this disease.6,7 One of the difficulties is how to express consequences such as
time absent from unpaid work (housekeeping, voluntary work) or help of family members,
the so-called non-market resource inputs, in monetary units. In cost effectiveness analyses
it seems obvious to reflect the consequences of inability to work in monetary terms, thus
valuing productivity loss as being costs.8 When analysing productivity costs due to absence
from work, days absent from work are to be measured, after which the number of days is
valued.9 The number of days registered as being ‘lost’ must be multiplied by the productiv-
ity costs per day. The productivity costs are estimated by using the average gross wage per
day, including employers’ social benefit premiums for the Netherlands (i.e. gross earnings
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before deductions, plus employer-paid social benefits).6,7 Lost leisure time or volunteer time
inputs are hard to value. The most common way to value lost leisure time is at zero. Anoth-
er way is not to try and value volunteer and leisure time inputs, but to describe them
alongside the other costs when reporting results.6
So, many difficulties are to overcome before a cost price is calculated. Therefore, in the
final report of a CEA a clear description of how a cost price is realised is necessary to be able
to interpret the price and to judge whether the costs are applicable in another situation.
The Effects
The consequences of the treatment can be divided in the changes in health state
(physical, social or emotional functioning of individuals) and financial benefits (money that is
saved because of the effect of the programme). For example, if a treatment leads to a longer
disease free time, fewer treatments in a period of time are needed and the resources can be
spent elsewhere.6 Another very important factor of an economic evaluation is that the ef-
fectiveness of a treatment has to be validated. Precedent or simultaneous evidence of effec-
tiveness is required. Effectiveness is not the same as efficacy. Efficacy of a treatment means
that the treatment can work if the patient fully complies with the associated recommen-
dations (these assessments are often made under optimal conditions, with closely monitoring of
the patient to ensure compliance and highly motivated patients and physicians). Efficacy of a
treatment does not tell us that the therapy will be effective in clinical use as well. The
effectiveness of a treatment is established if the treatment works in a normal clinical
setting.6 Effectiveness of a therapy can be expressed in different ways. By using clinical
measures or life years gained, the outcome of interest of the therapy is established. Besides
this, the impact of medical interventions on the Health Related Quality of Life (HRQoL)
can also be a measure of the effectiveness of therapy. To measure HRQoL, validated
HRQoL-scales can be used (also see Chapter 3).3,6
The incremental cost effectiveness ratio
The summary outcome of an economic evaluation in general is an incremental cost
effectiveness ratio, which is calculated by dividing difference in costs between alternatives
by difference in consequence or effect. This ratio reflects the investment that is necessary
to gain one unit of effect. Although comparison of the simple ratios of costs to outcomes for
the three alternatives we used would perhaps do, a more complete comparison is the one of
incremental costs over incremental outcomes. This can be illustrated graphically on a four-
quadrant diagram known as the cost effectiveness plane.6,10
In the cost effectiveness plane the horizontal axis represents the difference in effect
between the intervention of interest (A) and the relevant alternative (O), and the vertical
axis represents the difference in cost. The alternative (O) could be the status quo or a com-
peting programme. If point A is in quadrants II or IV the choice between the programmes is
clear. In quadrant II the intervention of interest is both more effective and less costly than
the alternative. That is, it dominates the alternative. In quadrant IV the opposite is true. In
quadrants I and III the choice depends on the maximum cost effectiveness ratio one is will-
ing to accept. The slope of the line OA gives the cost effectiveness ratio.
36
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
In most economic evaluations the impact of the interventions falls in quadrant I. That is,
they add to cost but increase in effectiveness, certainly when compared with no inter-
vention. To be able to place the outcome of the incremental analysis in a broader light, also
the total costs (and effects) need to be reported. This also enlarges the comprehension and
practicability of the study in another clinical setting or situation.3
Statistical analysis and sensitivity analysis
The incremental ratio is a point estimate that does not give insight into the uncertainty
of the study findings. Every study will contain some degree of uncertainty, imprecision, or
methodological controversy. There are different statistical methods to study the uncertainty
of this ratio. The department of Medical Statistics of the University of Nijmegen performed
the statistical analysis of our results. In this thesis, the statistical approaches will be high-
lighted briefly, for further details the reader is referred to our report to the Health Care
Insurance Board11 and the CEA in Chapter 2.2. There are a number of sources of uncer-
tainty in economic evaluation. Data may be unavailable and informed guesses are required.
Estimates may be available but they may be known to be imprecise. This may be the case
for estimates of hospital costs where only the average cost per day, or per admission, is
known. There may be methodological controversy, or value judgements may be incorporat-
ed in the study. This may be the case for analytic decisions, such as the choice whether or
not productivity changes should be included.6 Some data used in our research (i.e. cost of a
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Cost difference +
Intervention less effective and more costly than O
Intervention less effective and less costly than O Intervention more effective and less costly than O
Intervention more effective and more costly than O
Effect difference –
IV I
III II
Effect difference +
Cost difference –
The cost effectiveness plane
dermatologist consultation) are deterministic (known only as a point estimate). The effect of
these deterministic data can only be tested by a sensitivity analysis. To perform this, all
critical methodological assumptions or areas of uncertainty are established. The sensitivity
of the results and conclusions to changes in these deterministic assumptions or estimates
are tested. This means that the analysis programmes are performed several times with
different estimated values for deterministic data. When large variations in the assumptions
or estimates do not produce significant alterations in the results then one tends to have
more confidence in the original results. If the converse occurs, more effort is required to
reduce the uncertainty and/or improve the accuracy of the critical variables. Finally, sensitiv-
ity analysis is used to explore if the study results can be generalised to other settings. This
is often an issue, even where the estimates within a given study are known to be precise. In
general, sensitivity analysis involves three steps: identify the uncertain parameters for
which sensitivity analysis is required, specify the plausible range over which uncertain
factors are thought to vary and calculate study results based on combinations of the best
guess, most conservative, and least conservative estimates.
What will happen with the study results?
When a new medical device or technology is developed, its implementation depends
greatly on the coverage and reimbursement by the insurance (What is included in the pack-
age and under what conditions?). As far as the social health insurance companies are con-
cerned, the government makes these decisions, with an important advisory and implemen-
tation role for the Health Care Insurance Board. The private health insurance companies
have got autonomy in deciding what to include but they tend to follow the corresponding
packages in the social health insurance companies.1
There are four major users of information from economic evaluation studies in the
Netherlands: the Health Care Insurance Board, the Minister of Health, Welfare and Sport,
the medical profession, and the hospital management.
The results of this study are presented to the Health Care Insurance Board in a compre-
hensive report.11 From this report the Board will judge the applicability of the programme
in different settings and assess whether any costs or consequences have been omitted in the
analysis.6 The Health Care Insurance Board writes a formal advice to the Minister of
Health. This advice contains recommendations for further action on the basis of the study
results. These recommendations can be regarding inclusion of the technology in the pack-
age of benefits, restrictions on the production capacity or places where the technology is
provided, and setting guidelines for use.1 This advisory report will be used to decide,
whether or not to accept the principle of treatment of psoriasis in a day-care setting, into
the package of benefits of the social health insurance companies. Acceptance of the treat-
ment implicates that this treatment will become accessible to all patients with moderate to
moderate-severe psoriasis. When a reimbursement fee exists, more hospitals, day-care
centres and medical practitioners will be able to implement this treatment into their daily
practice.
38
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
The medical doctors and the hospital managers take the final step to implementation of
a new medical device. Further distribution of our study results will be done mainly through
publications in scientific journals. Scientific publications however always take time, so
there is a delay between the performance of the study and publication of the final results.
The implementation of research results, coming from a study funded by the NFIM, is also
the responsibility of the Health Care Insurance Board. They are working on implemen-
tation programmes. The co-operation of different university hospitals in this study (multi-
centre study) will also promote an effective spread of the information.4 For the medical
doctors, information on cost effectiveness of medical programmes or technologies is helpful
in defining standards or clinical guidelines for good medical practice or ‘appropriate care’.1
These standards or guidelines and protocols are primarily written by the national medical
societies.4 Still, the question arises if doctors implement this advice in daily practice? It is
stated that medical professionals do not use guidelines well.12 Individual doctors lack the
time, resources and skills to manage scientific information and quality assurance activities
on their own.4 In addition to that there are several other barriers to changing medical
practice, like patient expectations, professional autonomy, financial disincentives and tradi-
tion. Hospital management has to cope with budget constraints, but as long as the medical
specialist has got a powerful role in decisions on investments in, and use of new medical
technologies, decisions on new technology are taken on the basis of many arguments. Eco-
nomic appraisal is one argument, but important others are prestige of the hospital, drive for
innovation, and budgetary consequences.1
So to attain that short contact dithranol treatment for psoriasis in a care instruction
programme on a day-care unit will be implemented in the daily care of the dermatologist,
besides an approval of the Minister of Health, the dermatologists themselves play a very im-
portant role. 
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Summary
The goal of this study was to compare the costs of treatment of moderate to severe
psoriasis by dithranol short contact therapy in a care instruction programme (short contact
therapy) to UVB phototherapy (UVB), and inpatient dithranol treatment (inpatient treat-
ment), and relate these costs to treatment effectiveness. The analysis was performed
alongside an open randomised controlled multi-centre study. The costs (both medical and
non-medical) were calculated for the following periods: during treatment, per month dur-
ing remission, after a relapse, and following an unsuccessful treatment. The effectiveness
measures were the clinical response rate and the number of clearance days during follow up.
Analysis was performed on data of 216 patients. The mean overall costs per patient
during treatment were € 1,641 (short contact treatment), € 1,258 (UVB), and € 7,706 (in-
patient treatment). During the clearance period the mean costs per month per patient were
€ 19 (short contact treatment), € 5 (UVB), and € 25 (inpatient treatment). The clinical re-
sponse rates were 57% (short contact treatment), 57% (UVB), and 85% (inpatient treat-
ment). The mean number of clearance-days after short contact treatment was 160 (median
119; interquartile range [0-357]), which was not significantly different from the other two
strategies: 211 clearance-days after inpatient treatment (241 [99-350]) and 136 clearance-
days after UVB (81 [0-266]). Concluding short contact treatment is an attractive alternative
for patients with moderate to severe psoriasis currently treated by inpatient treatment, as
the costs of short contact treatment were significantly lower and the number of clearance
days was comparable. Considering the higher costs, it can be concluded that short contact
treatment is not a first choice treatment when compared to UVB.
Introduction
Psoriasis is a chronic skin disease by which patients can be impaired considerably in
work and social life. Treatment often leads to a period of relief after which new treatment
is necessary. Therefore the costs of psoriasis treatment are substantial. A large spectrum of
treatments is available for patients with psoriasis: topical treatments, systemic drugs, or
photo (chemo) therapy.
For moderate to severe psoriasis UVB phototherapy or classical inpatient 24 hours’
applications of dithranol are suitable and available treatment modalities.1,2 Both modalities
know their limitations. UVB is limited by side effects such as skin aging and a slight
cumulative risk of non-melanoma skin cancer.3 Dithranol inpatient treatment is an effec-
tive and safe treatment without any long-term side effects. To prevent irritation and stain-
ing by dithranol, hospitalisation is compulsory, which generates high costs and it may have
a great impact on the daily life of a patient.4
The costs of treatments are becoming an increasingly important factor in the choice for
a treatment. Therefore, outpatient or day-care treatments are gaining popularity. Inpatient
treatment is described to be far more expensive than treatments in a day-care centre.5,6,7
These papers however did not present the results of a real cost effectiveness analysis, in
which both the costs and effectiveness were compared between he treatment modalities.
In this paper, we present the results of a cost effectiveness analysis (CEA) that was
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based on a societal perspective. Short contact dithranol treatment in a care instruction pro-
gramme at a day-care centre was compared to UVB phototherapy and inpatient dithranol
treatment.
Methods
Design and patients
The CEA was performed alongside an open randomised multi-centre study (from April
1996 until December 1999). Three treatments were evaluated: inpatient dithranol treat-
ment (inpatient treatment), UVB phototherapy (UVB) and short contact dithranol treat-
ment in a care instruction programme (short contact treatment) at a day-care centre. Two
extramural day-care centres and four university centres with day-care facilities participated. 
Randomisation was concealed (envelopes), patients were randomised within three
parallel randomisation strata over the three treatments under study. Stratum I contained all
three treatments, stratum II contained short contact treatment and inpatient treatment and
stratum III contained short contact treatment and UVB. 
UVB treatment was started with 50% of the minimal erythemal dose (MED), and in-
creased according to a scheme just below erythema. Patients were treated three times a
week. During inpatient treatment dithranol (0.05% - 5.0%) in petrolatum was applied dif-
fusely for 24-hours. Tube-bandages were used to cover the dithranol ointment and to pro-
tect the patients’ clothes and environment. Short contact dithranol treatment was per-
formed in a care instruction programme at the day care centre. Patients were treated and
instructed at the day-care centre twice a week, and they treated themselves at home the
other five days of the week. Dithranol (0.1% - 5.0%) was applied in a cream and washed
off after 15-45 minutes. Patients were treated with a maximum duration of 12 weeks for
UVB and short contact treatment and of 8 weeks for inpatient treatment. They regularly
visited the investigator during treatment. Following successful treatment patients were seen
monthly until a relapse occurred, with a maximum period of 1 year. After therapy failure
and following a relapse, followed up was performed by correspondence to complete the
cost-diaries. Details on the study design, randomisation procedure, and treatment protocols
are discussed elsewhere.8
Costs
Medical and non-medical costs were determined. They were calculated on the basis of
real costs. The costs per patient were calculated by multiplying prospectively measured
quantities of care per patient with a specific cost price and converted to Euro (€ 1= DFL
2.2). The quantities were measured using registration forms that were filled in by the
nursing staff at the treatment wards and using patient-diaries, covering a period of four
weeks. Patients started filling in the diaries at the start of therapy and continued after the
end of therapy, until one year of follow-up was completed.
The cost prices were calculated according to Dutch guidelines for economic evaluation
in health care research.9,10 All prices were based on the price level of 1998. Older prices
were adjusted by an index to the price level of 1998. 
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Cost prices were calculated for the following items: dithranol, dermatologist’s time, nurse’s
time, the use of the UVB unit, the use of the day-care unit, outpatient visits dermatologist,
and day in hospital. These prices were calculated in both a university hospital and a day
care centre. A weighted mean price was calculated using the ratio of the number of patients
in this study treated in general hospitals and treated in teaching hospitals. A cost price per
tube or pot with 40 grams dithranol was calculated for each concentration. The same prices
were used for dithranol cream and dithranol ointment. The costs of the dermatologist in
the university hospital were based on the Dutch wage classification. The costs of the
dermatologist in the extramural day care centre were based on guidelines.9 The costs of the
nursing staff were based on the wage classification in the university hospital and the day
care centre. The cost prices for the use of the UVB unit and day care unit were calculated
excluding the employee costs, because time of the nurse and the dermatologist and dithra-
nol used were registered and valued separately. For UVB or short contact treatment that
occurred after the treatment under study (during follow up), integral cost prices were calcu-
lated that included employee costs. In the day care centre, no overhead costs (costs for hous-
ing, cleaning, and the costs of non-productive departments) could be calculated. The prices
were adjusted using the percent overhead costs of each price in the university hospital. 
The non-medical costs included costs of absenteeism from work, travelling, and remain-
ing expenses, such as new clothes and medication not on prescription. During UVB or
short contact treatment these non-medical costs were measured with the diaries. The hours
of absenteeism in the inpatient group were based on the number of working hours per
week (measured with a questionnaire). The cost price of one hour of absenteeism was based
upon the mean national costs of paid work per hour. Travelling costs and other expenses of
inpatients were measured with the diaries.
Clinical effectiveness parameters
The Psoriasis Area and Severity Index (PASI) and the ‘Area of involved skin’ were used
to quantify the severity of the psoriasis and to follow the course of the disease during
treatment.11 The ‘Area of involved skin’ at the start of treatment was used as a reference
(baseline Area).
Two outcome measures that reflect the clinical effectiveness were used in the CEA: the
clinical response rate and the number of clearance-days. The clinical response rate is the
percentage of patients with clearance, which was defined as a reduction of the baseline area
with at least 90% within the maximum treatment period. The number of clearance days
was calculated for all patients, irrespective of the treatment result. For patients with clear-
ance it was defined as the days from clearance until relapse (return of at least 50% of the
baseline area). For patients with a therapy failure it was set on 0 days, and for patients with-
out a relapse during follow-up, it was set on 365 days. The mean, median, and interquartile
range of the number of clearance-days were calculated for each treatment. 
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Analysis
The data were analysed according to the intention to treat principle. Every patient who
was randomly assigned to a treatment and who had appeared on the first study-visit to the
research doctor during treatment was included in the analysis. 
Diaries were corrected for missing periods using the patient-year-approach.12 For each
patient, the missing periods were filled with the mean quantities and expenses they had
before they dropped out. Patients with an extreme number of missing diaries were excluded
from the cost effectiveness analysis. Of the missing diaries during follow-up a histogram
was made of the number of missing days. The upper 5% was considered as ‘extreme
number of missing days’.
After correction, the mean, median, and interquartile range of the costs during the treat-
ment period were calculated for the three groups. Further, the mean costs per month dur-
ing clearance, after relapse, and after an unsuccessful treatment were calculated. 
Firstly, the differences in costs and the differences in effectiveness were tested separate-
ly. The differences in costs between the treatment groups were analysed with the Wilcoxon
test. The effect variables were analysed with the (uncorrected) χ2 -test (clinical response
rate), and the Wilcoxon test (number of clearance days).
Further, two incremental cost effectiveness ratios (ICERs) were calculated. In the first
ratio, differences between the treatment groups in the mean costs per patient during the
treatment period were related to differences in the clinical response rate. Two comparisons
were made: short contact treatment compared to UVB and short contact treatment com-
pared to inpatient treatment. In the second ratio, differences between the treatment groups
in the costs during the treatment and remission periods were related to differences in the
number of clearance days. Again, two comparisons were made: short contact treatment
compared to UVB and short contact treatment compared to inpatient treatment. 
The confidence intervals around the ICERs were analysed with the Bootstrap method.13
The principle of bootstrapping is that a random sample of size n with replacement from the
data is taken a large number of times. In this analysis, we took 1000 samples from the origi-
nal data. For each sample, an ICER was calculated (an estimated ICER). All estimated
ICERs were plotted in a figure.
Finally, a one-way sensitivity analysis was performed to examine the robustness of our
findings.14 The price of the hourly wage for a dermatologist, the cost price per visit to the
UVB, the cost price for short contact treatment, and the price for stay in hospital were
varied. Besides the baseline estimate for each of these prices, three values were available:
charges, calculated costs in a teaching hospital, and the calculated costs in a general hospi-
tal. The lowest and the highest values of these three prices were included in the sensitivity
analysis. 
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Results
Patients
Overall, 250 patients were included in the study. The ‘intention to treat’ group existed of
238 patients. There were 160 men and 78 women, with a mean age of 46.7 years (SD
14.3). The mean baseline PASI was 15.3 (SD 6.9) and the mean baseline area was 21%
(SD 13.8). Figure 1 shows the flow of the patients under study. During treatment, 13 pa-
tients stopped treatment. A total of 155 patients had a successful treatment and was fol-
lowed-up clinically. Sixteen patients were lost during follow-up. Seventy-two patients had a
relapse within one year of follow-up. For 10 patients, the follow-up period was shorter than
one year because the study ended. 
Twenty-two patients did not complete the cost-diaries. The remaining 216 patients were
included in the cost effectiveness analysis (short contact treatment n=94; UVB n=70; in-
patient treatment n=52). The following data concern these 216 patients.
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Figure 1. 
Flowchart of patients under
study.
Costs
Table 1 presents the mean quantities of care during the treatment period. The cost
prices that were used to value these quantities are presented in Table 2. The mean overall
costs per patient during treatment were € 1,641 for short contact treatment, € 1,258 for UVB,
and € 7,706 for inpatient treatment (Table 3). The mean costs of absenteeism during treat-
ment were € 594 (short contact treatment), € 321 (UVB) and € 796 (inpatient treatment). 
The mean costs per month per patient during clearance were € 19 (short contact treat-
ment), € 5 (UVB), and € 25 (inpatient treatment). The mean costs per month per patient
after a relapse were € 264 (short contact treatment), € 219 (UVB), and € 220 (inpatient
treatment). The mean costs during treatment and remission altogether were € 1,776 for
short contact treatment, € 1,273 for UVB, and € 7,964 for inpatient treatment.
Effectiveness
Clinical response rates were 57% (short contact treatment), 57% (UVB), and 85% (in-
patient treatment) respectively. The number of clearance-days after short contact treatment
was 160 (mean), with a median of 119 and an interquartile range of 0-357. This was not
significantly different from the number of clearance days after inpatient treatment: 211
clearance days (241 [99-350]), or UVB: 136 clearance days (81 [0-266]). The number of clear-
ance days after inpatient treatment was significantly higher then after UVB (p=0.008).
The clinical effectiveness is described in detail elsewhere.8
Cost effectiveness
The ICER in which differences in the mean overall costs per patient (during the treat-
ment period) between inpatient treatment and short contact treatment were related to the
differences in clinical response rates, was (€ 7,706 - € 1,641) / (0.85 - 0.57) = € 6,065 /
0.28. So, per patient € 6,065 extra was needed to increase clinical response rate with 28
percent. The clinical response rate for short contact treatment was comparable to the cli-
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Table 1.
Mean quantities per patient and inter quartile range (IQ range) during treatment period
units dithranol*
IQ-rangemean
22 17-32
inpatient (N=52)
IQ-rangeIQ-range meanmean
–46-9562
hospital days 35 27-44––
visits UVB unit or day-care unit –2916-2420 24-36
nursing time (hours) 12 7-1567-129 5-7
consultations 18 13-2334-1610 1-4
visits to general practitioner 0 0-000-00 0-0
outpatients visits dermatologist 0 0-000-00 0-0
outpatients visits other specialist 0 0-000-00 0-0
home help (hours)
home help (professional) 0 0-010-00 0-0
help family/husband/wife 21 0-0130-3633 0-13
absenteeism (hours)**
during working hours 48 0-143180-5334 0-25
during unpaid work 60 0-79100-09 0-0
during leisure time –5621-10875 8-90
UVB (N=70)short contact (N=94)
* The number of tubes or pots with 40 grams of dithranol ceam or ointment.
** Inclusive time on outpatient clinic, travelling and treatment at home. The number of patients with paid work was 75
in the short contact group, 58 in the UVB group, and 20 in the inpatient group. The number of patients with unpaid
work was 53 in the short contact group, 40 in the UVB group, and 33 in the inpatient group.
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Table 2.
Cost prices and the ranges that were used in the sensitivity analysis (Euro, €)
unit dithranol
cost price range in senitivity analysis
4.19 - 9.06**
hospital stay (per day) 179 171 - 265
use of the UVB unit (per 10 minutes)* 12 9 - 14
use of the day-care unit (per 30 minutes)* 9 7 - 11
use of the UVB unit including time nurse 16 14 - 25
use of the day-care unit including time nurse 19 16 - 17
dermatologist (per hour) 61 34 - 108
nurse (per hour) 19
outpatients visits dermatologist 35 31 - 43
visits general practitioner 16
outpatients visits other specialists 59
absence paid work (per hour) 18
travelling costs (per kilometre) 0.20
* These are the costs for the use of the day-care unit or UVB unit (nurses and specialist’s time excluded).
** Price per tube or pot with 40 grams of dithranol cream or ointment, dependent on dose.
Table 3.
Mean, median and inter quartile [IQ range] of the costs per patient (Euro, €) during study treatment
primary treatment
median
[IQ-range]
meanmedian
[IQ-range]
meanmedian
[IQ-range]
712 [543-954] 555 [421-673] 6.380 [5.200-8.486]
mean
738 566 6.807
medical 723 [554-988] 585 [458-744] 6.380 [5.200-8.519]765 600 6.823
non-medical 503 [156-1.148] 321 [135-872] 49 [2-906]876 658 883
total costs* 1.305 [917-1.991] 981 [671-1.562] 8.103 [5.700-9.511]1.641 1.258 7.706
inpatient (N=52)UVB (N=70)short contact (N=94)
* Short contact versus UVB: p=0.013; short contact versus inpatient: p=0.0001.
nical response rate for UVB. If the effectiveness of two interventions is comparable, an
ICER is meaningless and a comparison of the mean costs suffices. A comparison of the
mean costs showed that short contact treatment was more expensive then UVB treatment.
The number of clearance days after treatment also was comparable for all three treat-
ments. Therefore, again no ICERs could be calculated. The comparison of the mean costs
showed that short contact treatment was more expensive compared to UVB, and less ex-
pensive compared to inpatient treatment.
In Figure 2, the results of the bootstrap re-samples of the comparison between short
contact treatment and inpatient treatment were plotted. Most of the re-samples were plot-
ted in the third quadrant, which means that short contact treatment gave lower costs and
less clearance days on average compared to inpatient therapy. In Figure 3, seventy-five per-
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Figure 2. 
Bootstrap re-samples.
Each point is an estimated
ICER describing the difference
in costs and number of
clearance days between short
contact treatment and
inpatient treatment for one
sample of the original data.
Figure 3. 
Bootstrap re-samples.
Each point is an estimated
ICER describing the difference
in costs and number of
clearance days between short
contact treatment and UVB
for one sample of the original
data.
cent of the re-samples were plotted in the first quadrant, indicating higher costs and more
clearance days after short contact treatment compared to UVB. However, a small part of the
confidence interval (19%) indicated higher costs and less clearance days for short contact
treatment.
In the sensitivity analysis, the cost prices are changed within the defined range. These
ranges are presented in Table 2. The impact of changes in cost prices on the mean total cost
per patient was limited (Table 4).
Discussion
We investigated the costs of short contact dithranol therapy as compared to UVB or in-
patient treatment and related these costs to the effectiveness. In our study, inpatient treat-
ment was more expensive than short contact treatment. Short contact treatment was slight-
ly more expensive than UVB. Sander et al. also reported that inpatient treatment was the
most expensive treatment as compared to several oral therapeutics, UVB and PUVA.7 How-
ever, they did not perform a cost effectiveness analysis, but estimated the annual costs of
psoriasis. Furthermore, they presented the annual costs per year, but did not distinguish be-
tween treatment, clearance or relapse. In our study, we did make distinction between these
states. We found that the mean costs per month per patient after a successful treatment
(during remission) were low as compared to the mean costs per month after a therapy fail-
ure or after a relapse. Following a therapy failure or a relapse, patients searched for treat-
ment. So to control the costs, the clinical response rate and the number of clearance days
both are of importance. 
Because the disease occurs at an age at which many people work, we did not only take
the medical costs into account, but societal costs like time lost at work as well. Despite the
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Table 4.
Sensitivity analysis: the mean total costs per patient during study treatment, dependent on the used cost
prices (Euro, €)
cost price dermatologist high* 1,722 1,283 7,845
cost price dermatologist low* 1,597 1,245 7,628
cost price UVB high* 1,641 1,321 7,706
cost price UVB low* 1,641 1,131 7,706
cost price short contact high* 1,696 1,258 7,706
cost price short contact low* 1,605 1,258 7,706
cost price hospitalisation high* 1,641 1,258 10,683
cost price hospitalisation low* 1,641 1,258 7,438
* The highest and lowest prices that were used in the sensitivity analysis were presented in Table 2.
inpatient (N=52)UVB (N=70)short contact (N=94)
relative high prevalence of psoriasis (1.5-3.0%)15, the societal costs due to psoriasis are re-
ported to remain modest. Only a small proportion of the patients are absent at work
because of their psoriasis.16,17 Our results showed that patients treated by UVB neglect paid
work the least, treatment by short contact treatment leads to a higher absence, and in-
patient treatment leads to the highest absenteeism. Costs related to absenteeism seemed
comparable during short contact treatment and inpatient treatment. However, the maxi-
mum period on which these costs were calculated was shorter for inpatient treatment as
compared to short contact treatment (8 weeks and 12 weeks respectively). Furthermore, the
number of patients with paid work was smaller in the inpatient group. 
We found a higher clinical response rate of inpatient treatment compared to short con-
tact treatment, which is in concordance with other data on the costs and efficacy of in-
patient treatment compared to day-care treatment with a combination therapy of dithranol
with UVB.5
Although it was not possible to calculate ICERs using the number of clearance days for
effectiveness, we estimated the confidence intervals around the original ICERs with the
bootstrap method. Bootstrapping leads to a conservative estimate of the confidence inter-
val.18 The difference in the number of clearance days for short contact treatment compared
to inpatient treatment was not significant, while most of the re-samples indicated lower
costs but also less clearance days for short contact treatment. These results showed that
short contact treatment is less expensive as compared to inpatient treatment, but not neces-
sarily less effective. The uncertainty in the difference in the number of clearance days was
great. The bootstrap figure of UVB compared to short contact treatment showed that there
was a wide spread in number of clearance days. The largest part of the re-samples indicated
that short contact treatment (although more expensive) might result in more days of clear-
ance compared to UVB.
The results of this study showed that short contact treatment with dithranol in a care
instruction programme is an attractive alternative for patients with moderate to severe
psoriasis currently treated by inpatient treatment. Considering the higher costs, short con-
tact dithranol treatment in a care instruction programme is not a first choice treatment
when compared to UVB. 
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Chapter 3
The impact of psoriasis on
Health-Related Quality of Life (HRQoL)
Psoriasis lesions on a back;
before and after four weeks
of inpatient dithranol treatment.
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Chapter 3.1
Quality of life and psoriasis
The burden of psoriasis
Patients with psoriasis must live with different kinds of stressful experiences. In addi-
tion to coping with the physical discomforts of psoriasis and its treatment, they also suffer
from emotional distress caused by their skin disease. Therefore it is not surprising that pso-
riatic patients report poorer Health Related Quality of Life than the general population,
especially in the emotional domain.1 Psoriasis is a chronic disease in which genetic, envi-
ronmental, and psychosocial factors contribute in varying degrees. Psychosocial factors
have been reported to play an important role in a varying percentage of patients, from 40%
up to 80%.2 Individuals differ in the way they adjust to chronic illness. In coping with
chronic disease in general, a patient has to manage the treatment, the necessity to control
symptoms, the management of assaults upon body image and self-esteem, and the possibil-
ity of leading a normal life.3
Patients rank “embarrassment over one’s appearance” as the worst thing about having
psoriasis4, and 90% of a sample of psoriasis outpatients reported experiencing shame and
embarrassment because of the appearance of their skin.5 In different studies patients
reported that their disease lead to various psychosocial consequences, such as feelings of
anger, depression, shame, helplessness, self-consciousness, embarrassment, frustration, an-
xiety as well as social isolation.3-6 Other studies reported interference with sexual relation-
ships in 50% of the patients7, and trouble forming social relationships in general in 84% of
the patients.8 More recently, 19% of the patients under study reported incidents in which
they were explicitly asked to leave a restaurant, swimming pool, health club, hairdresser’s,
or other public place.9 As a result, many people with psoriasis avoid activities that expose
their lesions to others, such as swimming and sunbathing and going to a hairdresser.7
This psychosocial impact of psoriasis is likely a function of several factors. The most
important determinant is the severity of the disease and the location of the plaques. Other
factors that may affect the impact of psoriasis include age (adolescent and young adults
may be more bothered by the social impairments of the disease than elderly adults), marital
status, and employment status.10 Younger patients (from 18 to 45), patients having more
severe symptoms (subjective, perceived severity), hospitalised patients and patients with
less robust physical health report being significantly more disabled in relation to the degree
of their psoriasis.11 In addition, the social and emotional consequences of having psoriasis
appear to be most clearly tied to the patients’ concerns about how they are perceived and
evaluated by other people.9,10,12 People with a fear of negative evaluation try harder to
conceal their disease and avoid other people more regularly. These people also rate the
quality of their social lives, family relationships, leisure, and emotional well-being lower
and report to have difficulties in interpersonal relationships and in everyday activities.12 13
Unlike stress from a major life event, the psoriasis-related stress is most likely present to
some degree in every patient. Chronic, low-graded stress, such as that resulting from having
to cope with psoriasis, can have a more adverse impact on physical health than stress from
major life events.2 Moreover, this form of stress contributes significantly more to the vari-
ance in patients’ disability in everyday life than any other medical or health status variable.13
This adverse impact of psoriasis upon the quality of life can result in significant chronic
stress, which may in turn exacerbate the psoriasis in a subgroup of patients.2,14 Given the
degree to which psoriasis creates interpersonal difficulties, the high incidence of anxiety
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and depression among psoriasis patients is not surprising.5,8,12 The findings that about 8%
of the patients experienced suicidal thoughts because of their psoriasis underline the
tremendous influence of the disease on the psychic condition of the patients.15
Quality of care
Taking the physical and psychosocial impact of psoriasis in account, the psoriasis patient
largely depends on the quality of received medical care. This quality of care can be
determined in different dimensions of medical care. Like the accessibility of care, the extent
and working level of the health services (university, peripheral, day-care centre) and the
contentment of the consumers.16 The contentment of the consumers can be expressed in
terms of their quality of life. Nowadays there is a growing patient population with chronic
disease, for whom there exists a great relevancy in obtaining and keeping a certain level of
quality of life. Medical interventions are supposed to improve the patients’ quality of life or
at least keep it at the same level. A good quality of life for the psoriasis patient is not
guaranteed by the availability of good facilities for psoriasis care alone. It depends, too,
upon therapeutic modalities that do not interfere with normal life to a significant degree.
This means that the therapeutic modalities employed regularly or for long periods of the
patient’s life, must preferably not smell, be discolouring, or make it impossible to use
ordinary clothing. They also have to be so effective that the lesions can be easily controlled,
and they must be relatively free of long-term side effects. Otherwise the fear of undesired
effects of the treatment might seriously disturb the patient’s sense of wellbeing. In meas-
uring patients’ contentment about care the psychological effects of psoriasis have to be
taken into account. Psychological stress and social problems may interfere with the care of
the disease and the psychological strength that is needed for a regular treatment of psoriasis.17
To assume that a patient is satisfied as long as his or her clinical parameters improve is
becoming more and more obsolete. This is a far too restricted approach. To evaluate a clini-
cal treatment or medical intervention, besides clinical parameters also Health Related
Quality of Life questionnaires are used. The primary goal of psoriasis health care has to be
to maximise functioning in everyday life and to achieve or maintain the highest possible
level of wellbeing or quality of life.
Health Related Quality of Life 
When quality of life is measured in a medical study, those aspects of life that are not
directly related to disease and health care (e.g. financial situation, social status, and political
situation) are left out of consideration. Therefore it is called Health-Related Quality of Life
(HRQoL). HRQoL-research evaluates how big the burden of a disease is and whether a
medical treatment gives any improvement in this burden. HRQoL is hard to measure
directly, just like happiness, social-economic status or intelligence. It is a so-called ‘con-
struct’, a theoretical feature of someone. Therefore it is described within different domains,
which together represent the feature ‘quality of life’ as good as possible. The World Health
Organisation describes health as a state of physical, psychological and social wellbeing, and
not only the absence of a disease. Using this as a guideline the three domains of quality of
life research are the physical domain, the psychological domain, and the social domain. The
physical domain is expressed by physical activities that a patient is (still) able to perform,
and the physical complaints he or she experiences. This domain describes daily activities
from washing and dressing, to sporting. In describing the psychological domain, complaints
such as fear or depression, but also positive feelings are expressed. In the social domain the
way the disease and/or treatment influences the patients social role, like functioning within
the family, work, going out with friends, leisure time, etcetera is expressed. Besides these
three domains often questions are asked about the global or ‘overall’ quality of life. HRQoL-
research can serve two goals: describing the impact of a disease and supporting medical
decisions.18
To examine HRQoL, different instruments are developed. It is preferred to use existing
and regularly used HRQoL-instruments to insure the comparability of the study with ex-
isting study results. HRQoL-instruments can be divided in three groups: generic-, disease
specific- and domain-specific ones. Generic instruments measure HRQoL in terms that are
relevant for every human being, irrespective of a specific medical diagnosis. It comprises
the physical, the psychological and the social domain. They can be applied very broadly,
and make it possible to compare quality of life of patients with different diseases or stages
of a disease. Disease-specific instruments intend to measure the consequences of a specific
disease on HRQoL. These lists can go into detail on those aspects in life that are under
influence of a specific disease. Domain-specific instruments intend to measure specific con-
sequences for one aspect of life, for example lists concerning depression, or concerning
general daily activities to investigate the physical state of a person. Domain-specific instru-
ments are used as a supplement besides generic- and disease-specific ones.18
Of course a patient has to fulfil some conditions to be able to respond to a HRQoL ques-
tionnaire. He or she might be less capable because of the following conditions: too young,
too sick, serious psychopathology (i.e. psychosis), serious cognitive pathology (i.e. dementia),
inability to communicate (i.e. aphasia), inability to speak the language, inability to read
because of illiteracy or eye-disease, or inability to write (i.e. Parkinsonism). 
Patients need to be aware that the study is independent of the treatment and vice versa.
If patients are not aware of this separation, there exists a chance of socially desirable an-
swering behaviour.
The effects of an intervention on HRQoL are preferably analysed in a longitudinal study
with measurements before and one or more after-measurements. This gives the opportu-
nity to base the analysis on differences in the same patients. A research with repeated
measurements per patient has got less influence of variance between patients.18
In the following chapter the impact of treatment of moderate to severe psoriasis with
UVB phototherapy, dithranol short contact therapy in a care instruction programme, or in-
patient dithranol treatment, on HRQoL is described.
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Chapter 3.2
Health-Related Quality of Life of patients with
moderate to severe psoriasis.
The effect of short contact dithranol treatment in
a care instruction programme, UVB phototherapy,
and inpatient dithranol treatment.
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Submitted
Summary
Psoriasis is a chronic skin disease with substantial impact on patients’ social and rela-
tional ways of living and subsequently on their quality of life. The aim of this study was to
evaluate Health-Related Quality of Life (HRQoL) of patients with moderate to severe
psoriasis treated with short contact dithranol treatment, UVB phototherapy (UVB), or in-
patient dithranol treatment. Analysis of HRQoL was performed in an open randomised
multi-centre study by appliance of the Dutch short form of the Sickness Impact Profile
(SIP68) and the Psoriasis Disability Index (PDI). 250 Patients were included. Successful
short contact dithranol treatment and UVB phototherapy both lead to a comparable im-
provement in HRQoL immediately after treatment until the end of the follow-up (max. 1
year). Inpatients experienced a more impaired HRQoL and showed no significant improve-
ment in HRQoL directly following treatment. At the end of the study HRQoL became
comparable for all treatment groups. Concluding all three treatment modalities lead to
substantial improvement in HRQoL, however patients treated by short contact treatment
or UVB showed a better HRQoL compared to inpatients. 
Introduction
Psoriasis can be treated by a scale of topical treatments, systemic drugs or photo(chemo)-
therapy. Because no curable treatment is available yet, all interventions are merely focused
on the temporary relief of the burden of psoriasis and improvement in health status or
quality of life (i.e., Health-Related Quality of Life: HRQoL). To evaluate HRQoL, generally
two different variants of HRQoL instruments are available. Generic HRQoL instruments
are designed to be used for all kinds of diseases and medical treatments, whereas disease-
specific HRQoL instruments are designed to assess HRQoL in specific diagnostic groups of
patient populations.1
The subjective appraisal of psoriasis seems to be highly affected by factors such as the
location of the plaques, age, marital status, and employment status.2 Psoriasis patients
report a lower HRQoL compared to the general population. A prominent factor in the
evaluation of psoriasis, is the patients’ concern about how they are perceived and evaluated
by others. To a large extend this determines the experienced social and emotional conse-
quences of psoriasis.2-4 Common reactions to psoriasis are social discomfort, embarrass-
ment, impaired daily activities, anxiety, anger, depression and social isolation.5 All these
reactions may be reflected in higher scores on HRQoL instruments, especially on the
domains: social lives, family relationships, leisure time, and emotional well being.3,6,7
To evaluate the effect on HRQoL of three currently available treatment modalities for
moderate to severe psoriasis8 we performed an open randomised multi-centre study. The
study was performed alongside a cost effectiveness analysis concerning the same three
treatments.9 The treatments under study were: short contact dithranol treatment in a care
instruction programme (short contact treatment) at a day-care centre, UVB phototherapy
(UVB), and inpatient dithranol treatment (inpatient treatment). Two HRQoL instruments
were applied, a generic- and a disease-specific one.10,11
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Material and methods
Design 
An open randomised multi-centre study was designed with the following treatments:
short contact dithranol treatment in a care instruction programme at a day-care centre,
UVB phototherapy, and inpatient dithranol treatment. Two extramural day-care centres
and four university centres with day-care facilities participated. 
Randomisation was concealed (envelopes); patients were randomised within three paral-
lel randomisation strata over the three treatments under study. Stratum I contained all
three treatments. Stratum II contained short contact treatment and inpatient treatment, so
patients with a contra-indication for UVB phototherapy or who did not want this therapy
were randomised within this group. Patients who rejected inpatient treatment were
randomised in stratum III, containing short contact treatment and UVB. 
Short contact dithranol treatment was performed in a care instruction programme at a
day care centre. This care instruction programme aims at instructing the patient to recog-
nise the different aspects of his/her disease and to react adequately to it by treatment. Pa-
tients are treated and instructed at the day-care centre twice a week, and treat themselves
at home the other five days of the week. Dithranol (0.1% - 5.0%) is applied in a cream and
washed off after 15-45 minutes. UVB phototherapy was performed three times a week.
Treatment was started with 50% of the minimal erythemal dose (MED), and increased
according to a scheme just below erythema. During inpatient treatment dithranol (0.05% -
5.0%) in petrolatum was applied diffusely for 24-hours. 
The Psoriasis Area and Severity Index (PASI) and the total percentage of involved body
surface (area) were used to evaluate clinical effectiveness.12,13 The area at the start of treat-
ment (baseline area) was chosen as most prominent reference value to evaluate the treat-
ments. Following successful treatment (90% clearance of the baseline area) patients were
seen monthly until a relapse occurred (recurrence of 50% of the baseline area), with a maxi-
mum follow-up period of 1 year. Therapy during follow-up after a successful treatment was
protocollised and existed of topical treatments only (descaling ointment, coaltar shampoo,
betamethason- or desoximetason lotion or emulsion, clobetason-, fluticason-, beta-metha-
son-, or clobetasol cream or ointment, calcipotriol ointment, and petrolatum 50% in cr.
Lanette I). Therapy failure was defined as less then 90% clearance of the baseline area
after the maximal treatment period of 12 weeks for short contact treatment or UVB, or
after 8 weeks of inpatient treatment. When there was no improvement of the psoriasis
during treatment, stop criteria were defined to determine if a treatment could be classified
as a therapy failure. These criteria were less then 25% improvement in PASI after 2 (in-
patient treatment) or 3 (short contact treatment/UVB) weeks of treatment, less then 50%
improvement in PASI after 4 (inpatient treatment) or 6 (short contact treatment/UVB) weeks
of treatment. After therapy failure the study ended.
Evaluation of HRQoL was performed at four moments: the start of treatment, the end of
treatment, three months follow-up and the end of study. A generic- and a disease-specific
instrument were applied. 
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Table 1.
Short form of the Sickness Impact Profile, SIP68
Somatic Autonomy (SA) 17 Someone’s basal somatic functions like dressing, eating,
walking or the need of help concerning these matters.
Motor Control (MC) 12 Motor functioning concerning walking, and hand- and
arm control.
Psychological Autonomy and Communication (PAC) 11 If someone functions independently psychically,
including verbal communication, with questions on e.g.
concentration, being confused, stuttering, and making
decisions.
Social Behavior (SB) 12 Possible consequences of a disease concerning
interpersonal contacts such as sexual activity, visiting
friends, and joining group activities.
Emotional Stability (ES) 6 The emotional consequences of a disease with
questions on irritability and irritation concerning
oneself and others.
Mobility Range (MR) 10 Usual daily activities like shopping, cleaning the house,
and handling financial matters, and to what extent the
patients participate in these.
questions concerningitemssubscales
Sickness Impact Profile (SIP68)
As generic HRQoL instrument the Dutch short-form of the Sickness Impact Profile
(SIP68) was used. The SIP68 was developed in the Netherlands in 1994. It contains 68
items that form 6 sub-scales covering aspects of health and someone’s functional status
(Table 1).16 Patients are asked to report on their today’s situation. It takes 10 minutes to
answer the questions, which are in a yes-no mode, no is rated 0, and yes is rated 1. Scores
range from 0 to 68, with higher scores implying higher impairment. The SIP68 correlates
well with the original 136-items version of the SIP14, which was proven to be appropriate
in other psoriasis studies.10,15
Psoriasis Disability Index (PDI)
As disease-specific HRQoL instrument the Dutch translation of the Psoriasis Disability
Index (PDI) was used, which score expresses an accumulation of psoriasis-related disability
in daily activities, at work, in personal relationships, in leisure activities and in treatment.
The PDI was the first developed disease specific HRQoL instrument for psoriasis pa-
tients.17-19 The instrument was designed to measure treatment induced changes in disabil-
ity caused by moderate to severe psoriasis.20,21 The clinical severity of psoriasis is described
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to be no indication for the severity as experienced by the patient. Consequently clinical
severity hardly ever correlates with the experienced quality of life as measured by the PDI.
10,22 The instrument was used to reveal the relative benefit of treatment from the patient’s
view. Respondents consider the past four weeks, rating questions on a 7-point linear
analogue scale on which ‘0’ indicates no disability and ‘6’ represents maximum disability.
An overall index of disability is derived, representing the sum of all answers, with scores
ranging from 0 to 90. The higher the score, the greater the disability.23
Statistical Analysis
Included in the analysis was the ‘intention to treat’ population, consisting of all patients
randomised who, after baseline measurements, appeared at least once during treatment. At
three months follow-up only patients still in remission were analysed. Only completed
HRQoL instruments were included; no imputation methods were employed to replace
missing data. Due to the design of the study and the patients’ flow, different numbers of
patients were included at the four possible measurement periods. Prior to the analysis we
checked whether there was a statistical significant difference between the different centres. 
The PDI and SIP68 scores were transformed to a 0 to 100 point score to facilitate inter-
pretation. For each treatment separately, paired t-tests were performed to detect statistically
significant differences in HRQoL between the four moments of measurement. Testing for
differences between the three treatment groups was performed by ANOVA (post-hoc test for
unequal variances, Dunnett’s C). Association measures (Pearson correlation, two-tailed) were
applied to determine the relationship between the clinical severity scores (PASI, Area score)
and the HRQoL measures (SIP68, PDI).
Results
Overall 250 patients were included in the study. 12 Patients were excluded because they
did not return after the baseline assessment (short contact treatment: 7, UVB: 4, and in-
patient treatment: 1). The ‘intention to treat’ group consisted of 238 patients, 160 men and
78 women. The mean age was 46.7 years (SD 14.3). The mean baseline PASI was 15.3 (SD
6.9) and the mean baseline area of involved skin was 21.0% (SD 13.8). The number of pa-
tients and patient flow are depicted in Figure 1. The mean treatment duration until suc-
cessful treatment was 75 days (SD 16) for short contact treatment, 72 days (SD 17) for
UVB and 37 days (SD 14) for inpatient treatment. The relapse rate after 1 year for short
contact treatment, UVB and inpatient treatment was 38%, 58%, and 70% respectively. Pa-
tients successfully treated by short contact treatment had a significant longer remission
time compared to inpatient treatment. 
The results (mean and SD) of the SIP68 and the PDI are listed respectively in Table 2
and 3. At the end of inpatient treatment the PDI showed a major hospitalisation effect.
Therefore at the end of inpatient treatment the PDI was left out of analysis, not reflecting
psoriasis disability, but merely disability caused by hospitalisation. Statistical analysis showed
that there was no influence of centre on the HRQoL scores. The SIP68 and the PDI scores
Table 3.
Mean (SD) overall and sub-scores of the SIP68  for each of the treatment modalities at the four
measurements, including somatic autonomy [SA], motor control [MC], psychological autonomy and
communication [PAC], social behavior [SB], emotional stability [ES], and mobility range [MR]
Short Contact
treatment (sub)score SIP start of treatment end of treatment
therapy failure successful
3 months
follow-up
end of study
SA 0.3 (1.7) 0.7 (3.1) 0.1 (0.8) 0.1 (0.8) 0.3 (1.2)
MC 5.6 (13.4) 11.0 (23.6) 3.0 (9.8) 3.1 (10.0) 2.0 (8.0)
PAC 9.3 (19.7) 7.0 (16.5) 6.6 (15.3) 4.8 (11.6) 3.0 (8.5)
SB 11.3 (17.7) 16.0 (21.2) 6.4 (12.4) 5.8 (13.8) 5.3 (13.6)
ES 12.5 (24.0) 8.6 (22.6) 5.1 (12.5) 3.4 (10.2) 2.8 (10.0)
MR 3.5 (11.9) 5.4 (16.5) 0.7 (2.5) 0.4 (1.2) 0.4 (2.0)
SIP68 7.1 (11.4) 8.1 (14.3) 3.6 (6.1) 2.9 (6.0) 2.3 (5.2)
UVB SA 0.1 (0.7) 0.0 (0.0) 0.3 (1.2) 0.5 (2.2) 0.4 (1.5)
MC 5.6 (14.5) 6.1 (12.6) 4.4 (14.5) 6.7 (18.6) 8.3 (20.6)
PAC 9.4 (19.5) 7.0 (16.9) 6.0 (17.4) 7.3 (18.8) 6.7 (18.9)
SB 13.4 (20.6) 10.6 (16.9) 6.8 (17.6) 6.7 (17.0) 12.2 (24.7)
ES 14.1 (23.6) 9.0 (15.8) 6.8 (17.7) 5.1 (14.8) 7.2 (19.9)
MR 3.6 (9.3) 2.3 (8.2) 1.8 (6.6) 0.8 (2.8) 1.7 (5.9)
SIP68 7.7 (10.9) 5.8 (6.7) 4.3 (10.3) 4.5 (10.1) 6.1 (12.0)
Inpatient SA 1.4 (4.1) 1.2 (2.6) 0.7 (2.5) 0.8 (2.4) 0.7 (2.8)
MC 9.7 (14.2) 8.3 (11.8) 7.8 (16.1) 5.8 (14.0) 5.3 (14.1)
PAC 13.7 (23.3) 12.7 (23.7) 12.3 (25.0) 14.8 (16.9) 6.5 (18.3)
SB 23.7 (24.3) 25.0 (21.2) 18.6 (26.4) 10.7 (19.5) 9.6 (13.3)
ES 21.8 (28.1) 23.3 (19.0) 15.4 (29.2) 11.9 (25.5) 6.8 (17.0)
MR 7.1 (13.9) 32.0 (39.6) 5.5 (12.1) 3.7 (9.9) 2.3 (7.1)
SIP68 12.9 (12.4) 17.1 (11.3) 10.1 (14.7) 8.0 (12.3) 5.2 (8.6)
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Table 2.
Results of PDI, mean and (SD) for each of the treatment modalities at the four moments of measurement
Short Contact 25.2 (17.6) 27.7 (18.7) 15.2 (10.0) 7.0 (8.9) 9.5 (12.0)
UVB 27.7 (18.0) 21.7 (17.7) 11.5 (15.6) 8.5 (13.8) 14.0 (19.3)
Inpatient 39.7 (21.7) – – 12.4 (13.1) 19.6 (16.5)
treatment start of treatment end of treatment
therapy failure successful
3 months
follow-up
end of study
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correlated well on all four measurements (p<0.01). A correlation between the Area and
the PASI on one hand and the PDI- or SIP68 scores on the other hand, was found for
inpatient treatment at three months follow-up (Area/SIP68 p<0.05; Area/PDI p<0.01;
PASI/PDI p<0.01).
Overall patients with a therapy failure tended to score worse compared to patients with a
successful treatment, a significant deteriorated score was found for the PDI (UVB p<0.05,
short contact treatment p<0.001). Figure 2 and 3 show the results of the scores of the
SIP68 and the PDI with the numbers of completed instruments at the four measurements.
In general, an improvement in the HRQoL score can be observed for the three treatments,
for the SIP68 as well as the PDI.
Short contact treatment led to a statistical significant improvement in HRQoL (SIP68
p<0.05, PDI p<0.001) directly following treatment, which further improved during the
first three months of follow-up and remained at an equivalent level until the end of study.
When comparing the SIP68 sub-scores at the start of treatment with those at three months
follow-up, patients experienced a significant improvement in Mobility Range (p<0.01) and
Emotional Stability (p<0.05). 
UVB phototherapy gave a statistical significant improvement in HRQoL (SIP68 p<0.05,
PDI p<0.001) directly following treatment, which remained significant after three months
of follow-up (SIP68 p<0.01, PDI p<0.001). At the end of study the PDI worsened signifi-
cantly (p<0.05) when compared to three months follow-up. Comparing the SIP68 sub-
domains at the start of treatment with three months follow-up, a significant improvement
was observed in Social Behaviour (p<0.01).
Inpatient treatment did not lead to a statistical significant improvement in the SIP68
score directly following treatment. At three months follow-up, the improvement in HRQoL
became significant (SIP68 p<0.05, PDI p<0.001). From three months follow-up to the
end of study the PDI score showed a significant worsening (p<0.001). Comparing the sub-
domains of the SIP68 from the start of treatment with three months follow-up, a significant
improvement could be observed for Social Behaviour (p<0.01).
It is remarkable how inpatients scored significantly worse on both HRQoL instruments
at the start of treatment compared to the other two treatment groups, also they remained at
a relative higher level during the study. At the end of treatment inpatients scored signifi-
cantly worse on the SIP68 (p<0.01) compared to patients with short contact treatment,
which difference remained significant up to three months follow-up (p<0.05). Compared
to both other treatment modalities the Social Behaviour sub-domain of the SIP68 for
inpatient treatment was impaired more at the start and the end of treatment (p<0.01). At
the end of treatment, additionally inpatient treatment scored worse in the Mobility Range
subdomain (p<0.01) compared to short contact treatment. At the end of the study both
HRQoL scores became comparable for the three treatment modalities, except for the PDI
score for inpatient treatment. This was significantly worse (p<0.05) compared to the PDI
score for short contact treatment. Although HRQoL was impaired more in inpatient treat-
ment, and it did not lead to a significant improvement in HRQoL at the end of treatment,
the actual gain in HRQoL was comparable for any of the three treatment modalities at
three months follow-up.
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Figure 1. 
Flowchart of patients under
study.
Figure 2. 
Mean SIP68 scores (standard
error of the mean) of short
contact treatment (SCT), UVB
phototherapy (UVB) and
inpatient treatment (Inpat) at
the four measurements, with
the number of patients that
completed the instrument.
Figure 3. 
Mean PDI scores (standard
error of the mean) of short
contact treatment (SCT), UVB
phototherapy (UVB) and
inpatient treatment (Inpat) at
the four measurements, with
the number of patients that
completed the instrument.
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Discussion
In our study short contact dithranol treatment, UVB phototherapy and inpatient dithra-
nol treatment all led to an improvement in Health-Related Quality of Life (HRQoL), al-
though at different time intervals following therapy. Improvement in HRQoL following
different local-, systemic-, combined- or inpatient treatments was reported in many other
studies.7,24,25 Inpatients are known to score worse on HRQoL instruments, reporting more
anxiety and depression, an impaired ability to express anger, and having worse scores for
irritability and aggression.26,27 Inpatient treatment in this study also led to worse HRQoL
scores compared to the other two treatment modalities, although inpatient treatment result-
ed in a higher clinical response rate (Figure 1) and the treatment time was shorter, there
was no improvement in HRQoL at the end of treatment. Only after three months of follow-
up the HRQoL of inpatients showed significant improvement. The worse HRQoL score at
the end of treatment is thought to be partly due to clinical treatment itself, as this has a
substantial impairment on a person’s social and leisure time activities. The fact that in-
patients showed higher impairment in the sub-domains Social Behaviour and Motor Range
supports the assumption that inpatients are substantially disabled because of hospitalisa-
tion. This assumption may also explain why the HRQoL scores improved during the
follow-up, as reflecting the improved appraisal of HRQoL due to returning into their nor-
mal social surroundings. A significant improvement in Emotional Stability following treat-
ment was only observed after short contact treatment. Probably this is a direct consequence
of the care instruction programme used, which gives the patient a feeling of control over
the disease and consequently might positively effect ones emotional stability.
The individual perception of living with psoriasis varied considerably. A correlation
between the PDI and the SIP on one hand and the clinical severity of the psoriasis on the
other hand is hardly ever found in other studies.27 Only at three months follow-up we
observed such a correlation. A possible explanation might be that following inpatient
treatment, the remission period was shorter compared to the other two treatment modal-
ities. The (rather quickly) recurring psoriatic lesions might negatively influence someone’s
emotional and behavioural reaction to these recurring lesions, and consequently yield
worse HRQoL scores.
Developed as a general measure of health and focused primarily on performance- and
activity- based dimensions, the SIP68 was not expected to score high in patients with
psoriasis, who in general are healthy and active.7 Though the original SIP has been used
successfully in psoriasis studies7,10, the SIP68 was never used in this field before. Studies
using the SIP68 in other patient populations can be used as an indicative point of reference.
Our patients with psoriasis experienced an impairment comparable to patients suffering
from M. Crohn (SIP68 = 8.7), M. Bechterew (SIP68 = 13.7) or patients with back- and neck
complaints (SIP68 = 7.6). They experienced far less impairment in general HRQoL com-
pared to patients with a spinal lesion (SIP68 = 29.6) or with cancer (SIP68 =16.9).28 The
PDI scores we found are consistent with PDI-scores reported in other studies on HRQOL
in psoriasis patients.10,11,22,29,30
The fact that already at the start of treatment inpatients scored higher on both HRQoL
instruments compared to patients treated with short contact treatment or UVB might be
interpreted as a drawback of this study. A possible factor responsible for the higher score of
the inpatients could have been the randomisation procedure that might have partially led to
a selection bias. It can also partly be attributed to a difference in patients’ perception of
their disease. Patients who experience their psoriasis as very severe and disabling, will
probably have less problems with inpatient treatment compared to patients who are not
disabled by their psoriasis. Consequently, the knowledge that treatment was going to be
clinically might have evoked that these patients went to experience their psoriasis as more
impairing.
Although the gain in HRQoL at three months follow-up in any of the three treatment
modalities was equal, inpatient treatment induced a smaller improvement of HRQoL scores
compared to short contact treatment or UVB up to three months follow-up. When com-
paring HRQoL following short contact treatment with HRQoL following inpatient treat-
ment, short contact treatment deserves preference. Therefore, we may conclude that we
should be rather reserved with inpatient treatment for patients with moderate to severe
psoriasis and take the influence of a treatment on a patients’ Health-Related Quality of Life
under serious consideration.
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Part II
Formulations and applications of dithranol
cream in short contact treatment
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Chapter 4
Dithranol
Psoriasis on an elbow; before and after
dithranol short contact treatment.
History
Chrysarobine is the active ingredient of Goa powder, which was extracted from the
medulla of the araroba tree that grew in Brazil. The Portuguese transported the powder
from Brazil to India via the port of Goa. It was used at the end of the nineteenth century to
treat dermal fungus infections. By misdiagnosis in 1876, Dr. B. Squire accidentally found
chrysarobine to be effective in the treatment of psoriasis.1-3 In 1916 dithranol was first syn-
thesized, it has the chemical structure 1,8-dihydroxy-9-anthrone (Figure 1). Dithranol, also
called anthralin (North-America) or cignolin (Germany), is the synthetic analogue of Chry-
sarobine (3-methyl dithranol).
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Figure 1. 
The chemical structure
of dithranol:
1,8-dihydroxy-9-anthrone.
Pharmacology and working mechanism
Dithranol is a yellow, odourless, microcrystalline powder. The molecule has a hydro-
philic end, containing the hydroxyl and carbonyl groups, and a lipophilic end with exclu-
sively carbon and hydrogen atoms. These hydrophilic and lipophilic characteristics give
dithranol the ideal structure to penetrate the skin rapidly.2,4,5 Dithranol is unstable, and under-
goes spontaneous oxidation to quinones and quinone dimers. The main oxidation products are
danthron, dithranol(hydro)dimer [di-anthrone], and anthraquinone dimer. These are inactive
or less active in their antipsoriatic potency, in their antiproliferative and antirespiratory acti-
vity, in their glucose-6-dehydrogenase (G-6-PDH) inhibitory properties, and in their tumour-
promoting activity.3 Dithranol oxidation is enhanced by day-light, ultra-violet (UV)-light,
exposure to air and molecular oxygen, temperature increase, the presence of trace metals or
tar, alkaline solutions, contact with proteins and lipids, and enzymes. Intermediate oxida-
tion-products, such as dithranol anions, dithranol radicals, and oxygen radicals are thought
to be responsible for both the antipsoriatic effect and the dithranol dermatitis. The anthra-
quinone dimer and polymers stain the skin and clothes.6,7
Dithranol penetrates normal uninvolved skin three times less compared to the involved
skin in psoriasis patients. One of the limiting factors in penetration is the condition of the
epidermis itself, in particular the barrier function of the horny layer, which is disturbed in
the psoriatic lesion.8 When dithranol is applied to the skin, oxidation takes place as it
comes into contact with oxygen, light and warmth.
Dithranol inhibits a variety of cell functions and is cytotoxic.9,10 It interacts within sev-
eral minutes with cell membranes and the mitochondria, giving an antirespiratory and anti-
proliferative effect on the cell. Mitochondrial respiration is inhibited by the oxidative
pentose phosphate pathway, and the oxidative glycolysis via the citric acid cycle.11-13 It does
not bind to DNA, changes in the nucleus are thought to result from changes to the cell
membrane, resulting in inhibition of DNA replication and repair.9,14 The cell membrane
(plasma cell membrane and mitochondrial membrane) is altered in function and structure by
affecting the lipids as well as membrane proteins and enzymes.11,13,15 Dithranol has several
enzymes as target, amongst which are ornithine decarboxylase and 5-lipoxygenase. The
main target enzyme is glucose-6-phosphatase (G-6-PDH), which activity is increased in
psoriasis. Another enzyme that is inhibited is protein kinase C (PKC) in stimulated kera-
tinocytes and polymorphonuclear (PMN) cells. This effect is correlated with inhibition on
keratinocyte proliferation and PMN activity. Inhibition of PKC is also seen in other anti-
psoriatic modalities such as cyclosporine A and PUVA therapy.9,16 Another recently
described target enzyme of dithranol is 5-ribonuclease P, which is an essential enzyme in
tRNA cleavage. Dithranol gives a dose-dependent inhibition of 5-ribonuclease P activity.17,18
Side effects
Dithranol is traceable in the blood after topical application, although in very low amounts.
It is excreted as oxidation products, predominantly in the urine. Even though a systemic
effect of dithranol treatment is suggested by a response of untreated lesions during dithra-
nol therapy, no systemic toxicity has been described.19-21
During dithranol therapy, dithranol irritation and dithranol staining may occur. Dithra-
nol irritation is caused by an inflammatory reaction of the skin to the formation of a super-
oxide radical due to the loss of a hydrogen atom from the methylene group at position C-10
(Figure 1).5,22 The erythema is maximal at 48 to 72 hours and described to subside within
4 to 7 days.23,24 Psoriatic lesions have got an increased extracellular free radical scavenging
system (thioredoxin reductase) and are therefore less sensitive to the oxidative dithranol
irritation than the surrounding skin.25,26 There is no difference in irritant reaction of the
non-lesional skin between normal and psoriatic subjects. Skin type I patients (always burn,
never tan after sun exposure) tend to be more sensitive to dithranol irritation.23,27 The brown
staining of the skin and clothing is due to oxidation products of dithranol (anthraquinone
dimers and polymers) which are brown and black respectively.6,7 Besides staining also post-
inflammatory hyperpigmentation can add to the brownish colour of the skin.
Although dithranol has got a tumour promoting action and is described to be mutagenic
in mice28-30, there is no evidence for a higher incidence of skin cancer or other cancers in
humans.21,31,32
Dithranol allergy has been described33-35, but is controversial and, as illustrated in Chap-
ter 6.1, there might also be a very high sensitivity to dithranol that mimics an allergy.36,37
75
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
76
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
Dithranol formulations
The uptake of dithranol into the skin depends on the water content or hydrophilic prop-
erties of the vehicle. Best skin penetration is from lipophilic vehicles, like petrolatum, fol-
lowed chronological by water/oil (w/o) emulsion, oil/water (o/w) emulsion, and the least
skin penetration exists from dithranol in polyethylene glycol.38
Dithranol can be prescribed in an ointment, paste, cream or stick. In general, prepara-
tions with low dithranol concentrations are less stable compared to those with relatively
high dithranol concentration. White soft paraffin or vaselinum album is the optimal vehicle
(dithranol ointment), because of its lipophilic property, its penetration and stability.39 Appli-
cation of dithranol ointment can be locally or diffuse. The ointment softens when it warms
up on the skin and spreads easily beyond the boarders of the psoriatic lesions. To treat
locally, Pasta Lassar is one of the traditional vehicles for dithranol. It is a compound of
dithranol in zinc oxide, salicylic acid, starch and white soft paraffin. The salicylic acid is
necessary to prevent oxidation of the dithranol within the paste by the zinc oxide. Because
of the stiffness of the paste, it hardly spreads among the boarders of the psoriatic lesions, so
higher concentrations of dithranol can be used, without irritation of the surrounding skin.5
For short contact therapy a cream (o/w base) is used, that can be easily washed off. To
prevent oxidation salicylic acid and ascorbic acid are added to the formulation.3,5
Dithranol sticks have got hard waxes or paraffin as a base and are used to treat recal-
citrant lesions with relatively high dithranol concentrations.3
Treatment regimens
24 hour treatment
Dithranol is applied for 24 hours, in pasta Lassar or stiff paraffin on the psoriatic lesions,
or in white petrolatum on the involved and the non-involved skin (diffuse). Dithranol in
pasta Lassar or in stiff paraffin result in the quickest clearance.40-42 24 Hours application of
dithranol in a cream is less effective.2 Because of the staining of clothes and furniture at
home, inpatient treatment is necessary with 24-hours treatment.
Short contact treatment
Short contact treatment was first described by Schaefer in 1980.43 The higher uptake of
dithranol in psoriatic lesions compared to the noninvolved surrounding skin gives the
opportunity to treat the psoriasis adequately, while the side-effects remain modest. After
this publication, other authors described short contact therapy with different application
times to be safe and effective.44-49 Because of the short contact time, patients can be treated
at home. Compliance is very important in dithranol short contact treatment, and possibly
the most important reason why outpatient short contact treatment with creams, sticks or
ointments lead to disappointing results when compared to inpatient treatment.50,51 To
optimise therapy, frequent concentration adjustments are necessary.52 Patients should be
controlled at least once weekly, to instruct and guide the patient and stimulate compliance.
This can be in an intensified outpatient setting or in a day-care setting. Dithranol short
contact treatment can be adjusted to the patient’s possibilities and needs, as is lined out in
Chapter 6.
Combination treatment
Ingram (1953) developed a treatment that consisted of a combination of a 10 minutes tar
bath, followed by phototherapy (UVB), followed by dithranol in a paste, application of 24
hours.53,54 Other combination therapies have been described with varying therapy results:
dithranol and topical corticosteroids, dithranol and UVB (broad band and narrow band),
dithranol and tar baths, dithranol and UVA or PUVA, dithranol and occlusive dressings,
and dithranol with oral retionoids or oral cyclosporin.55
Indications and contra-indications
In general dithranol treatment is prescribed for patients with a moderate to severe stable
plaque psoriasis. Depending on the patients’ general condition, therapy motivation and the
patients’ own perception of the treatment and their ability to practice the treatment by
themselves at home, inpatient or short contact therapy can be chosen.
Generalised psoriasis pustulosa and erythrodermic psoriasis are contra-indications for
dithranol treatment.1 The Dutch instruction leaflet of dithranol describes that there are
insufficient data about side effects during pregnancy to judge possible harmfulness.57 As
described in chapter 5.1, a cream without salicylic acid can be manufactured. The use of
salicylic acid during pregnancy is not prohibited according to the Dutch guidelines. Salicylic
acid can be prescribed during pregnancy with a restriction in the dosing of at maximum
twice-daily application of 2-5% salicylic acid, or once daily application of 6-10% salicylic
acid, applied on not more than 10% of skin area.56 As dithranol cream only contains
0.01% salicylic acid, this can not be the restricting factor in prescribing it.
Reducing the side-effects
The inflammation of the non-affected psoriatic skin is caused by oxygen radicals, which
are also responsible for the therapeutic effect of dithranol. Therefore it is difficult to sepa-
rate effects from the side effects.58 Attempts have been made to reduce the side effects of
dithranol by changing the treatment time or the vehicle, or by a combination of dithranol
with other drugs. Also the critical C-10 position of the dithranol molecule has been tried to
modify, to reduce side effects.59,60 This way new dithranol derivatives have been developed.
The so called “minimal structure” of the anthrones that is required for a good antipsoriatic
effect consists of a 1-hydroxy-9(1OH)anthrone that contains a hydroxy group at the C1 po-
sition neighboring the C9 carbonyl group and an unsubstituted C10 methylene group.61 Di-
thranol derivatives, such as triacetoxyanthracene62 and butantrone63-66 were very promis-
ing and appeared to be less irritating. The first however was less effective, the latter could
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not be proven to be superior to dithranol. Still new derivatives are being developed in the
hope to find an equally or more effective, less irritating dithranol analogue.3
In order to diminish dithranol irritation, a water-in-oil-in-water (w/o/w) base cream was
developed. In this cream the dithranol is microencapsulated by means of crystalline mono-
glycerides. With this cream the dithranol is delivered more directly to the dermis and has
got fewer side effects in the epidermis. This cream did not have a higher efficacy when
compared to the o/w base cream, while it was more difficult to prepare. It is not used in the
Netherlands.67,68 To prevent irritation, the addition of anti-oxidants or oxidation radical
scavengers has been tried,69 just as the addition of alkaline amines to the skin after washing
off the dithranol, which can inactivate dithranol by facilitation of its oxidation in the skin.70,71
Prostaglandin inhibitors (indomethacin, aspirin) had no significant effect on dithranol
inflammation, nor did H1-receptor blockers (chlorpheniramine, terfenadine).72-74
Conclusion
Psoriasis is a chronic disease with a recurring need for treatment. Therefore, the necess-
ity of an extra therapy option for psoriasis always exists. This therapy option has to be safe,
effective and as less a burden as possible. Dithranol short contact therapy is a very welcome
alternative, it improves the ability of the patient to do things independently, especially
when compared to inpatient dithranol treatment. Dithranol has no long term side effects
and can be given as long and as often as needed or desired. Of course the side effects during
treatment remain, but intensive patient guidance and explanation can prevent severe irrita-
tion and staining, and make the treatment a very acceptable alternative. Research to im-
prove pharmacological availability from a cream and to evaluate application methods of
dithranol in practice has to be continued, to improve dithranol short contact therapy effec-
tiveness and make the treatment possible for a broader group of patients. In Chapter 5 the
role of the dithranol cream formulation will be highlighted on the hand of two studies
concerning the formulation of the cream and the way of processing the dithranol in the
cream. In Chapter 6 applications of dithranol in clinical practice are described, to illustrate
the broad treatment indication for treatment with dithranol short contact therapy.
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Chapter 5
Cream formulations for
dithranol short contact treatment
Test sites with irritant reactions
to dithranol cream,
on the back of a healthy volunteer,
as described in Chapter 5.1.
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Chapter 5.1
Skin irritation by dithranol cream; a blind
study to assess the role of the cream
formulation
M. Prins1, O.Q.J. Swinkels1, E.G.W. Kolkman1, E.W. Wuis2, Y.A. Hekster2, P.G.M. van der Valk1
1  Department of Dermatology, University Medical Centre Nijmegen, The Netherlands. 
2  Department of Clinical Pharmacy, University Medical Centre Nijmegen, The Netherlands.
Acta Derm Venereol (Stockh) 1998; 78: 262-265.
Summary
In connection with a national cost effective evaluation study of short contact dithranol
therapy for psoriasis, the question arose if dithranol cream irritation is influenced by con-
stituents of the vehicle. To establish the role of the different components of the vehicle in the
mechanism of dithranol irritation, the dithranol 3% cream used in the evaluation study, and
its vehicle with 9 different combinations of its components were tested in a blind study. The
creams were applied for 15, 30 and 45 min on the backs of 12 healthy volunteers. Irritation
was scored as erythema by visual and colorimeter scoring. The dithranol creams with sali-
cylic acid among its stabilizers showed 42% more irritation compared to the dithranol
creams with only sorbic acid or no stabilizers at all. Stability tests showed no significant
degradation of dithranol in the two less irritating creams, when kept at 4°C for 11 months.
Salicylic acid in the cream aggravates dithranol-induced erythema. 
Introduction
Dithranol (1,8-dihydroxy-9-anthrone), also known as cignolin or anthralin, is used as an
anti-psoriatic drug since 1916. Its anti-psoriatic and related irritative effect is caused by
oxygen radical formation during auto-oxidation.1,2 Dithranol disintegrates into danthrone
and various dimers. Its decomposition is catalyzed by light, air, oxygen, water, high pH, and
high temperature. The breakdown products have no effect on psoriasis, but are related to
dithranol staining.3,4 Dithranol irritation varies widely between individuals and between
different parts of the body. The axilla, scrotum, breasts and the inside of the thighs are the
most sensitive parts.5-7 Dithranol irritation on the non-affected skin, can be diminished by
shortening of the dithranol contact time. The contact time can be reduced to 10-45 min,
without loss of clinical efficacy.7-9 Different ointments, sticks and creams have been devel-
oped for this short-contact treatment. We are using dithranol cream because it is easy to
apply and to wash off. The dithranol concentration varies from 0.1% to 5.0%. The cream
is applied for 15 to 45 min and washed off with water. Five years of experience showed that
dithranol cream applied in this way sometimes irritates even more than dithranol in a fatty
basis or paste, applied overnight or for 24 h, with comparable clinical efficacy. Therefore,
the question arose whether constituents of the vehicle influence the irritation. To establish
the role of the different components of the vehicle in dithranol irritation, the dithranol 3%
cream used in the evaluation study and its vehicle with 9 different combinations of its com-
ponents were tested in a blind manner on 12 healthy volunteers.
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Material and methods 
Subjects
After having given written informed consent, 12 healthy Caucasian volunteers (5 males,
7 females, aged 23-28 years), without signs or history of skin disease, were tested on their
backs. Because of the controversial role in dithranol irritation the subjects did not use anti-
inflammatory agents such as antihistamines, NSAID’s or corticosteroids from one month
prior to the test until after the test.5,10 Approval of the study had been obtained from the
hospital ethical committee.
Test substances
The test substances consisted of the 3% dithranol cream and of 9 different combinations
of the components of the cream with and without dithranol 3% (Tables 1 and 2). The
creams were prepared by the hospital pharmacy, and coded 1 to 10. The test creams with
dithranol were freshly prepared one day prior to the test and were controlled for their di-
thranol concentration on the test day itself. The stability of the less irritating dithranol
containing creams (2 and 3), kept at 4°C in aluminum coated tubes, was tested. The stabil-
ity was 100% after 4 months and 95% after 11 months.
Exposure
On the back of each subject three columns of 10 marked test-sites (columns I to III), were
situated on the left, middle and right side of the back, respectively. Of each testsubstance
0.05 ml was applied in the centre of these test-sites (diameter 2.5 cm) and spread carefully
and equally within the site, using a fresh finger condome for every application. Each sub-
stance was applied once, in every column. To avoid the influence of site variation in irrita-
Table 1.
Formulation of dithranol cream 3% as used in short contact therapy
Vehicle
Stabilizers
Cetiol V
Cetamacrogol emulsifying wax
Liquid paraffin (viscosity 110-230 mPa.s.)
Sorbic acid
Ascorbic acid
Salicylic acid pulv < 90
Distilled water
Dithranol 30 grams
230 grams
150 grams
150 grams
1.5 grams (0.15%)
0.5 grams (0.05%)
10 grams (1.0%)
up to 1.0 kilograms
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Table 2.
Test creams, numbered 1 to 10, as prepared by the hospital pharmacy
1
2
3
4
5
6
7
8
9
10
Dithranol 3% vehicle, sorbic acid, ascorbic acid, salicylic acid
Dithranol 3% vehicle, sorbic acid
Dithranol 3% vehicle, ascorbic acid
Dithranol 3% vehicle, salicylic acid
Vehicle, sorbic acid
Vehicle, ascorbic acid
Vehicle, salicylic acid
Vehicle, sorbic acid, ascorbic acid, salicylic acid
Vehicle
Dithranol 3% vehicle
tion on the back, applications were performed according to the Latin square principle. In-
traindividually the creams in columns I, II, and III were distributed similarly. Creams in
columns I, II, and III, were left in place for 15, 30 and 45 min, respectively. To avoid the
influence of the side of the back (right, middle or left), times of exposure of columns I, II,
and III, varied interindividually. To avoid other irritation than dithranol-induced irritation,
the creams were removed with tapwater only. One examinator, who did not know the
application and exposure scheme used, performed all evaluations. The creams were applied
and washed off by someone else.
Visual scoring
Thirty minutes and 8, 24, 48, and 72 hours after removal of the creams, all 30 testsites
were evaluated. Visual scoring was performed for the appearance of erythema and oedema,
vesicles and pustules. Itching or pain was also noted. The erythema and oedema score has
been used earlier in another dithranol irritation study11 and consisted of: no erythema=0,
hardly perceptible redness=1, weak but definite erythema=2, marked erythema=3, marked
erythema with minimal oedema=4 and marked erythema with marked oedema=5. For
visual scoring, the central part of the testsites were scored, corresponding with the area
scored by the colorimeter. The scoring for itching and pain were classified as: none=0,
slight=1 and evident=2.
Colorimetric scoring
Colorimetric quantification of erythema has been used in the past for erythema induced
by UV-light, sodium-lauryl sulphate and dithranol 3%.11-13 We used a Minolta tri-stimulus
colorimeter, model CR-200. This meter contains a probe consisting of a 4 cm perspex plate
with a central opening of 11 mm through which flashes of natural daylight from a xenon
lamp are sent towards the skin. The skin-reflected light is analysed by silicone photo cells.
Every measurement is composed of three consecutive light flashes. Using this method,
erythema is expressed in an objective measure, which correlates positively with clinical
scoring of erythema.12,13 According to the guidelines for measurement of skin colour and
erythema14, all test-sites were left uncovered and motionless for at least 5 min prior to the
measurements. Subjects were placed in a standardised position and room temperature was
between 19 and 23ºC. Direct sunlight was prevented. The meter was calibrated according
to the manufacturer’s instructions and a baseline colour analysis was performed for each
subject on all 30 untreated, non-dithranol-exposed test-sites on the first day of the test. The
treated sites were expressed against the subject’s own baseline standard.
Dithranol concentration
The dithranol concentrations in the creams were measured after extraction using a
straight-phase High Pressure Liquid Chromatographic (HPLC) method.15 The measure-
ments were carried out at room temperature. The conditions were briefly as follows: extrac-
tion fluids: dichloromethane, n-hexane; internal standard: 1 g 2-nitro-aniline in 10 ml
methanol; chromatograph: P1000 isocratic pump, AS 1000 autosampler, SCM 400 solvent
conditioner, and UV 1000 detector (Thermo Separation Products); column: Lichrosorb SI 60-
5-L, 15 cm (4.6 mm I.D.) (Chrompack 28802); detection wavelength: 354 nm; integrator:
ChromJet 4400 (Thermo Separation Products); mobile phase: dichloromethane + n-hexane
+ glacial acetic acid (5+82+1); flow rate: 2 ml/min and injection volume: 20µl.
Statistics
Data were statistically analysed by the Tukey’s Studentized Range (HSD) test and the
General Linear Models Procedure. Correlation of the visual score and the colorimetric values
were calculated with the Spearman’s rank test (α=0.05).
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Results
Visual scoring
Overall 360 test sites (12 subjects x 3 rows x 10 test substances) were evaluated.
Long lasting erythema appeared at t=24 h in all 180 test sites exposed to a cream con-
taining dithranol. We did not observe oedema. Dithranol brown staining occurred in 7 sub-
jects and showed a high inter-individual variability in intensity. There was no correlation
between the grade of brown-coloration and the cream number used on the stained test site.
In 73 of the 360 test sites (20.2%) a transient erythema appeared 30 min after removal of
the creams 1,3,6, and 9. In 15 test sites (4.1%) it appeared as a central redness, and in 58
test sites (16.1%) as an erythemal ring on the rim of the test sites. This erythema had dis-
appeared at t=8 h. There were no vesicular reactions. Two subjects developed a slight
pustular reaction after 72 hours, both on two different testsites which were exposed to a
dithranol-containing cream (creams 2, 3 and 5). Slight pain was reported in 4 subjects, which
was transient and independent of the exposure time, the cream number nor the testsite.
Slight itching was noted in 5 subjects, especially on testsites of creams 3, 4 and 5.
Colorimetric scoring
Colorimetric evaluation of the sites before application of the creams showed an inter-
individual variability. To eliminate the influence of this variability, all colorimetric values
were assessed against the patients’ own baseline measurements. At t=8 h the colorimeter
showed a clear rise on sites treated with creams 1 to 5 and a small rise on sites with cream
6 to 10. The mean erythema score for creams 1 to 5 showed a rising tendency up to 72 h.
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Figure 1. 
Mean colorimetric erythema
values of 12 subjects (± SD),
adjusted to their own baseline
values, 72 h after removal of
the creams.
Colorimetric value
Cream value
Creams 6 to 10 showed no significant changes in erythema scores. In the 180 dithranol ex-
posed test sites, 49 times (27.2%) the erythema maximum was reached after 48 hours and
131 times (72.3%) the erythema scores were rising up to 72 hours. The mean colorimetric
erythema scores of the sites with brown-staining showed no significant difference from the
mean scores of the sites without staining. Apparently this did not influence our colori-
metric measurements.
The mean maximum score for erythema was found at 72 h. Erythema values showed no
significant difference between 15, 30 or 45 min of exposure, so the measurements of all ex-
posure times together were used for evaluation. The visual and colorimetric scores showed
a significant correlation as expressed by the median Spearman Rank’s Correlation Coeffi-
cient of 0.75 (range 0.47-0.90). The colorimetric results at 72 h were used for statistical
analysis. A significant difference in erythema score was found between cream 1 and 5 com-
pared to creams 2 and 3. Creams 1 and 5 showed a mean erythema score at 72 h of 4.92;
creams 2 and 3 only reached 2.88, which is 42% less. Cream 4 showed an intermediate re-
action. (Figure 1) None of the creams without dithranol (creams 6 to 10) elicited erythema
or other signs of irritation, except for the transient visually scored erythema at t=30 min,
as mentioned above.
Dithranol concentration
All dithranol-containing creams complied with the British Pharmacopoeia require-
ments.15 When kept at 4°C in aluminum-coated tubes for 11 months, the dithranol concen-
tration in the less irritative creams (2 and 3) was still within the accepted range.
Discussion
The normal skin of psoriatic and non-psoriatic individuals shows no difference in reac-
tion to dithranol, nor is there any association with age, gender or skin type and original
skin thickness.6 The higher erythema score of dithranol from an oil-in-water emulsion
compared to more lipophilic bases, might be caused by a significantly faster release of
dithranol from a cream, as shown in vitro.16 However, dithranol penetrates best from more
hydrophobic ointments, which was shown in vivo with tritium-labelled dithranol.17,18 Di-
thranol erythema is dose dependent, with a higher dose giving an earlier and more severe
reaction.5,19 A concentration of >1% dithranol is able to elicit pustular reactions, which
we observed in two subjects.7 In agreement with earlier reports, long lasting erythema
occurred 24 h after dithranol exposure and reached its maximum in both visual and colori-
metric scores at 48-72 hours.1,11,20,21 The transient early erythema was not detected by the
colorimeter, probably because it concerned a ring of redness in most cases, which was not
seen by the 11 mm wide ‘eye’ of the colorimeter. Because the transient redness was
localized centrally only in 15 of the 360 test sites this did not influence the measurements
significantly. This erythema was probably provoked by sorbic acid, which we add to our
cream as a preservative in a concentration of 0.15%. This is described to exert a transient
erythema appearing within 20 min after application.22 Dithranol from a hydrophilic oint-
ment penetrates in a small but constant amount into the epidermis and shows only little
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difference in epidermal penetration after 10 and 30 min of exposure.17 This might be the
explanation why we did not observe a significant difference in erythema scores at different
exposure times.
Besides dithranol 3% and the vehicle, salicylic acid was the corresponding ingredient in
our most irritating creams (1 and 5), which implicates that salicylic acid in our cream for-
mulation promotes irritation. Our assay supports the assertion that salicylic acid by itself is
not pro-inflammatory (cream 8).6,23,24 Not much is known about the effect of salicylic acid
on the clinical efficacy of dithranol therapy. Salicylic acid is described to promote the re-
lease of dithranol from a cream and enhance skin penetration.1,17,25 This implicates that the
irritation we saw was caused by a higher skin concentration of dithranol. On the other
hand not all authors confirm an enhanced skin penetration by salicylic acid.24,26 It might be
that the salicylic acid influences the dithranol irritation itself by a so far unknown mecha-
nism, without influencing the penetration of dithranol. If the latter statement is true, a
cream without salicylic acid would irritate less. This could lead to a quicker rise in dithra-
nol cream concentration during treatment and a higher clinical efficacy. 
In water-based dithranol formulations, oxygen dissolved in water oxidizes the dithranol
and causes loss of activity.3 Stabilizers, such as ascorbic acid and salicylic acid, are added in
a cream base formulation to prevent or delay this oxidation.27 This stabilizing function of
salicylic acid in dithranol cream is in dispute, some authors even state that salicylic acid in a
cream would diminish its stability.1,28-30 Salicylic acid is also added as a preservative to
dithranol in white petrolatum or pasta Lassar, in which it does not lead to increased irrita-
tion, so possibly also the vehicle-base plays a role in the mechanism of enhanced irritation
in dithranol cream. One should bare in mind that we used a 3% dithranol cream, which
disintegrates much slower and irritates much faster compared to a dithranol cream of a
lower concentration. Further study is needed to establish the irritant potential, the dithra-
nol stability and the clinical efficacy of a cream with a lower concentration of dithranol,
with and without salicylic acid as a stabilizer.
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Chapter 5.2
Dithranol in a cream preparation:
disperse or dissolve ?
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Summary
In the search for the ideal dithranolcream preparation for short contact treatment of pso-
riasis we investigated the clinical efficacy, side-effects and patients appreciation of two
dithranolcream preparations (creams A and B) in a double-blind left-right comparing study.
Dithranol was dissolved at preparation in cream A and dispersed in cream B. Cream A is
known to have a shelf life of one year, cream B has got a much shorter shelf life (several
months). Ten patients with a chronic plaque type psoriasis were treated during seven weeks
in a short contact regimen. The clinical efficacy was monitored by scoring of erythema, in-
duration, scaling and involved area (PASI), skin irritation was scored visually and patients
appreciation was evaluated by means of a multiple-choice questionnaire. Dispersion of di-
thranol in a cream was associated with less irritation and less discoloration of the skin and
its efficacy was comparable with that of the cream in which the dithranol was dissolved. As
the dispersed dithranol formulation is easier to be manufactured its quality will be less de-
pending on the pharmacists experience and equipment, and so more reliable. Besides, it will
be less expensive to prepare. We advise to use this formulation for short contact treatment.
Introduction
The anti-psoriatic component chrysarobine was found to be effective in the treatment of
psoriasis more than 100 years ago. In 1916 its synthetic analogue, dithranol (anthralin,
cignolin) was introduced. Many dithranol treatment regimens and different vehicles have
been used since then.1 In 1980 Schaefer introduced the dithranol short contact treatment.2
In this approach it is essential that the dithranol can be washed off easily, so a cream is pre-
ferred as vehicle. However, the dithranol molecule is very sensitive to oxidation, especially
in a cream. Many authors searched for the best formulation for a stable cream.3-7 The com-
mercially available dithranol cream preparations do not exist in a concentration range per-
mitting optimal performance of short contact treatment as provided at our day-care depart-
ment. Therefore our hospital pharmacist developed a dithranolcream (cream A), based on
an article of Ros et al.7, in which dithranol is dissolved at preparation in the fatty phase of
the cream. This cream formulation showed its good clinical efficacy and stability in the past
6 years.8 Its preparation however is time-consuming. Because of the growing need of a
dithranolcream on prescription, we looked for a cream with comparable efficacy but which
is easier and less time consuming to prepare. The formulary of the dutch pharmacists
(FNA) developed a dithranolcream formulation (cream B) which meets these conditions. In
this formulation dithranol is dispersed and not dissolved in a cream base. Cream B has got a
shorter shelf-life comparative to cream A (2 to 6 months, compared to 1 year), but long
enough for individual preparation, when no stock is needed. In a double-blind left-right
comparing study we investigated to what extent the difference in processing of dithranol in
the creams affects the clinical effectiveness, side-effects and patients appreciation of both
creams.
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Patients and methods
Treatment
10 patients (2 men, 8 women, mean age 50, range 24-72) with a stable chronic plaque type
psoriasis were treated with dithranol creams A and B. Depending on the severity of the
psoriasis and the comparability of the psoriatic plaques, arms or legs were chosen (arms 5
times, legs 5 times). Patients needed to have at least two comparable psoriatic plaques with a
diameter of 3 centimetres or more. A wash-out period of 2 weeks for topical corticosteroids
was used. During a treatment period of 7 weeks the creams were applied diffusely to the
chosen limbs. According to our clinical experiences we expected to notice differences in
efficacy and side-effects if any, within this period. The dithranol short-contact treatment
schedule of our day-care department was used. This implies once daily diffuse application
of dithranol cream, starting with a concentration of 0.1% during 15 minutes, washed off
with water only. After three days the application time is elevated to 30 minutes and after
another three days to 45 minutes. When no irritation occurs, the dithranol cream concen-
tration rises and the application time schedule is restarted. We used the following con-
centrations: 0.1%, 0.2%, 0.3%, 0.4%, 0.6% and 0.8%. The lesions were evaluated by the
same examinator twice weekly. When irritation occurred the treatment was stopped until
the irritative reaction had ceased, after which treatment was continued with a lower dithra-
nol concentration and/or a shorter application time. 
Cream preparation
Table 1 shows the formulation of both creams. Cream A was prepared by the depart-
ment of Clinical Pharmacy in our hospital. Preparation of this cream is as follows; Cetiol V,
Cetomacrogol emulsifying wax and liquid paraffin are warmed to a temperature of 70°C.
Then, salicylic acid and subsequently dithranol are mixed with the melted fats. In the
meantime 400 ml of water is boiled and sorbic acid and ascorbic acid are dissolved in it.
When cooled to 70°C, the fat and water phases are combined and stirred as short as pos-
sible by means of a rotorstator mixer. Eventually the evaporated water is substituted and
the cream is stirred by hand until it is cool. Cream B was produced and given at our disposal
by the Scientific Institute Dutch Pharmacists. Preparation is as follows: dithranol, salicylic
acid and ascorbic acid are mixed and added to a cream base (we used cremor Lanette I).
Both creams were packed into resembling 40 grams aluminium coated tubes immediate-
ly after preparation. Creams with a dithranol concentration below 0.6% were saved at 4°C
to guarantee its stability. The department of Clinical Pharmacy performed a randomised
coding of the tubes, with an indication of left or right side. The examinator nor the patient
knew on which side cream A or B was used. Creams A and B were evaluated microscopi-
cally with and without polarisation filters at a magnification of 150x, for the presence of
crystallised ingredients such as salicylic acid or dithranol.
Clinical assessments
To monitor the clinical efficacy erythema, induration, scaling and area of the plaques
were scored, based on the Psoriasis Area and Severity Index (PASI).9,10 This score was used
separately for the treated right and left limb of the patient. To evaluate dithranol irritation
we used a 5-point visual irritation scale with the following scores: no irritation at all (0),
97
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
slight irritation (1), moderate irritation (2), severe irritation (3) and very severe irritation with
blistering, vesicles or pustules (4). These clinical evaluations were performed before start of
therapy and after 2, 4, 6 and 7 weeks of treatment. After 2, 4 and 7 weeks patients filled in
a multiple-choice questionnaire to evaluate their view on the spreadability of the creams,
discoloration of their skin, cloths or sanitary, skin irritation and preference for one of both
creams.
Results
At the end of treatment 7 patients showed complete clearance on the treated limbs. The
mean improvement of the clinical score was 95% (67%-100%). No difference was observed
in the clinical efficacy of the two creams. Irritative reactions were seen especially during the
first two weeks of treatment. In 9 patients irritation occurred at concentrations and applica-
tion times of 0.1% during 45 minutes (n=2) and 0.2% during 15 minutes (n=7). Irritation
especially occurred on non-psoriatic skin. The mean erythema score in the second week of
treatment was 1.8 for the cream A treated side and 1.4 for the cream B treated side. In all
Table 1.
Formulations of cream A and B, dithranol quantity per 1000 grams of cream can vary from 500 mg. to
50 gr. (concentrations of 0.05% to 5%)
Cream A
Dithranol x gram
Cetiol V® (decyl oleate) 200 + x grams
Cetomacrogol emulsifying wax 150 grams
Liquid paraffin 150 grams
Salicyclic acid 10 grams
Sorbic acid 1,5 grams
Ascorbic acid 0,5 grams
Purified water ad 1000 grams
Cream B
Dithranol x gram
Ascorbic acid 1 gram
Salicyclic acid 10 grams
Cremor Lanette I FNA ad 1000 grams
Cetiol V® (decyl oleate) 200 grams
Emulsifying cetostearyl alcohol 150 grams
Sorbitol 70 percent crystallising 40 grams
Sorbic acid 1,5 grams
Prurified water 585 grams
cream Bcream Bcream B
cases the erythematous area was larger on the cream A treated side, also on this side patients
complained of itching (n=4) linked to the burning pain caused by the irritation. The irrita-
tion resulting from treatment with cream A took more days to cease. Six people stopped
diffuse application and continued their treatment by application of the cream on the pso-
riatic plaques only. The questionnaire (Table 2) demonstrated a better judgement of the
spreadability of cream A in the first two weeks of treatment (lower concentrations). This
cream however caused more subjective complaints of irritation compared to cream B. Dis-
coloration of the clothes and sanitary by both creams was equal, whereas discoloration of the
skin was judged worse by cream A. Effectiveness of both creams was experienced as equally
good. After seven weeks both creams were judged equally in all aspects. There existed a pref-
erence for cream B in 4 patients and for cream A in 1 patient, 5 patients did not have a pref-
erence for one of both creams.
At microscopical evaluation of cream A with non-polarised light hardly any crystals
could be found. Only in a very thin preparation it showed to contain flat, plate shaped
yellow or barely coloured crystals (20-30µm) without braking. The crystals’ shape pointed
out that they had developed out of dissolved material. Cream B contained clearly yellow
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Efficacy wk2 9 7 1 3 0 0
wk4 9 10 1 0 0 0
wk7 9 9 1 1 0 0
Spreadability wk2 9 8 1 0 0 2
wk4 10 9 0 1 0 0
wk7 10 9 0 1 0 0
Discoloration of skin wk2 1 1 2 6 7 3
wk4 2 2 3 5 5 3
wk7 1 1 3 5 6 4
Discoloration of clothing and sanitary wk2 1 1 5 6 4 3
wk4 1 1 4 5 5 4
wk7 1 1 4 5 5 4
Skin irritation wk2 1 1 3 8 6 1
wk4 2 2 4 5 4 3
wk7 4 4 3 3 3 3
Table 2.
Results of the questionnaire (n=10) concerning the efficacy, spreadability, discoloration of the skin,
discoloration of clothing and sanitary, and skin irritation of creams A and B
nr of patients,
favourable
cream A cream A cream A
nr of patients,
unfavourable
nr of patients,
moderate
parts (5-20µm) in non-polarised light, which were sometimes present as an agglomeration
with a size up to 40µm. By looking with polarised light more and smaller crystals became
apparent. All crystals were yellow and pointed out as being dithranol crystals. No salicylic
acid crystals were seen.
Discussion
Dithranol irritation is the most important limiting factor in dithranol treatment. The
schedule of dithranol treatment at our day-care unit is characterised by a relatively low
occurrence of irritation of the skin. Table 3 provides an overview of studies described in
the literature of efficacy and side-effects by different dithranol formulations. In addition to
dithranol, other constituents might contribute to the irritative response, without contribut-
ing to the antipsoriatic effect. For example sodium lauryl sulphate, which is an anionic sur-
factant, is known for its pronounced irritant effect.11
The present study has shown that cream B induces less irritancy, whereas the effective-
ness at the end of treatment is similar to cream A’s effectiveness. Several explanations can
be given to explain this difference with respect to the dithranol cream irritation
Cream A contains paraffin, an occlusive agent which is described to enhance penetra-
tion.11 For a penetration enhancing effect cream A probably was applied too shortly, but
because of the paraffin, a microscopically thin layer of cream containing dithranol remains
on the skin after washing, whereas in cream B the total amount of cream is washed off
completely. This leads to an unwanted sustained availability of dithranol in cream A. The
examinator and some patients experienced a better spreadability of cream A compared to
cream B in the lower concentrations. A better spreadability, meaning a lower viscosity of a
cream, is described to lead to a better release of dithranol from the cream.4,5 In an earlier
study we found that salicylic acid was an irritation enhancing component of cream A.12
Since also cream B contains salicylic acid there has to be an additional reason why cream A
irritates more in the lower dithranol concentrations. Another explanation is found in the
difference with respect to the processing of the dithranol. At microscopical evaluation it
becomes clear that the physical form in which dithranol is present in both preparations
clearly differs. The flatter form of the crystals and the fact that dithranol is in a saturated
solution in cream A both lead to a more intense contact of dithranol with the skin. As the
crystals in cream A have developed after dissolving of the dithranol with salicylic acid at
preparation, the crystals will contain dithranol-salicylic acid complexes.5 These complexes
protect the dithranol from oxidation and thereby early disintegration after contact with the
skin, leaving more dithranol available for oxidation after penetration into the skin and
subsequently leading to a higher irritative reaction. As dithranol stability is concentration
dependent3, the presence of salicylic acid as a stabilising factor on the skin is of importance
especially in the lower concentrated creams, leading to a higher bio-availability of dithranol
and thereby to a higher clinical effectiveness but also to more irritation in these creams.
When our department started with dithranol short contact treatment at the day-care
unit, we looked for the best available dithranol cream. Commercially available dithranol
creams did not exist in a sufficient concentration range, so a hospital preparation was manu-
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factured. The formulation of the cream was especially chosen for its long shelf-life.7 How-
ever, manufacturing cream A is time consuming, complicated and thereby expensive. To be
able to prescribe a dithranolcream which is easier to prepare in public pharmacies and less
expensive in staff and facilities, we searched for a preparation with comparable efficacy, a
good stability and a less complicated formulation. These conditions were found in cream B.
The clinical efficacy and patients appreciation of both dithranol cream preparations is com-
parable. Both cream formulations are very suitable for short contact dithranol treatment.
Patients with less extensive localised plaque psoriasis could best be treated topically to
prevent as much as possible the irritative reactions. The preference of the patients for
cream B is probably a consequence of its lesser degree of irritation. Patients could continue
treatment with less delay after an irritative reaction, which made it easier for them to fol-
low the treatment schedule and to comply to the treatment.
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Table 3.
Efficacy and side effects (irritation and staining) when comparing different dithranol formulations as
described in the literature
Authors Cream I
Cream A 0.1% to 0.6% Cream B 0.1% to 0.6%Present study
Micanol® 1% cream Dithranol 1% in white petrolatumVolden et al. [13]
Micanol® 1% cream Amitas® stickVolden et al. [13]
Micanol® 0.1% or 0.25% cream Amitase® cream 0.1%Christensen et al. [14]
Drithocreme® 0.5% Drithocreme® 1.0%Miller AC et al. [15]
Hospital cream 0.5% Psoricreme® 0.5%Ros et al. [6]
Dithrocream 0.1% - 1.0% Dithranol 0.1% - 1.0%
in yellow soft paraffin
Grattan CEH et al. [16]
Cream II
Conclusion
Dissolving or dispersing dithranol in a cream does not directly influence short-contact
therapy effectiveness. Cream B however is easier to prepare and its quality will thereby be
more reliable when prepared by different pharmacists. Besides, it will be less expensive to
prepare. Also, the sustained and more direct availability of dithranol at low concentrations
in cream A lead to too much irritation of the healthy skin and subsequently delay of treat-
ment with consequently less compliance of the patient or eventually failure of therapy. For
these reasons, we advise cream B for short contact therapy.
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Table 3.
continued
equal equal Cream II15 - 45 min. daily
Cream II Cream I Cream I30 min. daily
Cream II equal equal30 min. daily
equal Cream I Cream IIovernight
equal Cream I Cream I30 min. daily
equal equal equal1 hr. daily
equal Cream I equal10 min. twice daily
Treatment
schedule
Best
Efficacy
Less staining
of clothes
Less iritancy,
perilesional staining
Drithocreme, psoricreme and dithrocream are the same products prepared in different countries. The formulation
contains: Dithranol, White Soft Paraffin, Salicylic Acid, Cetostearyl Alcohol, Chlorocresol, Ascorbic Acid, Sodium Lauryl
Sulphate and Purified Water. Micanol cream contains microencapsulated dithranol in crystalline monoglycerides. It
consists of: 1-Glycerylmonolaurate 7%, 1-Glycerylmonomyristate 21%, Dithranol 1%, Citric Acid 1%, Sodium hydroxide
0.14% and Water to 100%. Cream A and the Hospital cream have got the same formulation, which is described in Table 1.
References
1. van de Kerkhof PCM. Dithranol treatment for psoriasis: after 75 years, still going strong! EJD 1991; 1:79-88.
2. Schaefer H, Farber EM, Goldberg L, Schalla W. Limited application period for dithranol in psoriasis.
Br J Derm 1980; 102:571-573.
3. Green PG, Kennedy CTC, Forbes DR. Anthralin stability in various vehicles. J Am Acad Dermatol 1987; 16:984-988.
4. Kneckze M, Rahm C, Landersjo L, Lundgren P. In vitro release of anthralin from white petrolatum and an o/w cream.
Acta Pharm Nord 1989; 1(5):249-257.
5. Kneckze M, Rahm C, Landersjo L, Lundgren P. The influence of salicylic acid on the in vitro release of anthralin from
an o/w cream. Acta Pharm Nord 1990; 2(5):313-318.
6. Ros JJW, van der Meer YG, De Hoop D, De Kort WJA, van Andel P. In vitro and in vivo comparison of creams
containing dithranol 0.5%. Pharm Weekbl [Sci] 1991; 13(5):210-214.
7. Ros JJW, van der Meer YG. Preparation, analysis and stability of oil-in-water creams containing dithranol.
Eur J Hosp Pharm 1991; 1(3):77-84.
8. Prins M, Swinkels OQJ, Snater E, Metsers HC, Gerritsen MJP, van de Kerkhof PCM et al. Gecombineerde dag- en
thuisbehandeling van psoriasis met kort-contact-dithranolapplicaties. NTvDV 1997; 7:1-4.
9. Frederiksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-242.
10. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis.
Br J Dermatol 1991; 124:235-240.
11. Wiechers JW. The barrier function of the skin in relation to percutaneous absorption of drugs.
Pharm Weekbl (sci) 1989; 11(6):185-198.
12. Prins M, Swinkels OQJ, Kolkman EGW, Wuis EW, Hekster YA, van der Valk PGM. Skin Irritation by Dithranol Cream.
A Blind Study to Assess the Role of the Cream Formulation. Acta Derm Venereol (Stockh) 1998; 78:262-265.
13. Volden G, Bjornberg A, Tegner E, Bang Pedersen N, Pla Arles U-B, Agren S et al. Short-contact treatment at home
with Micanol. Acta Derm Venereol (Stockh) 1992; Suppl.[172]:20-22. 
14. Christensen OB, Enstrom Y, Juhlin L, Reidhav I, Svensson A, Bjellerup M et al. A novel Dithranol formulation in the
over night treatment of Psoriasis at home. Acta Derma Venereol (Stockh) 1992; Suppl.[172]:25-27. 1992. 
15. Miller AC. Anthralin Cream as Short Contact Therapy for Psoriasis. 1985; Cutis [June]:578-582. 
16. Grattan CEH, Christopher AP, Robinson M. A paired comparison of cream and ointment-based dithranol in short
contact treatment of psoriasis. Br J Dermatol 1987; 116:279-280. 
102
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
103
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
Chapter 6
Clinical applications of dithranol
short contact treatment
Psoriasis on a left arm;
before and after seven weeks of
dithranol short contact treatment.
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Chapter 6.1
Dithranol treatment of psoriasis
in dithranol sensitive patients
M. Prins, O.Q.J. Swinkels, J.M. Mommers, M.J.P. Gerritsen, P.G.M. van der Valk
Department of Dermatology, University Medical Centre Nijmegen, The Netherlands
Contact Dermatitis 1999; 41: 116-117.
Summary
In the past years we have seen several dithranol sensitive patients who were treated
successfully with dithranol despite a supposed allergy. Here we describe a well-documented
case, which demonstrates the possibility to treat a dithranol-sensitive patient by adjusted
low concentrations and/or exposure times. The mechanism that causes dithranol sensitiv-
ity (allergy or irritation) may be irrelevant in the treatment of the individual patient.
Introduction
Extreme sensitivity to dithranol has been described by several authors.1-5 Our broad
experience with inpatient and short contact treatment with dithranol learned us that ex-
treme irritation is rare. In the past years we treated several of the patients who reacted to
low dithranol concentrations, with adjusted dithranol concentration and/or application
time. In the individual it remains a point of discussion whether dithranol sensitivity repres-
ents a delayed type allergy or a non-immunological phenomenon. The irritant potential of
dithranol causes problems in distinguishing between allergy and irritation by patch-testing.
We report a well-documented case which demonstrates that dithranol treatment is possible
in very sensitive patients. 
Case report
Patient A, a 39 years old female psoriatic patient since 12 years, was treated with dithra-
nol elsewhere, with good clinical results. During short contact treatment with dithranol in
our day-care centre, she experienced a generalised severe exanthemic reaction after two
days of diffuse application of dithranol cream 0.1% during 15 minutes. A 3 mm punch bi-
opsy from the left upper leg showed a subacute dermatitis. She recovered in a few days and
after two weeks the majority of her psoriatic lesions had disappeared. We performed patch-
testing with the constituents of the dithranol cream base (Table 1) at which she showed no
reaction. Nine months later we performed a patch-test with different low concentrations of
dithranol in the cream base (results in Table 2). When her psoriasis deteriorated (PASI
11.3, with 20% involved skin) she started short contact therapy with 0.01% dithranol
cream. The cream was applied diffusely, left in place for 5 minutes and washed off with tap
water only. After three days the time of exposure was prolonged to 10 minutes and three
days later to 20 minutes. The exposure time was gradually prolonged to 45 minutes and
thereafter the concentration was elevated to 0.03%, with an application time of 15 min-
utes. At this step she experienced irritation. Treatment was stopped for 3 days, after which
she continued with 0.03% for 5 minutes. She experienced no more irritation and treatment
was successfully ended two weeks later (PASI 0.4, with an area of 0.5%). The dithranol
concentration had not exceeded 0.03%.
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Discussion
This case report indicates that dithranol treatment is possible in dithranol sensitive pa-
tients, even when history and patch testing are suggestive for dithranol ‘allergy’. Viluksela
et al.5 studied the contact sensitising potential of dithranol by 3 animal models (guinea pig
maximisation test, closed patch test and the mouse ear swelling test). They concluded that
dithranol has a minor contact sensitising potential and that allergy to dithranol is likely to
be very rare. Patch-testing with dithranol in sensitive patients is advised by most authors,
however they describe different irritant threshold concentrations.1-5, 7-11 There is a wide
range of dithranol concentrations (0.5% to 0.001%) which is found to be the threshold for
a positive reaction in patch-testing. This might be explained by differences in the freshness
of the test-substances, addition of stabilisers, the kind of vehicle, application-time and appli-
cation method. Our patient showed increased dithranol sensitivity. Treatment was started
with a low dithranol concentration, which was chosen after performance of a patch test to
determine the individual Minimal Erythemal Concentration (MEC). The test was perform-
ed using freshly prepared dithranol creams. The patches were left in place for 48 hours and
read at 48 hours and 72 hours. Test-chambers were obtained from van der Bend BV.,
Brielle, The Netherlands and were fixated to the testsite with Fixomull® stretch from
Beiersdorf AG., Hamburg, Germany. We started short contact treatment with a 10 times
higher dithranol concentration than the MEC. This was possible because there exists no
occlusion during treatment and the exposure time is much shorter compared to the patch
test. As described before by Haustein and Lohrisch (1986), the dithranol concentration
could be increased gradually and the psoriatic lesions could be cleared with low concen-
trations of dithranol.11 In patients with a history of high sensitivity to dithranol, a patch-
test with very low concentrations of freshly prepared dithranol, might be advised to deter-
mine the patients’ individual threshold to dithranol. Treatment should be started with an
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Table 1.
Constituents of the dithranol cream base
Vehicle
Stabilizers
Cetiol V
Cetamacrogol emulsifying wax
Liquid paraffin (viscosity 110-230 mPa.s.)
Sorbic acid
Ascorbic acid
Salicylic acid pulv < 90
Distilled water
230 grams
150 grams
150 grams
1.5 grams (0.15%)
0.5 grams (0.05%)
10 grams (1.0%)
up to 1.0 kilograms
adjusted dithranol concentration. With gradual elevation of concentration and/or exposure
time treatment should be adapted, according to the skin reaction of the patient. We postulate
that in psoriasis patients with increased dithranol sensitivity treatment with low concen-
trations and/or exposure time of dithranol can be considered useful. Whether this increased
sensitivity is caused by a delayed type allergy or by intolerance is probably irrelevant in the
treatment of the individual patient.
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Table 2.
Patch-testing results after 24 hours of application of different concentrations of dithranol cream, read
after 48 and 72 hours. ? = Erythema, no induration; + = palpable erythema; ++ = palpable erythema and
vesicles
Patient A
48 hrs
–
72 hrs
?
Dithranol concentration
0.00025 %
– ?0.0005 %
+ ?0.001 %
+ ?0.0025 %
+ +0.005 %
+ +0.01 %
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Chapter 6.2
Dithranol short contact treatment
of scalp psoriasis
M. Prins, O.Q.J. Swinkels, B. Bertholet, P.G.M. van der Valk
Department of dermatology, University Medical Centre Nijmegen, The Netherlands.
Journal of Dermatological Treatment 1999; 10: 13-17.
Summary
Scalp psoriasis often presents itself as rather therapy resistent and very patient impair-
ing. There are not many alternative treatments when descaling ointments and cortico-
steroids fail. Dithranol short-contact therapy is used as a very effective treatment in pso-
riatic lesions on the body. Little is known about its applicability on the scalp. We studied
the efficacy and side effects of dithranol short contact treatment in scalp psoriasis. 13
Patients with moderate to severe, therapy resistent psoriasis of the scalp were included. We
used the Psoriasis Area and Severity Index (PASI) to assess the clinical efficacy. All re-
ported side effects were registered. The appreciation of the treatment by the patients was
evaluated by means of a multiple choice questionnaire. Twelve patients completed the treat-
ment. Six of them showed good results (clearance >80%), 2 patients showed moderate re-
sults (clearance 40%-80%) and 4 patients showed bad results (clearance <40%). The mean
clearance after treatment was 58%. After three months of follow-up it still was 55.8%. Nine
different side effects were reported. None of these side effects resulted in interruption of
treatment for more than two days. Dithranol short contact therapy can be considered as an
alternative in the treatment of scalp psoriasis in a selected group of patients in whom
descaling ointments and topical corticosteroids are not effective.
Introduction
Psoriasis of the scalp can be particularly difficult to treat. Steroid applications share the
relative contraindications of long-term topical corticosteroid use, and pomades containing
tar are cosmetically less acceptable.1 On both agents not all patients react satisfactorily.
There exists a need for an alternative treatment of scalp psoriasis. As dithranol has shown
to be a very effective and safe therapeutic agent in the treatment of psoriasis2, it might be a
good alternative in the treatment of psoriasis of the scalp. There are few studies in which
the efficacy, side effects and practical problems of treatment of scalp psoriasis with dithra-
nol are investigated.3-5 Other studies mention dithranol treatment as a possibility, but der-
matologists apparently are not convinced of the applicability of the treatment.6-9 The aim of
this open study is to evaluate the efficacy, side effects and applicability of dithranol short-
contact treatment as an alternative for relatively therapy resistent scalp psoriasis.
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Materials and methods
Patients
The patients had to be willing to spent one hour everyday on this treatment, with the
risk of side effects. They had to have visible psoriasis lesions with a minimum area of 10%
on the scalp, which did not react satisfactorily to treatment with tar-shampoo, descaling
products and/or corticosteroids. Systemic treatment in the last three months and pregnancy
were exclusion criteria. All therapies used on the scalp had to be stopped two weeks prior
to the start of dithranol treatment.
Treatment regimen
The patients were treated daily with dithranol cream in a short contact treatment sched-
ule. During the first week of treatment they visited our out-patient clinic three times, in or-
der to give treatment instructions. A video-tape with instructions about how to apply a
cream to the scalp was available. During the second and third week the patients visited the
out-patient clinic twice, and after the third week they came once a week. Patients were
instructed to use salicylic acid 10% in ax ungia overnight, at least during 3 nights before
starting the treatment in order to reach an optimal desquamation resulting in a better pene-
tration of the working agent. To protect the surrounding skin, especially ears, forehead and
neck, vaselinum album was used. During treatment we advised to use baby-oil on the scalp,
overnight to prevent the head from drying up which would cause scaling and pruritus. The
starting concentration and application time of the dithranol cream was 0.1% for 45 min-
utes, during 3 days. Every 3 days the dithranol concentration was increased. The dithranol
cream was washed out easily with water only, followed by washing with a mild shampoo.
When irritation on the treated skin occurred, patients were advised to pass over one day
and then start again with a lower concentration and the same application time of 45 min-
utes. When side effects were mainly localized on non-involved skin, we also gave them
more instructions to prevent those. During the follow-up period of three months the pa-
tients visited the out-patient clinic once a month and were allowed to use tar-shampoo
and/or a class III corticosteroid emulsion on the remaining or recurring lesions.
Assessments
Clinical assessment of the psoriasis severity of the scalp, was done before treatment,
followed by once a week, and 1, 2 and 3 months after treatment, using a modified Psoriasis
Area and Severity Index (PASI). This so-called head-PASI was used with the following
working formula:
• Head-PASI = (Erythema-score + Induration-score + Scaling-score) x Area-score.
Erythema, induration and scaling was scored on a 4 point scale and area on a 6 point scale,
as in the original PASI.10,11 In order to score the activity of the psoriasis in general, overall
body lesions were scored every two weeks and every follow-up control. In the weekly as-
sessments all side effects reported by the patients were registered. A certain side effect was
only registered once, although the patient could have reported this side effect many times.
Pruritus on the scalp was assessed on a 10-point scale; 0 representing no itch and 10 repre-
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senting intolerable itch. It was only registered as being a side effect if it became more in-
tense during the treatment. To be able to compare the color of the hair before and after
treatment pictures were taken. In order to gain information about the patient’s apprecia-
tion of the treatment a multiple choice questionnaire with questions regarding effective-
ness, side effects, practical performance and overall appreciation was developed.
Results
Thirteen patients (4 men, 9 women) with moderate to severe psoriasis of the scalp were
included after giving written informed consent. The mean age was 47 (range 23 to 75 years).
Treatment before participation to this study varied from doing nothing (because nothing
helped) to tar shampoo only and/or a class II, III or IV corticosteroid lotion/emulsion.
Twelve patients completed the treatment. All patients had a therapy resistant, difficult
to treat scalp psoriasis, with a mean involved area of 25.8% of the head (=about 50% of the
scalp). The mean results of the assessments are shown in Table 1. The improvement in
head-PASI (clearance) is expressed in percentages. Overall the clinical effects in the patients
can be divided in three groups. Group I with good results (clearance>80%), group II with
moderate results (clearance 40-80%) and group III with bad results (clearance <40%). At
the end of treatment the head-PASI was significantly decreased, with a mean clearance of
58%. There was no change in the activity of the psoriasis on the body of the patients. The
patient who did not complete the treatment stopped after two weeks because she found it
too time-consuming to perform without help from others and her hair was out of shape.
She is included only in the assimilation of side effects. We allowed patients to rise in appli-
cation time from 45 to 60 minutes. The ending concentration and application time varied
from 2%, 45 minutes (n=1) to 7%, 60 minutes (n=2). Most patients ended with a concen-
tration of 3% for 45 or 60 minutes (n=5).
Nine different side effects were reported (Table 2), with an average of 3 side effects per
patient, ranging from 2 to 5. None of these side effects resulted in interruption of the treat-
ment for more than two days. There was no significant relationship between height of con-
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Overall 13.8 5.8 58% 7.3
II (n=2) 16 8 50% 8
Table 1.
Means of head-PASI before and after treatment, % of clearance and duration of treatment for the three
groups of patients and overall
Patient group
I (n=6) 14.8 1.3 91.8% 7.1
III (n=4) 11.3 11.5 –1.8% 7
Head-PASI before Head-PASI after Clearance Weeks of treatment
centration and appearance of side effects, although there was a peak of prevalence of new
side-effects at a dithranol concentration of 1%. 
The multiple choice questionnaire was filled in at the end by all 12 patients who com-
pleted the treatment. Most people (n=7) needed someone to help them to smear their
head. The mean duration to carry out the treatment was 53 minutes, varying from 20 to
180 minutes per day. Some patients carried out their (household) work during the 45 or 60
minutes the cream stayed on their scalp. They only counted the time actually lost on smear-
ing their head and washing out the cream. Besides the results in Table 3 patients were
asked about staining of materials (sanitary, clothes, towels etc.), which occurred in 9 pa-
tients (75%). This staining was experienced as no problem at all in 4 patients and as a little
problem in 5 of them. In case of a relapse within a few months, 6 patients would certainly
perform this treatment again, 1 patient would perhaps try it again and 5 patients did not
want to undergo the treatment again. The reasons for not choosing again for this treatment
were: no/little effect (n=4), staining of materials (n=2), irritation of the eyes (n=1) and irri-
tation of the skin (n=1).
After three months of follow-up the mean clearance of the head-PASI was 55.8%. Three
patients in group I had a clearance of 100%, one patient had a clearance of 75% compared
to the head-PASI before starting therapy. The other two patients from group I had a relapse,
with 10% and 33% clearance compared to the head-PASI before treatment. In group II and
III two patients showed a deterioration of the head-PASI compared to the score before
treatment. The other four patients showed an improvement of their head-PASI of 60, 67,
75 and 100%, compared to the score before therapy.
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Table 2.
Reported side effects
Side effects
1. Irritation of non-involved skin
Nr. of patients
9
2. Burning/stinging of the scalp 8
3. Kerato-conjunctivitis 6
4. Pruritus of the body 5
5. Pruritus of the scalp 3
6. Pustules 2
7. Staining of hair 2
8. Hair out of shape 2
9. Dermatitis of hands 1
Discussion
There appears to be a large inter-individual difference in clinical response. The com-
parison of our study with other studies in which dithranol was used on the scalp3-5 is
impossible as other preparations and dithranol concentrations are used, treatment schemes
differ and the definition of psoriasis severity and clearance are different or lacking. The
side effects we observed were all known side effects of dithranol treatment, except for the
generalized pruritus observed in 5 persons. A possible explanation for the generalized
pruritus could be the higher frequency of taking showers resulting in dryness and itch of
the skin. However this explanation can be rejected by the fact that patients who washed
their hair behind a wash stand, also suffered from pruritus on their body. Another possibil-
ity is that pruritus is caused by systemic changes induced by this local treatment. Goodfield
et al.12 investigated the systemic effect of dithranol treatment in psoriasis. They concluded
that dithranol did not significantly accumulate in the blood or other tissues but that the
treatment probably induced changes in circulating factors as yet unknown. Perhaps one of
these factors plays a role in the mechanism of pruritus. A supporting fact in this hypothesis
is that the scalp is richly vascularized, resulting in a greater permeability to and absorption
of medications.6,8 The two patients who showed distinct discoloration of their hair at the
end of the study had grey hair and dyed blond hair respectively. The gray hair turned
purple, the blond hair colored reddish. Two patients reported their hair being out of shape,
which is explained by the use of a creamy preparation, which may have the same effect as a
cream-shampoo: hair gets soft and sleek. 
Despite the great number of side-effects reported, the subjective patient findings are
more positive. More information about the clinical response of the psoriasis can be obtained
by looking at the tendencies of improvement. In 5 patients a clearance of 50% or more was
seen in the first two weeks of treatment. After this rapid improvement, two persons experi-
enced a further improvement, one stayed at the same level and two slightly increased in the
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Table 3.
Subjective experiences of patients (n=12), after treatment
much / very much
nr. of patients
Efficacy
little / no
nr. of patients
8
2
5
4
4
9
10
4
7
8
8
3
Irritation of the scalp
Irritation of non-involved skin
Irritation of the eyes
Treatment time
Overall satisfaction
head-PASI (the original level was not reached). In these latter three patients the prolongation
of the treatment seemed to have either no, or an adverse effect. The same tendency is ob-
served in two patients who, after an initial improvement in head-PASI after four weeks of
treatment, show only a slow decrease of the score during the last four weeks of treatment.
The first improvement could have been caused primarily by descaling alone, but in the
head-PASI we also observed improvement of the induration and erythema score. Another
hypothesis is that these patients do respond in the right way to the dithranol, but the con-
centrations were increased too rapidly so either the skin became irritated or the effective
dithranol concentration was reached and passed too quickly. Apparently it is hard to dis-
tinguish between erythema and scaling on the scalp caused by irritation or by the psoriasis.
This might explain the improvement of the scalp psoriasis during follow-up in 6 patients. It
is also confirmed by the findings in two persons in whom treatment was stopped after 6
weeks because the psoriasis showed a tendency to worsen. After they stopped treatment,
the head-PASI showed a remarkable improvement within two weeks. During follow-up one
patient used corticosteroid emulsion for four days a week and the other patient only used
tar-shampoo once a week. Their psoriasis stayed calm and a clearance of 67% and 100%
respectively was seen after three months. Most probably the dithranol treatment induced
an irritant-contact dermatitis, which disappeared after interruption of the treatment. 
To prevent a too rapid increase in concentration we allowed patients to rise in appli-
cation time or apply the same concentration in the same application time for a longer
period (up to 10 days, as long as a therapeutic effect was still observed) before going to a higher
dithranol concentration. Three patients experienced the strongest improvement in the
fourth week, using concentrations 0.8 or 1%. It can be concluded that at least these con-
centrations have to be reached to distinguish between no response at all or response at a
higher dithranol concentration. 
Prescription of a dithranol concentration higher than 5% was first rejected because con-
centrations beyond 3-5% on psoriasis on the body, may not further improve the therapeutic
effect.13 Because not much is known about treatment of scalp psoriasis with dithranol in
higher concentrations, we allowed two patients, who had shown a good reaction on con-
centrations up to 5%, to use a dithranol concentration of 7%. It did not further improve the
therapeutic effect.
Dithranol short contact treatment of the scalp is a rather time consuming therapy which
has to be performed by motivated patients and a motivating doctor in order to succeed.
Taking into account that we treated a selection of patients, with a rather therapy resistent
psoriasis on the scalp, dithranol short contact therapy certainly appears to be an alternative
treatment worth trying in those patients in who other treatments fail.
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Chapter 6.3
The impact of the frequency of short contact
dithranol treatment. Twice daily applications
or thrice weekly applications of dithranol.
M. Prins, O.Q.J. Swinkels, P.C.M. van de Kerkhof, P.G.M. van der Valk
Department of dermatology, University Medical Centre Nijmegen, The Netherlands.
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Summary
Dithranol short contact treatment is usually applied once a day. For some patients this
does not fit their possibilities or needs. Therefore we investigated the efficacy of two other
treatment strategies in two small groups of patients. In the attempt to shorten the treatment
time a group of patients was treated twice daily. To not withhold short contact dithranol
treatment from patients who are unable to perform the treatment daily or at home, a thrice-
weekly treatment regimen was studied.
8 Patients were treated twice daily and all achieved at least a 90% reduction of the Area
of involved skin (clearance) within 12.3 (± 1.6) weeks. In the thrice weekly group six out
of eight patients achieved a clearance of their psoriasis within 13.1 (± 4.2) weeks. The aim
to shorten the treatment period was not achieved by twice daily treatment in a day-care
centre. However, the thrice-weekly treatment regimen certainly appeared to be an effective
one. Further studies are needed on larger populations of patients to find out the optimal
regimen for intermittent dithranol short contact treatment.
Introduction
Daily application is a well-established approach in the topical treatment of psoriasis.
However, twice-daily applications, proved to be more effective as compared to once daily
applications in topical vitamin D3 treatment.1 On the other hand intermittent treatments
have been advocated in topical treatment with corticosteroids 2,3, an approach that reduces
the toxicity potential, without reducing efficacy too much whilst enhancing compliance.
Dithranol short contact treatment is applied by many dermatologists, mostly in a proto-
collised treatment regimen in which patients are treated daily. In the department of derma-
tology of the University Medical Centre st Radboud at Nijmegen in the Netherlands, dithra-
nol short contact therapy is performed in the day-care unit. The treatment protocol exists
of daily 15 to 45 minutes of dithranol application. Patients are treated in a care-instruction
programme. They visit the day-care centre twice a week to be treated and are instructed
how to treat themselves at home the other five days of the week. Instruction also implies
how to descale, how to treat the scalp if this is not treated with dithranol, how to avoid as
much as possible dithranol staining at home, how to apply and wash off the dithranol
cream, and how to recognise and react to dithranol irritation. The treatment protocol fits
many patients, certainly when it is applied with the necessary flexibility, i.e. lowering the
starting concentration or treatment time when a patient is known to be very sensitive to
dithranol irritation. 
So far, few data are available on the efficacy of dithranol treatment regimens, which
deviate from the golden standard of once daily dithranol applications. There are studies
which indicate that diminishing the application frequency would significantly rise the time
needed until clearance.4 Others studied a twice-daily application frequency of dithranol in
pasta Lassar and found no shortening of clearance time.5 We wanted to investigate if in-
creasing the application frequency of short contact dithranol therapy from once to twice
daily would enhance the efficacy. Besides that we investigated if decreasing the application
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frequency to a thrice-weekly schedule, would still be effective, whilst such a schedule might
be better ‘doable’ for those patients who cannot afford the time for daily applications of di-
thranol.
Before designing large comparative studies we set out a small-scale trial to find out the
efficacy of a twice daily treatment schedule in order to maximise dithranol efficacy and a
thrice-weekly treatment regimen in order to maximise compliance of dithranol treatment.
Patients and Methods
All patients with plaque psoriasis who were referred to the day-care unit were asked to
participate in this study. Patients were not allowed to use oral anti-psoriatics, corticoster-
oids or immunosuppressives. There were no age-limits; patients had to be fit-for-his/her-
age. Patients were not included when they had recently (within one month) used oral anti-
psoriatics or when they had recently (within two months) been treated in the day-care unit
or the dermatological inpatient ward. There was no real rule-out period for topical treat-
ments. When patients visit the outpatient clinic and are referred to the day-care unit, they
are instructed only to use indifferent moisturisers till instructions on the day-care unit.
The Psoriasis Area and Severity Index (PASI) was used to monitor the severity of the
psoriasis.6 The ‘Area of involved skin’ expressed the extensiveness of the psoriasis plaques.7
The PASI and Area were registered weekly. Patients were treated until 90% clearance of
the Area had occurred. If they wanted to continue treatment at 90% clearance, this was
tolerated as long as progress in the treatment result was seen. There was no time limitation,
but if clearing of the lesions stagnated treatment was stopped.
The treatment protocol for twice daily application was essentially comparable with that
of once daily application. We used dithranol cream according to the prescription of the
Scientific Institute of Dutch Pharmacists (dithranol cream FNA). This cream has got a shelf
life of 2 to 6 months (depending on dithranol concentration) and was prepared freshly by the
patient’s pharmacist every time a concentration adjustment was made. Dithranol is dispers-
ed in this cream and it is known to have a clinical efficacy comparable to the cream accord-
ing to Ros.8, 9 Table 1 shows the prescription of the cream.
Treatment was started with a “diffuse application” of dithranol cream 0.1% for 15 min-
utes, covering lesional and non-lesional skin. The application time and concentration were
kept the same for three days. If no irritation occurred, the application time was lengthened
to 30 minutes for another three days, after which the time was lengthened again to 45
minutes for three days. If there were no side effects, the dithranol concentration rose to
0.2% and the application time returned to 15 minutes for three days. This way the dithra-
nol concentration rose every nine days and the application scheme could be applied over
and over. If irritation occurred the application time and/or dithranol concentration was
lowered. If patients were known or appeared to be sensitive to dithranol irritation a lower
concentration or shorter application time was chosen. Dithranol cream was prescribed in
the following concentrations: 0.1%, 0.2%, 0.3%, 0.4%, 0.6%, 0.8%, 1.0%, 2.0%, 3.0%
and 5.0%. If a lower concentration was necessary 0.01%, 0.03% or 0.05% could be used.
The treatment was performed in the morning and in the evening. The evening application
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had a fixed duration of 15 minutes, and was shortened in case of irritation. This applica-
tion was diffuse or restricted to lesional skin, depending on the patients’ skin reactions and
the severity and location of the psoriasis. The dithranol concentrations of the morning- and
evening application were allowed to rise independently. Patients visited the day-care unit
daily during the first week of treatment to be instructed and to get used to the treatment.
Following the first week, the visits to the day-care unit were limited to twice weekly. The
patients treated themselves the remaining five days. Besides dithranol creams they were
allowed to use descaling ointments (10% salicylic acid in vaseline for the skin and 10% sali-
cylic acid in ung. Cetomacrogolis for the scalp), moisturising ointments and if necessary inter-
mittent topical corticosteroid lotion (desoximetasone) to treat their scalp. 
In the treatment protocol for thrice-weekly treatment it was aimed to keep the swiftness
in rising of dithranol concentration comparable to that during the daily treatment (approxi-
mately every 9 days a higher concentration). Application times were lowered to minimise
irritation and applications did not exceed 20 minutes. The dithranol concentration or
application time was adjusted every two applications. Dithranol cream was prescribed in
the same concentrations as in twice daily treatment. Treatment was started diffusely with a
10 minutes application of 0.1% dithranol cream. If no irritation occurred after two appli-
cations, the application was lengthened to 20 minutes. After two applications the dithranol
concentration was increased to 0.2% and the application time returned to 10 minutes. Pa-
tients were treated in the day-care unit on Monday, Wednesday and Friday. Dithranol
treatment was not performed at home, which makes this treatment suited for patients who
are unable to treat at home because of age, immobility or lack of help. Dithranol was pre-
scribed in the same concentrations as in twice daily treatment. At home patients were al-
lowed to use descaling ointments (10% salicylic acid in vaseline for the skin and 10% salicy-
lic acid in ung. Cetomacrogolis for the scalp), moisturising ointments and if necessary inter-
mittent topical corticosteroid lotion (desoximetasone) to treat their scalp.
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Table 1.
Prescription of dithranol cream FNA
Dithranol cream FNA
Dithranol x gram
Ascorbic acid 1 gram
Salicyclic acid 10 grams
Cremor Lanette I FNA ad 1000 grams
Cetiol V® (decyl oleate) 200 grams
Emulsifying cetostearyl alcohol 150 grams
Sorbitol 70 percent crystallising 40 grams
Sorbic acid 1,5 grams
Prurified water 585 grams
Results
8 Patients (4 men, 4 women, mean age 45.3 years, spread 33-68 years) were treated twice
daily and 9 patients (5 men, 4 women, mean age 57.1 years, spread 32-74 years) thrice
weekly. The courses of the Area during both treatments are figured out for every patient
separately in Figure 1 and 2. At the start of treatment a large variation in severity of pso-
riasis was observed in both treatment groups. However, generally the “twice-daily group”
and the “thrice-weekly group” were comparable although patients in the thrice-weekly group
tended to have a more widespread psoriasis. One patient from the thrice-weekly group
developed a psoriatic erythroderma during the second week of treatment and was left out
of the analysis (Figure 2, pt6). Mean treatment results are illustrated in Table 2.
The twice-daily group showed a pronounced improvement. The mean Area was reduced
by 96.3% and the mean PASI by 94.2% following a treatment time of 12.3 ± 1.6 (mean ±
SD). All patients in this group achieved at least 90% clearance.
The thrice-weekly group also showed an impressive improvement. The mean Area was
reduced by 87.0% and the mean PASI by 82.3% following a treatment period of 13.1 ± 4.2
weeks (mean ± SD). In this group 6 out of 8 patients achieved a clearance of 90% or more.
One patient had to stop because of an operation on an aneurysm of the iliac artery (Figure 2,
pt5). This patient had a reduction of the Area by 81.5% after 13 weeks of treatment. Another
patient wanted to stop treatment because no significant improvement appeared beyond a
72.4% reduction of the Area after 15 weeks (Figure 2, pt.7)
Comparing the twice-daily schedule with the thrice-weekly schedule no meaningful
statistical analysis can be given at these sizes of study groups. However these preliminary
results provide evidence that the length of treatment is comparable and that the improve-
ment in the thrice weekly group is only slightly inferior to the twice-daily group. 
The occurrence of irritation was comparable in both groups. In both treatments 4 pa-
tients had to lower the starting dithranol concentration to 0.05% or lower (once 0.03% and
once 0.01%) because of irritation. During treatment irritation occurred in five patients of
the twice-daily group and in four of the thrice weekly group. To avoid irritation and pro-
mote therapy result, the second application in the twice-daily group was performed locally
in 5 patients. This way the dithranol concentration of the second application could rise,
while the first application could be adjusted to the patients’ skin reaction.
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Table 2.
Mean treatment time, Area and PASI at start and at the end (± SD), and success-rate
(percentage of patients with 90% clearance or more) of both treatment regimens
Treatment regimen
Treatment time (weeks) 12.3 (± 1.6) 13.1 (± 4.2)
Area at start 14.3 (± 8.1) 22.3 (± 14.4)
Area at end 0.5 (± 0.2) 2.9 (± 3.1)
PASI at start 10.4 (± 3.2) 12.8 (± 6.0)
PASI at end 0.6 (± 0.6) 2.3 (± 1.9)
Success-rate 100 % 75 %
Thrice weekly (N=8)Twice daily (N=8)
Figure 1. 
Time courses of the Area (%)
per patient of twice daily
dithranol treatment.
Figure 2. 
Time courses of the Area (%)
per patient of thrice weekly
dithranol treatment.
Discussion
Since the introduction of short contact therapy in 1980 different contact times and ap-
plication schemes have been described.4,10-15 Runne and Kunze4 studied the influence of
dithranol application, with dithranol in a salicylic acid/vaseline base, every second or third
day and found that it lengthened the necessary treatment time. We as well saw a lengthen-
ing of treatment time when treatment was performed thrice weekly instead of daily. They
also describe that patients who treated themselves at home took longer to achieve the same
clinical results compared to patients who were treated at the day-care centre. In the twice-
daily treatment, patients were expected to treat themselves at home five days a week. The
quality and regularity of the treatment in a day care center is not superior per se over home
treatment, but it is known that patients’ compliance is variable in home treatment. Of the
treatments performed at the day-care centre it is sure that they are performed the way it
was supposed to be. 
Recently a large study was carried out on the cost effectiveness of a care instruction
programme for short contact dithranol treatment (see Chapter 2.2). This approach was a
further popularisation of day-care by instructing the patients to carry out the treatment
themselves at home. Of that study, the outcome parameters “treatment time”, “Area at
start”, “PASI at start” and success-rate (percentage of patients with 90% clearance of the Area
of involved skin) are summarised in Table 3. We cannot really compare the results of our
pilot twice daily and thrice-weekly study with the outcomes of this large study. The study
groups differ too much in size and in the way the studies were set up. But the results of the
large once daily application study can function as a standard for the outcomes of the two
pilot groups. In a future study it would be possible to overcome the effect of interpersonal
varia-tion in reaction to dithranol and the lack of a control group by designing a left-right
com-paring study. This would also make it possible to study the efficacy of different
treatment regimens in relative small patient groups.
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Table 3.
The mean (± SD) treatment time, Area and PASI at start and success-rate (percentage of patients with
90% clearance or more) of once daily dithranol treatment in a day-care instruction programme
Treatment regimen
Treatment time (weeks) 10.3 (± 2.4)
Area at start 21.0 (± 13.8)
PASI at start 15.3 (± 6.9)
Success-rate 59 % (59/100)
Once daily (N=100)
If we compare the twice daily modification with the standard group of the care instruc-
tion programme for short contact dithranol treatment we cautious state that twice daily
dithranol application did not shorten the duration of the treatment as we hoped it would
do. Others were also unable to find a benefit of twice daily application. Statham5 studied
the effect of local application of Lassar’s paste for two hours twice daily and found no
quicker clearance. Still in our 8 patients there seemed to be a benefit in clearing the persis-
tent lesions when dithranol was applied twice daily. Also twice daily therapy seemed to be
more effective as it did lead to 90% clearance of the psoriasis in all patients. Therefore the
twice daily application schedule could be useful in patients having a poor improvement as
an attempt to enhance efficacy.
If we compare the thrice-weekly modification with the standard group, we see an indi-
cation that the thrice-weekly treatment regimen can be an effective regimen for patients
who are unable to treat at home or every day. Patients and doctors should however be
aware that thrice weekly treatment with dithranol takes longer compared to daily treat-
ment and is not a treatment regimen of first choice. Therefore we may offer this intermit-
tent schedule as a treatment approach for those patients who cannot afford daily treat-
ments in their daily life. Thrice weekly treatment with short contact dithranol applications
might also be used as an additive treatment in combination with UVB phototherapy 16,17 or
corticosteroids.18 An intermittent short contact dithranol treatment combined with calci-
potriol might prove to be effective as well.
This study was a pilot set up to investigate if there are differences in effectiveness be-
tween different treatment regimens and to evaluate if a larger study must be performed to
search the best treatment option. Because the two groups we studied are small and hetero-
geneous in PASI and Area, especially in comparison with our reference group, the prelimi-
nary conclusion can be that although twice daily and thrice weekly dithranol treatment can
be useful for specific patients, once daily dithranol treatment stays the ‘golden standard’.
Further studies in larger patient groups are certainly indicated to find out the possibilities
in modification of the frequency of dithranol application. 
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Chapter 7
Summary and Discussion
Introduction
Dithranol is a well-established treatment for patients with moderate to severe psoriasis.
In this thesis the cost effectiveness and improvement of health-related quality of life were
investigated in an open randomised controlled multicentre study comparing a care instruc-
tion programme for short contact dithranol treatment, classical inpatient dithranol treat-
ment and UVB phototherapy. In this study two aims were defined:
1.1 To assess the cost effectiveness of treatment of moderate to severe psoriasis with
dithranol short contact treatment in a care instruction programme at a day-care
centre, compared to inpatient dithranol treatment and UVB phototherapy.
1.2 To study Health-Related Quality of Life (HRQoL) in patients with moderate to
severe psoriasis treated with dithranol short contact treatment in a care instruction
programme at a day-care centre, inpatient dithranol treatment, or UVB phototherapy.
In order to popularise dithranol treatment, the cream compounds and the manufacturing
procedure of dithranol cream, together with several clinical applications were also investi-
gated. In this part two aims were defined:
2.1 To improve dithranol short contact treatment by studying the influence of the
dithranol cream vehicle and the way dithranol was proceeded in this cream.
2.2 To investigate and broaden the spectrum of use of dithranol short contact treat-
ment.
The most important conclusions of the thesis are summarised and discussed in this chapter.
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Part I 
Cost effectiveness and Health-Related Quality of Life 
Summary of results
Chapter 1 describes the clinical management of psoriasis and provides insight in the
current available treatments for moderate to severe psoriasis. Supplementary it discusses
dermatological and psoriasis day-care.
In Chapter 2 first the Dutch health care system and the basics of a cost effectiveness
analysis (CEA) are expatiated. The cost effectiveness of dithranol short contact treatment
in a care instruction programme at a day-care centre is described and contrasted with classi-
cal inpatient dithranol treatment and UVB phototherapy. 
The analysis included medical and non-medical costs of the three treatments. The mean
overall costs per patient during treatment were € 1,641 for short contact treatment, € 1,258
for UVB phototherapy and € 7,706 for inpatient treatment. During remission the costs per
month per patient were € 19 after short contact treatment, € 5 after UVB phototherapy and
€ 25 after inpatient treatment. The clinical response rates (at least 90% improvement of the
area of involved skin) were 57% (short contact treatment), 57% (UVB phototherapy), and 85%
(inpatient treatment). The mean number of clearance-days after short contact treatment was
160 (median 119; interquartile range [0-357]), which was not significantly different from
the other two strategies: 136 clearance-days after UVB phototherapy (81 [0-266]), and 211
clearance-days after inpatient treatment (241 [99-350]). Concluding: short contact dithra-
nol treatment is an attractive alternative for patients with moderate to severe psoriasis
currently treated by inpatient treatment, as the costs of short contact treatment were signi-
ficantly lower and the number of clearance days were not significantly different. Consider-
ing the higher costs, short contact treatment is not a first choice treatment compared to
UVB phototherapy.
In Chapter 3 Health Related Quality of Life (HRQoL) in psoriasis was studied. The
introduction describes the psychosocial consequences of having psoriasis. Patients cope
differently with psoriasis. Embarrassment, feelings of anger, depression, shame and trouble
forming social relationships are some of the psychosocial consequences reported by pa-
tients. There is a higher incidence of depression and suicidal thoughts amongst psoriasis
patients. The necessity of measuring HRQoL besides clinical measures to evaluate medical
interventions is pointed out, followed by a short explanation of what HRQoL is and how it
can be measured accurately. 
Health-Related Quality of Life of patients with moderate to severe psoriasis treated by
short contact dithranol treatment in a care instruction programme, UVB phototherapy, or
inpatient dithranol treatment is described. It was evaluated in an open randomised multi-
centre study by appliance of the Dutch short-form of the Sickness Impact Profile (SIP68)
and the Psoriasis Disability Index (PDI). All three treatment modalities led to substantial
improvement in HRQoL, however patients treated by short contact treatment scored signi-
ficantly better in several sub-scales compared to inpatients. Patients treated with UVB
phototherapy or dithranol short contact treatment had a better overall HRQoL compared to
inpatients. 
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Methodological consideration
Randomisation as close as possible to reality of care
The studies presented in Chapters 2 and 3 both resulted from the same national multi-
centre study. Randomised, double blind controlled studies is the optimal approach for
treatment evaluations. The present study is not double blind as the differences between the
treatments are not permitting a double blind approach. The randomisation comprised three
different strata in order to include patients in an as natural possible way.
In cost effectiveness and Quality of Life studies inclusion of patients should be as close
as possible to reality of care. Artificial designs of randomisation and masking of identity of
treatments to reach the double blind quality level do not permit quality of life and cost
effectiveness studies. It is clear that next to randomised double blind controlled studies, cost
effectiveness and quality of life studies are required that demand designs different from the
traditional double blind controlled approaches.
Considerations how to make a treatment selection
Patients with moderate to severe psoriasis in general have been treated with various
commonly used topical treatments such as vitamin D3 analogues, corticosteroids and
phototherapy. A limitation of topical treatments is that daily applications are demanding
for the patients. Besides, the efficacy of vitamin D3 monotherapy is not sufficient in at least
20% of the patients, and topical corticosteroids - although effective as monotherapy and in
particular in combination treatments - can only be used in a restricted way because of the
dose-related side-effects.1 Long-term safety data are limited and cutaneous and systemic
side effects may limit this approach.2
For patients with a restricted plaque psoriasis (< 10% of body surface involved) not re-
sponding to the formerly described therapies, a selection for UVB phototherapy or dithra-
nol according to a care instruction programme can be made. As the clinical response rates
are comparable and the remission time in restricted plaque psoriasis is best for UVB photo-
therapy, this approach should be preferred unless contraindications exist. In more wide-
spread psoriasis (≥ 10% of body surface involved) a selection for UVB phototherapy, dithra-
nol according to a care instruction programme, and inpatient treatment has to be made.
When considering the effectiveness in terms of clinical response rate and remission time,
treatment with dithranol according to a care instruction programme at a day-care centre
should be preferred.3 In the CEA next to clinical response rate, not the remission time but
the number of clearance days was considered as a measure of effectiveness. Considering the
higher costs, short contact treatment is not a first choice treatment compared to UVB
phototherapy, but certainly stands a very well second. Especially because of dithranol’s bet-
ter safety profile, and the recurrent need for treatment, both therapies can be used in turns
as long as no contra-indications exist for UVB phototherapy. Inpatient treatment with
dithranol is indicated in patients who have been shown to be not sufficiently responsive to
UVB phototherapy or short contact dithranol treatment according to a care instruction pro-
gramme.
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In patients who are not responsive neither to UVB phototherapy nor to dithranol short
contact nor to dithranol inpatient treatment, systemic treatments are indicated, including
photochemotherapy, methotrexate, cyclosporin, and acitretin.
There remains however a group of patients who are not responsive to the treatments
available so far. In fact, according to a survey under patients of the American patients asso-
ciation, 40% proved to be unsatisfied with the treatments available so far. Reasons are in-
sufficient efficacy, side effects and difficult to use.4 It needs noticing however, that dithranol
therapy is not commonly practised in the United States of America. Therefore research is
worthwhile to develop and improve the treatment of psoriasis. In general, two approaches
are possible to improve quality of care for psoriasis:
1. Development of care instruction programmes to improve compliance and to popularise
existing treatments. The care instruction programme for dithranol short contact treat-
ment as described in this thesis has been shown to provide an excellent example for fur-
ther treatment developments.
2. Development of new systemic therapeutics.
Implementation of Short Contact treatment in the current health care system
To be able to perform short contact dithranol treatment for psoriasis in a care instruc-
tion programme at a day-care centre some conditions have to be fulfilled:
1. More dermatological day-care facilities (intra- and extramural) should become known
with this kind of treatment, so a nation-wide network of care instruction centres arises,
that can develop treatment protocols and quality controls over the given treatments.
2. These day-care facilities have to treat a sufficient number of patients to gain and keep
the needed expertise amongst specialists and nursing staff.
3. The geographic spread of these centres has to be such that patients can reach the centre
within a reasonable time.
4. To finance high quality day-care facilities, that on one hand provide day-care for pso-
riasis patients nation-wide, but at the same time define and assure the minimum quality
criteria, in order to prevent a poor quality of day-care. 
The cost effectiveness analysis described in Chapter 2 must be considered as a paradigm
and one may speculate on extrapolation to other comparable care instruction treatment
programmes for atopic dermatitis, severe hand- and foot dermatoses, and leg ulcers.
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Part II 
Formulations and applications of dithranol
Summary of results
Chapter 4 is an introduction to Chapters 5 and 6 and provides evidence for the effec-
tiveness and safety of dithranol. It describes dithranol history, its pharmacology and mode
of action, its formulation and treatment regimens, indications and contraindications, its
side effects and what has been tried to deminish the most important side-effects (staining
and irritation) up to now.
Chapter 5 discusses the role of the cream formulation in dithranol irritation and in cli-
nical efficacy, side effects and patient appreciation. In Chapter 5.1 dithranol cream A was
used with different compositions of its ingredients. The major conclusions concerning this
study is that the formulation of dithranol cream is of importance in dithranolirritation,
whereas salicylic acid aggravated the dithranol-induced erythema in cream A. It gave rise to
42% more irritation than the dithranol creams with only sorbic acid or no stabilizers at all.
Stability tests showed no significant degradation of dithranol in the two less irritating
creams when kept at 4º C for 11 months. 
To evaluate clinical effectiveness, side effects and patients appreciation again cream A
was used and compared to cream B in Chapter 5.2 in a double-blind left-right comparing
study. Dithranol was dissolved at preparation in cream A and dispersed in cream B. Disper-
sion of dithranol in a cream was associated with less irritation and less discoloration of the
skin, and its efficacy was comparable with that of cream A. As the dispersed dithranol
formulation is easier to be manufactured, its quality is less affected by the pharmacist’s ex-
perience and equipment, and so the manufacturing is more reliable. Besides, it is less
expensive to prepare. 
As described in Chapter 6.1 the irritant potential of dithranol makes the distinction be-
tween allergy and irritation by patch testing difficult. Dithranol treatment, however, seems
possible even in very sensitive patients, though with extreme low concentrations. We pos-
tulate that although patients may have increased dithranol sensitivity caused by either a
delayed-type allergy or intolerance, their psoriasis still might be cleared by treatment with
dithranol. 
Scalp psoriasis is often rather therapy resistant and very patient impairing. The present
treatments for scalp psoriasis are limited. Dithranol short contact treatment is described in
Chapter 6.2 to be worth trying as an alternative in the treatment of scalp psoriasis in a
selected group of patients in whom descaling ointments and topical corticosteroids are not
effective. 
Dithranol short contact treatment is usually applied once every day. An intermittent ap-
plication regimen for short contact dithranol treatment is presented in Chapter 6.3 as an
effective dithranol treatment. On the other hand shortening the treatment period was not
achieved by twice daily treatment with dithranol short contact treatment in a care instruc-
tion programme at a day-care centre.
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Discussion
As cream A and cream B had a comparable effectiveness, with less irritation and an
easier manufactory of cream B, the day-care facility of the UMC st Radboud changed from
cream A to cream B. The fact that the preparation is less difficult is a very important
advantage. This provides availability of dithranol short contact treatment with a cream of a
reliable quality and with a shelf life of several months for all patients in the Netherlands.
Scalp involvement occurs in 79% of psoriasis patients. The most frequently used treat-
ment is topical corticosteroids and vitamin D3 preparations.5 The present thesis shows that
the use of dithranol creams provides an effective alternative principle that is well tolerated.
The application of dithranol three times a week provides an important advantage above
once daily treatment, it facilitates dithranol treatment of patients who are unable to treat
every day and by doing so, it makes dithranol treatment available for a larger group of pa-
tients.
Further research is needed to investigate if less irritating cream preparations with re-
maining clinical effectiveness can be formulated, and to further explore the clinical possi-
bilities of this old but still very effective psoriasis treatment.
Overall conclusions
Dithranol short contact treatment of patients with moderate to severe psoriasis is a
highly effective and safe treatment. The present thesis has shown that treatment in a care
instruction programme at a day-care centre is cost effective and results in improvement of
HRQoL. Besides that, it results in prolonged remissions when compared to UVB photo-
therapy and inpatient dithranol treatment. These conclusions are reported to the Health
Care Insurance Board.6 The report will lead to an advice to the Minister of health. If dithra-
nol short contact treatment is added to the package of benefits that is included in the social
health insurance schemes, this treatment will become possible in dermatological centres all
over the Netherlands.
Besides the thesis provides several ways to popularise this time honoured approach:
1. Availability of the cream by making the dithranol formulation easier
2. Treatment of difficult localisations such as the scalp
3. Treatment of dithranol sensitive patients
4. Intermittent treatment schedules adjusted to patients needs and possibilities
Dithranol sometimes is neglected as an appropriate psoriasis treatment because of its
irritating and staining properties. These two negative aspects should of course not be un-
derestimated, but they certainly should not overrule the positive aspects of dithranol. The
present thesis provides further evidence that dithranol is an excellent and outstanding
treatment facility for moderate to severe psoriasis, permitting a safe management of pso-
riasis, also if recurrent treatments are needed. The care instruction programme for short
contact dithranol treatment has optimised outpatient acceptability of dithranol treatment,
and this innovation permits a prolongation of a century of dithranol history.
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Samenvatting
Inleiding
Psoriasis is een chronische huidaandoening die voorkomt bij 2-3% van de West-
Europese populatie. Afhankelijk van de uitgebreidheid van de aandoening kan worden
gekozen voor verscheidene lokale of systemische therapieën Dit proefschrift richt zich op
de behandeling van matig tot ernstig uitgebreide psoriasis (>10% van het lichaamsopper-
vlak aangedaan) met de kortcontact ditranolbehandeling volgens een zorg-instructie pro-
gramma. Hierbij wordt de patiënt twee dagen in de week behandeld met ditranolcrème in
een dermatologisch dagbehandelcentrum of op een afdeling voor Arbeids- en Tijdsintensie-
ve Behandeling (ATB). De overige vijf dagen van de week behandelt de patiënt zichzelf
thuis. Het proefschrift is opgedeeld in twee delen. 
Deel I omvat resultaten van een Ontwikkelingsgeneeskunde project, gefinancierd door
het College voor Zorgverzekeringen (voorheen ziekenfondsraad). Middels een open, geran-
domiseerd, gecontroleerd onderzoek in zes centra in Nederland, is de kosteneffectiviteit
van de kortcontact ditranolbehandeling voor matig tot ernstig uitgebreide psoriasis geëva-
lueerd. Deze kosteneffectiviteit werd afgezet tegen die van de UVB lichttherapie, en van de
klinische ditranolbehandeling. Daarnaast werd de gezondheidsgerelateerde kwaliteit van
leven bij deze groep patiënten onderzocht. 
Twee vraagstellingen werden gedefinieerd:
1.1 Is de behandeling van matig tot ernstig uitgebreide psoriasis met de kortcontact di-
tranolbehandeling in een zorg-instructie programma kosteneffectief, vergeleken met
de UVB lichttherapie en de klinische ditranolbehandeling?
1.2 Wat is het effect van de kortcontact ditranolbehandeling in een zorg-instructie pro-
gramma, de UVB lichttherapie of de klinische ditranolbehandeling op de gezondheids-
gerelateerde kwaliteit van leven, van patiënten met een matig tot ernstig uitgebreide
psoriasis.
In Deel II worden kleinere, zijdelings uitgevoerde onderzoeken beschreven, met als doel de
beschikbaarheid en de populariteit van kortcontact ditranolbehandeling te vergroten. In dit
deel werden eveneens twee onderzoeksdoelen geformuleerd:
2.1 Verbetering van de kortcontact ditranolbehandeling door onderzoek naar de rol van
de samenstelling van het vehiculum en de manier waarop ditranol in de crème is ver-
werkt.
2.2 Onderzoek naar, en verruiming van, de klinische toepasbaarheid van de kortcontact
ditranolbehandeling.
In Hoofdstuk 1 worden de huidige inzichten over de ontstaanswijze van psoriasis, de
klinische kenmerken en de beschikbare behandelmogelijkheden uiteengezet. 
Dagbehandeling wordt in toenemende mate gezien als de toekomst voor therapieën die
momenteel klinisch gegeven worden. Er wordt ingegaan op dagbehandeling in het alge-
meen en dermatologische dagbehandeling, met de voorwaarden waaraan deze zou moeten
voldoen. 
134
Dithranol in Psoriasis Day-Care. The Short Contact Principle.
Deel I: kosteneffectiviteit en kwaliteit van leven
In Hoofdstuk 2.1 wordt een uiteenzetting gegeven over de organisatiestructuur van de
Nederlandse gezondheidszorg. De rol van het College voor Zorgverzekeringen en het minis-
terie van volksgezondheid, in de besluitvorming rond de financiering van voorzieningen
binnen de gezondheidszorg, wordt belicht. De grondbeginselen van een kosteneffectiviteits-
onderzoek (KEA) worden beschreven. 
In Hoofdstuk 2.2 wordt de kosteneffectiviteit van kortcontact ditranolbehandeling in
een zorg-instructie programma in dagbehandeling beschreven, en afgezet tegen de kosten-
effectiviteit van de UVB lichttherapie en de klassieke klinische ditranolbehandeling. Deze
analyse omvat medische en niet-medische kosten van de drie behandelingen. De gemiddel-
de algehele kosten per patiënt gedurende de behandeling waren € 1.641 (kortcontact behan-
deling), € 1.258 (UVB lichttherapie) en € 7.706 (klinische behandeling). Gedurende de
remissieperiode waren de kosten per maand, per patiënt € 19 na kortcontact behandeling,
€ 5 na UVB lichttherapie en € 25 na klinische behandeling. De behandeling werd als ge-
slaagd beschouwd, bij 90% reductie van de met psoriasis aangedane huidoppervlakte. Het
gemiddelde aantal dagen tot het optreden van een remissie (terugkeer van de psoriasis tot
50% van de oorspronkelijke oppervlakte aangedane huid) bij kortcontact ditranol-behande-
ling was 160 dagen [mediaan 119, interkwartiel interval 0-357], hetgeen niet significant
verschillend was van de andere twee behandelstrategieën. Uit dit onderzoek wordt gecon-
cludeerd dat kortcontact ditranolbehandeling een goed behandelalternatief is voor pa-
tiënten die momenteel behandeld worden middels klinische ditranolbehandeling, aangezien
de kosten lager, en het aantal dagen tot het optreden van een remissie niet significant ver-
schillend zijn. Gezien de hogere kosten, is het geen eerste keus behandeling vergeleken met
UVB lichttherapie.
In Hoofdstuk 3 wordt gezondheidsgerelateerde kwaliteit van leven bij patiënten met een
matig tot ernstig uitgebreide psoriasis onderzocht. In de introductie worden de psycho-
sociale consequenties van psoriasis beschreven. Schaamte, boosheid, depressieve gevoelens,
en problemen met het aangaan en onderhouden van sociale contacten en relaties, zijn enkele
van de uitgebreide lijst van genoemde psychosociale gevolgen, beschreven bij psoriasis-
patiënten. Er wordt een uiteenzetting gegeven over de noodzaak tot het meten van kwaliteit
van leven naast het meten van klinische effectmaten om medische interventies te eva-
lueren. Hierna volgt een korte uitleg over wat gezondheidsgerelateerde kwaliteit van leven
is en hoe deze het beste gemeten kan worden.
In Hoofdstuk 3.2 wordt de kwaliteit van leven van patiënten met matig tot ernstige
psoriasis behandeld met kortcontact ditranolbehandeling, UVB lichttherapie of klinische
ditranolbehandeling beschreven. In dit onderzoek is gebruik gemaakt van twee kwaliteit-
van-leven vragenlijsten: de Nederlandse verkorte versie van de Sickness Impact Profile
(SIP68) en de Psoriasis Disability Index (PDI). Alle drie de behandelingen leidden tot een
substantiële verbetering in kwaliteit van leven. Patiënten met kortcontact ditranolbehande-
ling scoorden significant beter in verscheidene subschalen, in vergelijking tot klinische
patiënten. Over het geheel genomen hadden klinische patiënten een slechtere kwaliteit-
van-leven score.
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Deel II: Formuleringen en toepassingen van ditranolcrème
Hoofdstuk 4 geeft een inleiding over ditranol, de geschiedenis, de farmacologie en het
werkingsmechanisme, formuleringen en behandelmethodes, indicaties en contra indicaties,
bijwerkingen, en de tot op heden uitgevoerde onderzoeken om deze bijwerkingen te ver-
minderen.
In Hoofdstuk 5 wordt de invloed van de samenstelling van ditranolcrème op ditranol-
irritatie, op overige bijwerkingen en op de klinische effectiviteit besproken. In Hoofdstuk
5.1 wordt ditranolcrème A in verschillende samenstellingen getest op irritatie, op de rug
van gezonde vrijwilligers. De belangrijkste conclusie is dat de samenstelling van de crème
invloed heeft op ditranolirritatie. In crèmes met salicylzuur, een van de stabilisatoren van
de crème, trad een 42% ergere irritatie op dan in crèmes met alleen sorbinezuur als stabili-
sator of zonder stabilisatoren. Stabiliteitstesten toonden geen significante degradatie van
ditranol in de twee minst irriterende crèmes, gedurende 11 maanden, bewaard bij 4ºC. 
De klinische effectiviteit, bijwerkingen en waardering door de patiënt werden getoetst in
dubbel-blind links-rechts vergelijkend onderzoek met crème A en crème B. De ditranol
werd bij de bereiding opgelost in crème A en afgewreven in crème B. Afwrijven van de
ditranol in de crème bleek minder irritatie en minder verkleuring van de huid te geven, ter-
wijl de effectiviteit van beide crèmes vergelijkbaar was. Het bijkomend voordeel van een
crème waarin de ditranol wordt afgewreven is dat deze makkelijker te bereiden is, waar-
door de kwaliteit van de crème minder afhankelijk is van de apotheker’s ervaring met het
bereidingsproces.
In Hoofdstuk 6 worden verschillende toepassingen van ditranol beschreven. Kortcon-
tact ditranolbehandeling in een zorg-instructie programma, uitgevoerd in een dagbehan-
delcentrum, is mogelijk in heel lage concentraties bij extreem ditranolirritatie-gevoelige
patiënten. Ditranolbehandeling van de hoofdhuid wordt beschreven en blijkt het overwe-
gen waard te zijn, als met de reguliere behandelingen geen resultaat wordt behaald. Ditranol-
behandeling in een behandelschema, aangepast aan de behoefte of de mogelijkheden van de
patiënt, wordt besproken. Tweemaal daags behandeling blijkt geen significante verkorting
van de behandelperiode te geven, driemaal per week behandeling blijkt echter een goed alter-
natief voor die patiënten waarvoor een dagelijkse behandeling onmogelijk is.
Concluderend kan worden gezegd dat de vraagstellingen van dit proefschrift zijn be-
antwoord en de doelstellingen zijn behaald. Er is een begin gemaakt voor verder onderzoek
naar de juiste samenstelling van ‘de ideale ditranolcrème’. De beschikbaarheid van ditranol-
behandeling voor elke patiënt in Nederland is vergroot, door gebruik van een minder inge-
wikkelde samenstelling van de ditranolcrème. Onderzoek in studies met grotere patiënten-
aantallen zijn gewenst om de ruime klinische toepasbaarheid van kortcontact ditranol-
behandeling verder uit te diepen.
Kortcontact ditranolbehandeling in een zorg-instructie programma is een kosteneffec-
tieve behandeling, die leidt tot een verbetering in de gezondheidsgerelateerde kwaliteit van
leven. Hiermee is een basis gelegd voor de goedkeuring van deze behandeling door het Col-
lege voor Zorgverzekering en daarmee de financiering van deze behandeling, zodat derma-
tologische centra in Nederland de behandeling kunnen aanbieden aan patiënten.
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Dit proefschrift heeft alleen tot stand kunnen komen door samenwerking met velen.
Niet iedereen zal hier bij name genoemd kunnen worden, toch wil ik een poging onder-
nemen om de belangrijkste mensen te vermelden.
Allereerst dank aan diegenen die dit proefschrift mogelijk hebben gemaakt.
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Ook dank aan Hanneke Metsers en Quintus Swinkels. Als ‘het onderzoeksteam’ hebben we
heel wat gezellige uren in kamer 007 doorgebracht met hard werken, discussiëren, de wereld
verbeteren en lachen. Daarnaast dank voor de hulp van Rianne Gerritsen bij het doorlezen
van stukken, evalueren van te volgen stappen tijdens de studie, en klinisch advies.
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met andere disciplines binnen het UMC st Radboud. Ab van Zon, staf medische zaken,
bedankt voor de raadgeving tijdens de stuurgroep bijeenkomsten. Theo de Boo, afdeling
‘Epidemiologie en Biostatistiek’, hartelijk bedankt voor je geduld, uitleg en adviezen over
de door ons soms moeilijk te begrijpen statistische methoden. Gert-Jan van der Wilt, Hans
Severens, Gina Wielink en Margriet Hartman, van de afdeling ‘Medical Technology Assess-
ment’: jullie waren altijd aanspreekbaar en gewillig om uitleg of advies te geven over
onderzoekstechnische zaken die ons de pet te boven gingen. Paul Krabbe, bedankt voor je
kundig advies bij het schrijven over kwaliteit van leven, en het maken van de figuren. Albert
Reintjes en Wim Lemmens heel hartelijk dank voor het maken van een statistiek program-
ma waarin al onze duizenden gegevens konden worden verwerkt en omgezet naar de uit-
eindelijke resultaten. 
De uitvoering van het Ontwikkelingsgeneeskunde project leidde tot veel contacten bui-
ten het UMC st Radboud. Mijn dank gaat uit naar de medewerkers van de afdeling derma-
tologie van het Universitair Medisch Centrum Utrecht, het ‘Psoriasis dagbehandelcentrum’
te Ede, het Academisch Ziekenhuis Rotterdam, het Academisch Ziekenhuis Groningen en
het dagbehandelcentrum ‘de Vuursteen’ van het Martini Ziekenhuis te Groningen. Met
veel plezier heb ik al die jaren samengewerkt met de artsen, verpleegkundigen, het onder-
steunend administratief en secretarieel personeel en overige belangstellenden uit de deelne-
mende centra. Altijd weer was er grote interesse in hoe het onderzoek verliep, en volop
medewerking in het werven van nieuwe patiënten, hetgeen soms niet meeviel.
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jullie wetenschappelijke stage hebben jullie mij enorm geholpen. Bedankt voor jullie inzet
en gezelligheid.
Daarnaast bedank ik alle gezellige collega’s op de afdeling Dermatologie voor jullie belang-
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Natuurlijk dank aan alle psoriasispatiënten en vrijwilligers voor het meewerken aan de
onderzoeken.
Ook mijn grote dank aan Hetty, onze lieve oppas, die het mogelijk maakt elke dag weer
zorgeloos naar mijn werk te gaan in de wetenschap dat de kinderen liefdevol verzorgd
worden.
Danielle, Diederik, Robbert, Jacolien, Wim, Marianne en overige familie en vrienden be-
dank ik voor hun steun bij het tot stand komen van dit proefschrift.
Lieve pap en mam, dit proefschrift draag ik aan jullie op omdat jullie altijd voor me klaar
staan, zonder jullie nimmer aflatende steun en vertrouwen, de hulp en de oppas, had dit
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Daan en Mees, bedankt voor jullie vrolijkheid, jullie laten me steeds opnieuw zien wat
nu eigenlijk het belangrijkste is in het leven.
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